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1 Introduction 
 
The① topiĐ① ‚oǆidatioŶ① ƌeaĐtioŶ͚① eŶĐoŵpasses① a① ǀast① Ŷuŵďeƌ① of① ĐheŵiĐal① aŶd①
biological reactions that take place not only in the round bottom flasks of lab 
chemists. In cooking pots, table sugar is oxidized to delicious smelling caramel[1] 
while many vitamins lose their biologic effect as consequence of oxidation when 
heated.[2] At the hairdresser, requests like perm-fixing and bleached blonde hair 
are fulfilled via oxidation[3] and in the liver, drugs are made excretable by enzyme 
catalyzed oxidation reactions[4,5] Even taking a hot shower in the morning and 
going to work by car quite comfortable was unthinkable for a long time without 
oxidation of hydrocarbons. In the heating system of houses or in the tank of cars, 
fuels - composed of alkanes, cycloalkanes and other aromatic hydrocarbons - 
undergo complete combustion with atmospheric oxygen as oxidant, yielding H2O 
and CO2. Thereby, chemical energy is transformed in propulsive power and heat. 
Altogether, it is not possible to imagine life as we know it without oxidation of 
alkanes.[6] 
 
For the controlled partial oxidation of unfunctionalized hydrocarbons in 
particular, a certain extent of skill and care is required since these unactivated 
compounds are quite inert and harsh conditions are typically necessary to realize 
oxidation in the lab. Particulary, the oxidation of cycloalkanes 1 from petroleum to 
a mixture of corresponding cycloalkanols 2 and cycloalkanones 3 is of economic 
importance since these compounds serve as industrial feedstock for the synthesis 
of bulk products. For example, the synthesis of nylon-6 (5) can be realized via 
cyclohexanone (3a) as well as via adipic acid (6, Scheme 1).[7] 
 
 
 
Scheme 1. Catalytic oxidation of cyclohexane (1a) with molecular oxygen for the 
synthesis of intermediates for nylon-6-production (5) 
Another current route starting from the corresponding cycloalkane 1, which is 
preferred for the synthesis of higher homologue cycloalkanones 3 from a size of 
ten carbon atoms (cyclodecanone (3b)) on a large scale is conducted in the 
presence of boric acid and molecular oxygen. A very important product of this 
BASHKIROV process with subsequent catalytic dehydration is cyclododecanone (3c), 
which is the feedstock of the synthesis of nylon-12 (7) (Scheme 2).[7-12] 
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In the presence of molecular oxygen cyclododecane (1c) is oxidized and the 
unstable cyclododecyl hydroperoxide (8) is formed. With boric acid, 8 is trapped 
to form the cyclododecyl perborate ester 9 in a condensation reaction. Additional 
reagent 1c is oxidized by the perborate ester 9 to cyclododecanol (2c), forming 
the relatively stable borate ester 10. A subsequent hydrolyzation gives access to 
the desired alkohol 2c, and by catalytic dehydration the important intermediate 
3c is obtained (Scheme 2).[10]  
 
 
Scheme 2. BASHKIROV process with subsequent catalytic dehydration is applied for 
the synthesis of cyclododecanone (3c), adapted and modified from MUSSER[10] 
Drawbacks of this protracted procedure are the application of stoichiometric 
amounts of boric acid meaning an expended effort in the waste water treatment, 
the low selectivity of the oxidation and the extensive separation of unreacted 
reagent 1c due to low conversions. Recently, in 2009 an innovative procedure was 
established by BASF, solving two problems simultaneously. Nitrous oxide (N2O), 
an unpleasant side product that incurs during the industrial synthesis of adipic 
acid (6), usually has to be disposed of elaborately. The innovative commercial 
application of this noxious greenhouse gas as oxidant in the synthesis of 
cyclododecanone (3c) shortens the multistep procedure shown in Scheme 2 and 
additionally obviates the disposal problem of N2O (Scheme 3).
[11-14]  
 
 
Scheme 3. Nitrous oxide (N2O) is applied for the synthesis of cyclododecanone 
(3c) in which only one catalyst is necessary[11] 
Furthermore, the oxidation of alcohols represents one of the most important and 
fundamental reactions in organic chemistry and therefore a vast number of 
oxidation methods is reported and summarized.[15] However, these reactions are 
often realized by the application of stoichiometric amounts of toxic and 
carcinogenic chromates. A range of industrial processes can be found in literature 
in which chromium-based oxidation steps are applied for the synthesis of, for 
example, active pharmaceutical ingredients (APIs), like cortisone (13), levofloxa-
cine (14), dapsone (15)[16] or talampanol (16).[17]  
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hydroxylation (40%)
alcohol / amine oxidation (22%)
desaturation (5%)
epoxidation (14%)
Baeyer-Villiger oxidation (5%)
dihydroxylation (14%)
A timely change in the environmental awareness in the more recent past initiated 
the call for substitution of these antiquated oxidation procedures, traditionally 
using metal catalysts or stoichiometric quantities of chromates by more contem-
porary procedures. Environmentally benign oxidants such as O2 or H2O2, whereby 
only water accrues as side product, represent a green alternative.[8] 
 
Besides these alternatives broached above, biocatalysis is a further, complemen-
tary growing branch for environmentally friendly oxidation reactions. Biocatalyzed 
oxidation reactions are carried out by a class of enzymes, called oxidoreductases, 
representing one of the six classes of enzymes, subdivided by an enzyme 
commission. The application of the different enzyme classes for organic synthesis 
is summarized in Figure 1 (left).[18] Oxidoreductase-catalyzed reactions make one 
fourth of these processes and about one half out of it accounts for oxidation 
reactions. On the right side of Figure 1, reaction types of biocatalytic oxidation 
reactions in industry are listed.[19] 
    
Figure 1. Application of the different enzyme classes for organic synthesis (left)[18] 
and types of biocatalytic oxidation reaction in industry (right)[19] 
As apparent from Figure 1 (right), oxyfunctionalizations account for the major part 
and hold a great potential for a further green alternative.  
 
hydrolases (65%)
lyases (5%)
isomerases (1%)
ligases (0%)
oxidoreductases (25%)
transferases (4%)
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2 Motivation and Aim 
 
As elaborated in the previous chapter, a new environmental awareness leads to 
the claim of substitution of traditionally applied, obsolete oxidation procedures by 
more contemporary and green procedures. Metal catalysts or stoichiometric 
quantities of chromates are widely used as oxidation agents in oxidation reactions 
what makes these processes highly questionable, considering the sanitary conse-
quences. In the particular case of large industrial-scale production of higher 
homologue cycloalkanones 3 with eight or more carbon atoms, the BASHKIROV 
process with subsequent catalytic dehydration is applied using molecular oxygen 
as the oxidant. However, several drawbacks of this procedure are the application 
of stoichiometric amounts of boric acid, the low selectivity of the oxidation and 
the extensive separation of unreacted reagent 1c due to low conversions.[10] 
 
Therefore the overall objective of this thesis is to develop a modern and green 
procedure for the direct functionalization of cycloalkanes 1 to cycloalkanones 3 
for the main part. Based on the previous work by BURDA and STAUDT which is 
described further down in this chapter, the desired cycloalkanone 3 shall be syn-
thesized directly by a one-pot process in water starting from the corresponding 
cycloalkane 1 and using atmospheric oxygen as oxidizing agent.[20-22] At different 
stages of the process design, all aspects - from efficiency of the working up and 
robustness of the analytical method in the beginning through to enzyme activities 
with variable substrates and finally the preparative oxidation of the substrates 
and whole cell biotransformation - should be considered. Prior to a preparative 
experiment or process, preliminary studies should ensure that by performing a 
certain procedure (reaction, working up, analytics) all circumstances that contri-
bute to a distortion of the results will be recognized and regarded. First off all, a 
mass loss analysis has to be done to find out if the starting materials have a strong 
disposition to evaporate, to undergo decomposition or to adsorb to surfaces.  
 
Therefore a simulation of reaction conditions and working up is carried out for 
substrate, intermediate and product. In an ideal case, the efficiency of the 
working up process should be considered separately first. Then the reaction time 
while also taking into account the method of working up is to be analyzed, and 
finally the reaction time while also taking into account the method of working up 
in the presence of biomass has to be investigated. Furthermore, a robust and 
exact analytical method for the absolute determination of all components (the 
respective substrate, intermediate and the product) should be established, ideally 
via gas chromatography in a concentration range relevant for the planned 
experiments. The definition of the methods detection limit (MDL) is an important 
step to get reliable results in the quantitative analysis of subsequent 
biotransformations. Aim of this section is to assure that neither a loss of material, 
nor an error-prone working up or an inappropriate analytical method leads to an 
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unrecognized distortion of the results. These sources of error that can appear in a 
preparative experiment are summarized in Figure 2. 
 
 
Figure 2. Sources of error in a preparative experiment 
A preselection and evaluation of substrates - for various reasons attractive to be 
hydroxylated by cytochrome P450 monooxygenases from Bacillus megaterium 
(CYP BM-3) that were made available by the research group Prof. Dr. U. Schwane-
berg (RWTH Aachen) - is to be investigated via UV/VIS-spectroscopy to find suit-
able substrate-enzyme combinations for subsequent preparative experiments.  
 
From the category monounsaturated cyclic hydrocarbons, cyclooctyne (17) and 
cyclododecene (18) are chosen as possible substrates. Cyclooctynes are highly 
reactive and therefore established as tools in bioconjugations, probing 
biomolecules in living systems (Scheme 4, left).
[23-24]
 Cyclododecene (18), is a 
versatile chemical intermediate for organic synthesis in general.
[25] 
 
Furthermore the aldehyde pentanal (19) is supposed to be an excellent starting 
compound for an enzyme mediated synthesis of γ-valerolactone (20) and 
δ-valerolactone (21) (Scheme 4, right). Due to its olfactory qualities, γ-valerolac-
tone (20) is used in the flavour and fragrance industry.
[26]
 δ-Valerolactone (21) in 
contrast is applied in the synthesis of polymers (polyesters).
[27]
 
 
 
Scheme 4. Cyclooctyne (17), bound to a reporter molecule ● (leV) and the desired 
products γ-valerolactone (20) and δ-valerolactone (21), starting from pentanal 
(19) (right) 
The third category to be tested is the class of cyclic alkanes 1. Due to its 
extraordinary role as feedstock for the polyamide production elaborated in the 
previous chapter, a successful oxidation of these substrates would be of high 
importance and should be analyzed excessively. The most promising substrates 
that result from the preselection and evaluation should then be analyzed in pre-
parative experiments testing the hydroxylation with CYP BM-3 to evaluate if a 
double oxidation is generally possible. Since without a second reaction step no 
intrasequential cofactor regeneration is possible, a common regeneration system 
using glucose dehydrogenase (GDH) should be applied for these experiments: 
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D-glucose (22) is oxidized by a GDH and D-gluconolactone (23) is formed which is 
spontaneously hydrolyzed whereupon D-gluconic acid (24) is formed. A 
subsequent neutralization with e.g. sodium hydroxyde forms the corresponding 
sodium salt of the D-gluconic acid (24) and the equilibrium is shifted towards the 
product. As a consequence the back reaction cannot take place (Scheme 5).[28]  
 
 
Scheme 5. Cofactor recycling by the coupled enzyme method with glucose 
dehydrogenase (GDH)[28] 
The substrates that show conversion in the first oxidation step, catalyzed by a CYP 
BM-3 with molecular oxygen yielding the corresponding alcohol, should then be 
applied in a double oxidation one-pot process, that can be described as a ͞dream 
reaction͟, a term that represents sustainable synthetic methods with high atom 
economy and efficiency.[8,29] In literature an enzymatic two-step one-pot process is 
already described by BURDA that basically can be applied for the synthesis of cyclic 
ketones 3. The concept of this direct synthesis of cycloalkanones 3 from the 
corresponding cycloalkanes 1 is based on the cooperation of two enzymes: The 
first step of this process is the CYP BM-3 catalyzed hydroxylation reaction, 
analyzed before. For this reaction, the reduced form of the cofactor NAD(P)H is 
required and oxidized to NAD(P)+. The second step is an alcohol dehydrogenase 
catalyzed oxidation of the in situ formed alkanol 2 in order to give the 
corresponding alkanone 3. In this subsequent step, the oxidized form of the 
cofactor, which is generated in the CYP BM-3 catalyzed hydroxylation reaction, is 
required and retransformed into the reduced form NAD(P)H by the alcohol 
dehydrogenase. In this way the application of a further cosubstrate becomes 
redundant.[20] The general reaction scheme is shown below.  
 
 
 
Scheme 6. General reaction concept of the biocatalyzed two-step one-pot process 
adapted from BURDA[20] 
 
Aiming to identify active mutants of the cytochrome P450 monooxygenase (CYP 
BM-3) from Bacillus megaterium for the hydroxylation of cyclic alkanes 1, BURDA 
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screened saturation mutagenesis libraries. The most promising mutants were 
cultivated, isolated, purified and lyophilized, then the concentration of the 
respective enzyme was determined via CO-difference spectroscopy. Furthermore 
the crude extracts were analyzed with regard to their ability to synthesize cyclic 
alcohols 2 from cyclic alkanes 1. Sequencing of the best mutant of the cytochrome 
P450 monooxygenase revealed valine at position 87 and therefore CYP BM-3 F87V 
was exclusively used for preparative experiments. To realize the second oxidation 
step, BURDA applied the (R)-enantioselektive alcohol dehydrogenase from 
Lactobacillus kefir (LK-ADH). [20] 
 
Moreover, STAUDT extensively analyzed the substrate-product-mixture cyclo-
octane (1d)/cyclooctanone (3d) in an aqueous reaction medium.[21,22] Despite the 
fact that these compounds have comparatively high boiling points (1d: 150-
152°C[25]; 3d: 195-197°C[30]), remarkable decreased amounts of the initially applied 
quantity were isolated according to 1H-NMR-spectroscopy as a result of evapora-
tion. Due to this evaporation, determination of conversion in a classical sense 
would be defective and instead the productivity (g/L) of the reaction was 
stated.[21] The well-established working up procedure developed by STAUDT 
comprises the removal of the solvent in vacuo (900 mbar) and the determination 
of the absolute amount of the respective cycloalkanone 3. Therefore, the crude 
product was analyzed via 1H-NMR-spectroscopy in the presence of pyridine (25) 
as external standard.[21,22] 
 
Both BURDA and STAUDT registered an increase in productivity when catalytic 
amounts of 2-propanol were used as additive. This procedure allows the 
application of the more cost-effective cofactor in its oxidized form (NADP+) since 
the required reduced form of the cofactor (NADPH) is generated in the course of 
the ADH-catalyzed oxidation of 2-propanol yielding acetone.[20-22] Aside from the 
wildtype and the above-mentioned mutant CYP BM-3 F87V, STAUDT investigated 
the mutant CYP BM-3 19A12 with regard to its efficiency to catalyze the afore-
mentioned reaction (Scheme 6). The best result, namely a productivity of 0.80 g/L 
cyclooctanone (3d), was obtained by using the mutant CYP BM-3 19A12 in 
combination with the above-mentioned LK-ADH for the conversion of 100 mM 
cyclooctane (1d) in phosphate buffer.[22] 
 
Hence the challenge is to analyze more active mutants of the cytochrome P450 
monooxygenase (CYP BM-3) from Bacillus megaterium for the hydroxylation of 
cyclic alkanes 1 and further convenient substrates. The biocatalyzed double 
oxidation which was extensively analyzed for cyclooctane (1d) by STAUDT, should 
be equally addressed applying the substrates cyclohexane (1a), cyclodecane (1b) 
and cyclododecane (1c). To avoid the application of pyridine (25) as external 
standard as well as the analysis via 1H-NMR-spectroscopy, a more economic and 
reliable GC-based analysis is planned to be established. In this way the removal of 
the solvent, which requires exact 900 mbar, can be circumvented. Applying the 
most stable system it should be analyzed if the immobilization of the cooperating 
enzymes is basically possible.  
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Finally, the most promising substrates that showed adequate product formation 
in the double oxidation experiments should be applied in a whole cell biotrans-
formation, since this concept was recently successfully described in literature with 
considerably high product formations (Scheme 7).[31,32] 
 
 
 
Scheme 7. Reaction scheme of the whole cell double oxidation 
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3 Preliminary studies  
3.1 Introduction, state of the art, and aim of this section 
 
Prior to a preparative experiment - regardless of whether a classic chemistry 
experiment or a biotransformation is planned - some preliminary studies about 
analytical techniques are absolutely essential to be conducted. It has to be 
ensured that by performing a certain procedure (reaction, working up, analytics) 
all sources of error will be identified and regarded. First of all, a loss of material 
might occur if the applied starting compounds have a strong tendency to 
evaporate, to undergo decomposition or to adsorb to surfaces. To clarify this, 
reaction conditions have to be simulated and a mass loss analysis has to be 
conducted. Next, the efficiency of the working up process resp. of the isolation of 
the product is to be analyzed. Since the isolation of the oxidation products is 
realized by liquid-liquid extraction, some general considerations have to receive 
attention. A liquid-liquid extraction system consists of two immiscible solvents 
and a compound that shows a varying solubility is in these solvents. A linear 
correlation exists - in case of ideal solutions - between the concentrations on 
either sides of the phase boundary. This correlation can be described by the 
NERNST distribution law.[33] 
 
 
 
The ratio of the concentration of compound A in solvent 1 and the concentration 
of A in solvent 2 are constant. K is the NERNST distribution coefficient and the 
NERNST distribution law is valid if only one compound is dissolved in both 
phases.[33] In reality, extraction mixtures often are non-ideal solutions which 
consist of more than one compound, making validations necessary. The efficiency 
of an extraction method is determined by the recovery, that describes the amount 
of a compound that is successfully extracted by a particular method.[34] 
Additionally, the recovery rate has to be analyzed with a convenient analytical 
method. Therefore a robust, fast and suitable analytical method is required and 
need to be tested in regard to its applicability. For example, there are different 
analysis methods such as HPLC, GC or NMR available and either an internal or 
external standard can be employed. By using an internal standard, the sample is 
mixed with a reference compound before extraction. This is an accurately 
quantified compound that is similar to the substance of interest but can be 
separated by analytical methods. Ideally, the signal ratio of the two compounds 
can be determined precisely with the chosen analytical method.[34] Is the concen-
tration of the internal standard changed it is expected that the concentration of 
the substance of interest changed in the same way. Another method is to use an 
external standard that is analyzed independently from the substance of interest. 
The results are two reports, one of the standard and one of the substance of 
interest, where the integrals of the peak areas can be compared.[34]  
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For a multipoint calibration, standard solutions of different concentrations are 
prepared and chromatographed under the same, predetermined conditions that 
are used to analyze the sample afterwards. Additional peaks have no influence on 
the result using this method.[35] The aim of this section is to assure that neither a 
loss of material, nor an error-prone working up or an inappropriate analytical 
method leads to an unrecognized distortion of the results. 
 
3.2 Results and discussion 
3.2.1 Simulation of reaction conditions and working up shown for cyclodo-
decane (1c), cyclododecanol (2c) and cyclododecanone (3c)  
 
A simulation of reaction conditions and working up was necessary and exemplarily 
realized for the desired product cyclododecanone (3c) first. Gas chromatography 
was used as analytical method and for the absolute determination of all 
components (the substrate cyclododecane (1c), the intermediate cyclododecanol 
(2c) and the product cyclododecanone (3c)), a straight calibration line was 
prepared. The detailed analytic procedure is described in the following chapter 
3.2.2. These experiments, shown in Table 1, were conducted considering a) the 
method of working up (entry 1 and 4), b) the reaction time while also taking into 
account the method of working up (entry 2 and 5) and c) the reaction time while 
also taking into account the method of working up in the presence of biomass 
(entry 3 and 6) (SOP 2). It is apparent from Table 1 below, that the extractive work 
up of the reaction mixture is only slightly defective in a concentration range of 
100 mM. Since the recovery is constantly below 100% it can be argued that the 
analysis of the data of the preparative hydroxylation will not yield results that are 
incorrectly increased. 
 
Table 1. Results of the simulation of reaction conditions and working up for 
cyclododecanone (3c) 
 
Entry Time Initial weight [mg] Output weight [mg]b) Recovery [%] 
1 5 min 18.40 17.29 94 
2 24 h 18.13 17.29 95 
3a) 24 h 18.40 --c) -- 
4 5 min 18.54 17.04 92 
5 24 h 18.15 17.28 95 
6a) 24 h 18.44 17.32 94 
 a)20 mg denaturated CYP BM-3 19A12 are added; b) calculated via GC;  c)lost during working up. 
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In summary, very high recovery rates were determined at concentrations of 
100 mM cyclododecanone (3c). Thus, the recovery rate in absence of biomass is 
95% and even when biomass is present, likewise high 94% of the applied 
compound 3c are isolated. Such a high recovery rate, especially in the presence of 
biomass, is not something that can be taken for granted and requires an 
appropriate working up procedure. This finding became clear when working up 
early experiments (SOP 1), where a notably correlation, namely the decreasing of 
the recovery rate with increasing biomass applied in an experiment, was 
observed. Without going into detail on the concept of the biotransformation, 
since at this point the main focus should be on the comparison of the applied 
biomass exclusively, it is noticeable that the recovery of 1c deviated distinctly 
althought same amounts of 1c were applied for both experiments (Table 2). 
Table 2. Results of the double oxidation of cyclododecane (1c) 
Entry 
CYP BM-3 
(biomass) 
Cyclododecanone 
(3c) [g/l] 
Recovery of 
substrate 1c [%] 
1 
CYP BM-3 19A12 
(19.6 mg) 
0 92 
2 
CYP BM-3 F87V 
(127.0 mg) 
0 83 
 
A possible explanation for this phenomenon can be found in the respective 
amount of biomass used for the experiment, regardless which mutant is applied. 
The initial step of the working up procedure is to denaturate the enzyme by 
adding dichloromethane. From this moment on different mutants of the cyto-
chrome P450 monooxygenase can be considered as the same nonfunctional 
protein with identical molecular weight. Certainly, different lyophilized mutants 
have different gravimetric activities. To keep the parameter ͞enzyme activity͟ 
constant in preparative experiments, different amounts of biomass have to be 
applied. For example, for the biotransformation with the mutant CYP BM-3 19A12 
only 19.6 mg protein were applied whereas with the less active mutant CYP BM-3 
F87V a more than sixfold higher amount of biomass, namely 127.0 mg protein was 
neccessary to compensate the lower activity. This considerably increased amount 
of biomass manifests itself in the recovery rate of the substrate 1c: while in the 
small enzyme pellet only traces of 1c are absorbed, the more voluminous pellet is 
able to hold back higher amounts. A one-time extraction is therefore insufficient 
to isolate the compounds enriched in the biomass completely. (Figure 3).  
 
 
Figure 3. Enzyme pellet from 19.6 mg biomass (CYP BM-3 19A12) (left) and 
enzyme pellet from 127.0 mg biomass (CYP BM-3 F87V) (right) 
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Taking this into account and aiming to further improve the recovery rate, the 
work up process of the reaction mixture was optimized. Likewise the aqueous 
phase, the enzyme pellet is also extracted three times. This optimized extractive 
work up of the reaction mixture ensures a high recovery rate, both in presence 
and absence of an enzyme pellet. 
 
A simulation of reaction conditions and working up was additionally necessary for 
the intermediates 2 and the substrates 1, as exemplarily established for 
cyclododecane (1c) and cyclododecanol (2c) (SOP 2). A further expansion of these 
preliminary studies to the application of lower substrate concentrations (1 and 
10 mM instead of the previous used 100 mM) and considering that the main focus 
is later on cyclododecanol (2c) as product was neccessary (SOP 2). These 
experiments, shown in Table 3 and Table 4, were conducted considering a) the 
method of working up (always entry 1,4,7), b) the reaction time while also taking 
into account the method of working up (always entry 2,5,8) and c) the reaction 
time while also taking into account the method of working up in the presence of 
biomass (always entry 3,6,9). Gas chromatography was used as analytical method 
and for the absolute determination of the substrate 1c and the intermediate 2c, a 
straight calibration line was prepared. The detailed analytic procedure is 
described in the next chapter 3.2.2. Ideally, the recovery should be 100%, in the 
following the average deviation from this ideal value is listed (Table 3-4).  
 
Table 3. Results of the simulation of reaction conditions and working up for 
cyclododecanol (2c) 
 
Entrya) 
2c   
[mmol] 
Time 
Initial weight  
[mg] 
Output weight  
[mg]d) 
Deviatione)        
[%] 
1 0.1 5 min 18.35 20.04 +9 
2 0.1 2 h 18.72 20.16 +8 
3b) 0.1 2 h 18.35 18.45 +1 
4 0.01 5 min 2.21 2.27 +3 
5 0.01 2 h 2.18 2.19 0 
6b) 0.01 2 h 2.20 2.13 -3 
7 0.001 5 min 0.184c) 0.151 -18 
8 0.001 2 h 0.184c) 0.150 -19 
9b) 0.001 2 h 0.184c) 0.136 -26 
a)All measurements are conducted in a twofold determination;  b)30 mg denaturated  CYP BM-3 
19A12 are added; c)weigh in via stock solution; d)calculated via GC; e)average deviation from a 
recovery of 100%. 
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Table 4. Results of the simulation of reaction conditions and working up for 
cyclododecane (1c) 
 
Entrya) 1c [mmol] Time 
Initial weight 
 [mg] 
Output weight 
 [mg]d) 
Deviationf)       
[%] 
1 0.1 5 min 16.89 18.26 +8 
2 0.1 2 h 16.95 18.35 +8 
3b) 0.1 2 h 16.97 18.03 +6 
4 0.01 5 min 1.80 1.87 +4 
5 0.01 2 h 1.75 1.79 +2 
6b) 0.01 2 h 1.92 1.86e) -3 
7 0.001 5 min 0.168c) 0.162 -4 
8 0.001 2 h 0.168c) 0.106 -37 
9b) 0.001 2 h 0.168c) 0.039 -77 
a)All measurements are conducted in a twofold determination;  b)30 mg denaturated  CYP BM-3 
19A12 are added; c)weigh in via stock solution; d)calculated via GC; e)loss of one drop during working 
up; f)average deviation from a recovery of 100%. 
 
 
It is apparent from Table 3 and Table 4 above, that the extractive work up of the 
reaction mixture is non-reliable for cyclododecane (1c) resp. cyclododecanol (2c) 
in the low concentration range of 1 mM. However, the recovery is constantly 
below 100%. In this regard, the analysis of the data of the preparative hydroxy-
lation will not yield results that are incorrectly increased. In the concentration 
range of 10 to 100 mM, this method provides solid results with an average 
deviation from a recovery of 100%, that is at all times below 10%.  
 
In summary, high recovery rates of 95% were determined at concentrations of 
100 mM cyclododecanone (3c) and even in the presence of biomass, 94% of the 
applied compound 3c can be isolated. Moreover, the extractive work up of a 
simulated reaction mixture for cyclododecane (1c) resp. cyclododecanol (2c) 
displays solid results with an average deviation from a recovery of 100%, that is at 
any time below 10%. This extensively realized simulation of reaction conditions 
and working up was exemplarily investigated for cyclododecane (1c), 
cyclododecanol (2c) and cyclododecanone (3c). The conclusions drawn from these 
experiments concerning the working up resp. the recovery rate of the respective 
compounds were then transferred to the further analyzed cycloalkanes 1.  
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Due to the structural similarity of cyclodecane (1b), cyclodecanol (2b) and 
cyclodecanone (3b) compared with the analyzed cyclododecane (1c), cyclodode-
canol (2c) and cyclododecanone (3c), it is expected that the properties are 
comparable to a certain extent. To provide a better overview with regard to the 
volatility, the boiling points of all relevant cycloalkanes 1, cycloalkanols 2 and 
cycloalkanones 3 are summarized in Table 5.  
 
Table 5. Boiling points of all relevant cycloalkanes 1, cycloalkanols 2 and 
cycloalkanones 3 at normal pressure 
 
 
Entry  
n = 1:  
Cyclohex- 
n = 5: 
Cyclodec- 
n = 7: 
Cyclododec- 
1 -ane 1 81°C[36] 201°C[37] 244°C[39] 
2 -anol 2 161°C[10] 244°Ca) 278°C[25] 
3  -anone 3 156°C[10] 197°Cb) [38] 277°C[25] 
a)Calculated with Advanced Chemistry Development ACD/Labs Software v11.02; b)The boiling point 
reported in literature is 106-107°C at 16 hPa[38]. Based on a boiling point depression of 15°C per 
halving of the pressure, the boiling point at normal pressure is calculated to be 197°C.[40] 
 
 
The boiling points of the non-volatile C12-rings 1c, 2c and 3c are in a range of 244-
278°C[25,39] and also the C10-rings 1b, 2b and 3b will not boil until temperatures of 
ca. 200°C and higher are reached.[37,38] Therefore it is assumed that the properties 
of the C12-rings 1c, 2c and 3c analyzed within the simulation- and working up 
studies can be transferred to the C10-rings 1b, 2b and 3b. The boiling points of 
the C6-rings 1a, 2a and 3a however are considerably lowered compared to those 
of the C10- and C12-rings.[10,36] Especially the substrate 1a has a low boiling point 
of 81°C and therefore a strong disposition to evaporate.[36] To meet this fact in 
particular and in order to include minor deviations in working up or recovery, an 
absolute quantification via gas chromatography secures that the final productivity 
(g/L) is not incorrectly increased.  
 
3.2.2 Simultaneous quantification of cycloalkanes 1, cycloalkanols 2 and 
cycloalkanones 3 via gas chromatography 
 
Quantification of cyclododecane (1c), cyclododecanol (2c), cyclododecanone (3c) 
 
Gas chromatography is a well-established and extremely robust method for the 
absolute quantification of volatile compounds. It was already used in some early 
experiments and the absolute determination of all components (the substrate 
cyclododecane (1c), the intermediate cyclododecanol (2c) and the product 
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cyclododecanone (3c)) in a concentration range of 0.1 to 10 g/L is realized with a 
six-point calibration line for each compound (10 g/L, 5 g/L, 1 g/L, 0.5 g/L, 0.3 g/L, 
0.1 g/L) (Method A for 1-3c, SOP 3). Furthermore, an expansion of the above-
mentioned method (Method A: 0.1-10 g/L) has been implemented to account for 
a considerably lower concentration range (Method B: 0.025-0.2 g/L). Moreover, 
the methods detection limit was defined to guarantee qualitatively and quantita-
tively correct results. Using this newly established methods for gas 
chromatography, an absolute determination of all components (the substrate 
cyclododecane (1c), the intermediate cyclododecanol (2c) and the product 
cyclododecanone (3c)) in a concentration range of 0.025 to 0.2 g/L (altogether 
four measured points: 0.2 g/L, 0.1 g/L, 0.05 g/L, 0.025 g/L) (Method B for 1-3c, 
SOP 3) is possible down to a concentration of 0.005 g/L.  
 
Definition of the methods detection limit (MDL) 
The definition of the methods detection limit (MDL) is an important step to get 
valid results in the quantitative analysis of subsequent biotransformations. By 
means of the straight calibration line samples with different concentrations 
(0.04 g/L, 0.02 g/L, 0.01 g/L, 0.005 g/L, 0.002 g/L) are analyzed via gas chromato-
graphy. All measurements are conducted in a twofold determination (Table 6). In 
summary, concentrations down to 0.005 g/L can be measured reliably. The GC-
determined percental deviation from the prepared concentrations is -13% for the 
substrate cyclododecane (1c), -2% for the intermediate cyclododecanol (2c) 
and -13% for the product cyclododecanone (3c). This detection limit is defined 
because very low concentrations (0.002 g/l, Table 6) are not detected reliably.  
 
Table 6. GC-determined percental deviation from the prepared concentrations of 
cyclododecane (1c), cyclododecanol (2c) and cyclododecanone (3c) 
Entrya) Compound 
Deviationb) at①a①ĐoŶĐeŶtƌatioŶ①of… 
…Ϭ.Ϭϰ g/L …Ϭ.ϬϮ g/L …Ϭ.Ϭϭ g/L …Ϭ.ϬϬϱ g/L …Ϭ.ϬϬϮ g/L 
1 1c +3% -7% -9% -13% -31% 
2 2c -1% -6% -6% -2% +6% 
3  3c -6% -8% -9% -13% -41% 
a)All measurements are conducted in a twofold determination; b)average deviation from a recovery 
of 100%. 
 
 
Quantification of cyclodecane (1b), cyclodecanol (2b), cyclodecanone (3b) 
 
Gas chromatography was used to establish an extremely robust and exact 
analytical method for the absolute determination of all components (the 
substrate cyclodecane (1b), the intermediate cyclodecanol (2b) and the product 
cyclodecanone (3b) in a concentration range of 0.1 to 10 g/L (Method A) with 
altogether five measured points (10 g/L, 1 g/L, 0.5 g/L, 0.3 g/L, 0.1 g/L) (Method A 
for 1-3b, SOP 3). In the context of the further expansion of this above-mentioned 
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method for detection (Method A: 0.1-10 g/L) to a considerably lower 
concentration range (Method B: 0.025 - 0.80 g/L, altogether six measured points: 
0.8 g/L, 0.4 g/L, 0.2 g/L, 0.1 g/L, 0.05 g/L, 0.025 g/L) (Method B for 1-3b, SOP 3), 
additionally the methods accuracy is investigated to ensure quantitatively correct 
results and to guarantee the reproducibility of the analysis via gas chromato-
graphy. Ideally, the recovery should be 100%, in the following the average 
deviation from this ideal value is listed (Table 7). It is apparent from Table 7 below 
that valid results are obtained even in microgram quantities. 
 
Table 7. Results of the verification of the GC-method for 1b, 2b and 3b 
Entrya) 
(method A) 
Compound 
Deviationc) at a concentration of…① 
…ϳ.Ϭ g/L …ϭ.ϰ g/L …Ϭ.Ϯ g/L 
1 1b -1.7% -3.6% 0.0% 
2 2b +2.9% n.d. -5.0% 
3  3b -1.4% -2.7% -8.6% 
Entryb) 
(method B) 
Compound 
Deviationc) at①a①ĐoŶĐeŶtƌatioŶ①of…① 
…Ϭ.ϴ g/L …Ϭ.ϭ g/L …Ϭ.ϬϮϱ g/L 
1 1b -1.4% -2.7% -10.0% 
2 2b -0.5% +0.1% +0.8% 
3  3b -1.5% -2.1% -5.0% 
a)All measurements are conducted in a fourfold determination; b)All measurements are conducted in 
a twofold determination; c)average deviation from a recovery of 100%. 
 
 
Quantification of cyclohexane (1a), cyclohexanol (2a), cyclohexanone (3a) 
 
Gas chromatography was used to establish an extremely robust and exact 
analytical method for the absolute determination of all components (the 
substrate cyclohexane (1a), the intermediate cyclohexanol (2a) and the product 
cyclohexanone (3a) in a concentration range of 0.15 to 1.5 g/L (Method A) with 
altogether six measured points (1.5 g/L, 1.0 g/L, 0.75 g/L, 0.5 g/L, 0.3 g/L and 
0.15 g/L) (Method A for 1-3a, SOP 3). In the context of the further expansion of 
this above-mentioned method for detection (Method A: 0.15 - 1.5 g/L) to a 
considerably lower concentration range (Method B: 0.025 - 0.80 g/L, altogether 
six measured points: 0.80 g/L, 0.40 g/L, 0.20 g/L, 0.10 g/L, 0.05 g/L, 0.025 g/L) 
(Method B for 1-3a, SOP 3), additionally the methods accuracy is investigated to 
ensure quantitatively correct results and to guarantee the reproducibility of the 
analysis via gas chromatography. Ideally, the recovery should be 100%, in the 
following the average deviation from this ideal value is listed (Table 8). It is 
apparent from Table 8 below that valid results are obtained even in microgram 
quantities. 
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Table 8. Results of the verification of the GC-method for 1a, 2a and 3a 
Entrya) 
(method A) 
Compound 
Deviationc) at①a①ĐoŶĐeŶtƌatioŶ①of…① 
…ϭ.ϯ g/L …Ϭ.ϵ g/L …Ϭ.Ϯ g/L 
1 1a +7.8% +12.2% +13.9% 
2 2a -1.3% -10.6%. -4.5% 
3  3a -5.5% -6.9% -6.7% 
Entryb) 
(method B) 
Compound 
Deviationc) at①a①ĐoŶĐeŶtƌatioŶ①of… 
…Ϭ.ϴ g/L …Ϭ.ϭ g/L …Ϭ.ϬϮϱ g/L 
1 1a +5.0% +9.5% +21.4% 
2 2a +4.5% +1.9% +2.1% 
3  3a -1.8% -5.3% -10.8% 
a)All measurements are conducted in a fourfold determination; b)All measurements are conducted in 
a twofold determination; c)average deviation from a recovery of 100%. 
 
Additionally, the direct analysis of the crude reaction mixture via headspace gas 
chromatography was investigated exemplarily for the substrate cyclododecane 
(1c), the intermediate cyclododecanol (2c) and the product cyclododecanone (3c), 
but not for cyclodecane (1b) or cyclohexane (1a) and their oxidation products. 
More importantly, this approach enables only a qualification of these compounds 
and is not appropriate for quantification in the concentration range required for 
this project. 
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4 Hydroxylation with cytochrome P450 monooxy-
genases from B. megaterium  
4.1 Introduction, state of the art, and aim of this section 
 
In our diamagnetic world, the naturally occurring molecular oxygen is - under 
standard conditions - fairly unreactive and therefore the oxidation of the biotic 
and abiotic environment is extremely slow. As a consequence, the atmospheric 
oxygen needs to be activated to interact with compounds of the environment. 
Compared with the paramagnetic triplet oxygen, activated singlet oxygen is 
diamagnetic and therefore a very effective oxidant (Figure 4).[41,42] 
 
 
Figure 4. Molecular orbital diagram of triplet oxygen (ground state, left) and 
singlet oxygen (excited state, right) 
In the presence of oxygen, that makes up about 20% of the Earth`s atmosphere, 
the most energetically stable form of carbon is carbon dioxide (CO2) and the 
thermodynamically favoured breakdown of organic materials resp. hydrocarbons 
principally yields carbon dioxide and water. This exotherm reaction, the oxidative 
combustion with oxygen, is releasing the energy which was previously fixed during 
photosynthesis.[43] Reasonably, the instant exhaustive breakdown of nearly all 
organic materials is limited for a specific activation energy must be overcome to 
induce a reaction: the transfer of electrons between states of different spin 
multiplicities is forbidden and since most molecules have spin-paired electrons 
and therefore exist in a singlet ground state, this spin barrier has to be overcome 
before a reaction with oxygen in the triplet ground state will take place. This was 
a brilliant achievement of evolution and a stroke of luck for the diversity of life as 
we know it.[43] 
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By means of biocatalysts these energy barriers are decreased and the activation 
energy is easy to overcome at moderate temperatures. In most cases these 
enzymes are metalloproteins and interaction of oxygen with the corresponding 
transition metal cation leads to activation of the oxygen. One example for oxygen-
binding metalloproteins are cytochrome P450 monooxygenases (CYPs) and their 
contribution in oxidation reactions will be the main topic of this chapter.[43] 
 
4.1.1 Cytochrome P450 monooxygenases (CYPs): Electron transfer, catalytic 
mechanism and coupling efficiency 
 
In the year 1958 GARFINKEL and KLINGENBERG investigated independently of each 
other liver microsomes and found a pigment with a characteristic absorption 
maximum at 450 nm that was attributed to the binding of a carbon monoxide 
(CO) ligand to the heme. Later the term cytochrome P450 was used to describe 
these①Đellulaƌ①pigŵeŶts①ǁheƌeďǇ①͞P͟①staŶds①foƌ①pigŵeŶt①aŶd①͞ϰϱϬ͟①is①deƌiǀed①fƌoŵ①
the UV absorption peak of the carbon monoxide complex. Thereby GARFINKEL and 
KLINGENBERG emerged as discoverers of the P450 superfamily which is nowadays 
one of the best known enzyme families.[44,45] 
 
In the heme center of CYPs the activation of molecular oxygen proceeds and this 
leads to the insertion of a single atom of oxygen into a substrate while the other 
oxygen atom is reduced to water. This mechanism of monooxygenation depends 
on a coupled and stepwise supply of electrons which are provided from NAD(P)H 
and supplied by a redox partner.[46] CYPs are divided into classes according to the 
different types of the electron transfer system they use. Although there is a 
number of additional classes identified in the recent past and reviewed by 
HANNEMANN et al.[47] the focus should be on the three best-known systems 
(Scheme 8): 
 
 
Scheme 8. Different types of electron transfer systems (taken from URLACHER et 
al.
[48] and modified according to HANNEMANN et al.[47]) 
Class I-CYPs include most bacterial and (eukaryotic) mitochondrial systems and 
use three separate proteins: a FAD-containing ferredoxin reductase (FdR) 
transferring the reduction equivalents (electrons) from NAD(P)H to the second 
iron sulfur protein, a ferredoxin (Fdx), mostly of the [2Fe–2S] type. This ferredoxin 
in turn reduces the cytochrome P450 itself. The first bacterial P450 system 
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discovered, the camphor hydroxylase CYP CAM, is organized in that way: electrons 
are transferred from NADH via a putidaredoxin reductase (FdR) and an iron-sulfur 
putidaredoxin (Fdx) to CYP CAM (Scheme 8, path a).[47] 
 
Class II-CYPs are mostly found in eukaryotes and show a high diversity in the 
catalyzed reactions. In mammals these enzymes play a key role in the oxidative 
metabolism of endo- and exogenous compounds.[47] The simplest form is located 
in the endoplasmatic reticulum of eukaryotes and is composed of two integral 
membrane proteins: a NADPH-cytochrome P450 reductase (CPR) within which the 
prosthetic group FAD accepts the electrons from NADPH and the FMN subunit 
transfers the redox equivalents to the cytochrome P450 itself (Scheme 8, path 
b).[47] In this way CPR is transferring the electrons from the two-electron donor 
NADPH to FAD and thence via FMN to the CYP and its one-electron acceptor 
containing heme. This ensures that electrons are delivered in two separated steps 
at the respective moments of the catalytic cycle. The third electron transfer 
pathway described in path c) of Scheme 8 illustrates the electron transfer of 
catalytically self-sufficient monooxygenases. These are CYPs which are fused to 
their reductase partner (CPR) in a single polypeptide chain. A very extensive and 
detailed studied member of this class is the cytosolic fatty acid hydroxylase 
flavocytochrome CYP102A1 (P450 or CYP BM-3, EC 1.14.14.1) of the soil 
bacterium Bacillus megaterium.[47]  
 
The catalytic cycle of cytochrome P450 monooxygenases is most often described 
in literature for the very well studied substrate camphor (26). It is summarized in 
Scheme 9 and described below, adapted and modified from different 
publications.[49-53] 
 
 
Scheme 9. Catalytic cycle of cytochrome P450 monooxygenases[49,50] 
The①foƌŵ①༃①of①the①pƌoteiŶ①shoǁs①the①suďstƌate①fƌee①ƌestiŶg①state①of①the①loǁ①spiŶ①
(ls) FeIII (d5, S = ½) with sixfold coordinated metal (porphyrine, cysteinate, water). 
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The substrate binding to the active site of the enzyme displaces the labile axial 
water coordinated as the 6th ligand of the heme iron and the low spin state is 
changed to the high spin state (S = ⁵⁄₂). The high spin state is favored in the 
presence of substrate.[49-52] 
 
The substrat binding can be described as an entropy-driven process: few water 
molecules are released from the active site resulting in a gain in entropy for the 
system.[51] It is known that in octahedral complexes the effective radius of the low 
spin FeIII is smaller than in the high spin configurated FeIII due to the lower 
repulsion of the ligands and therefore closer to the porphyrin plane.[42] In line with 
this, the transition of the six-coordinate low spin (ls) FeIII ༃①to①the①fiǀe-coordinate 
high spin (hs) FeIII ༄①effeĐts① a① displaĐeŵeŶt① of① the① iƌoŶ① fƌoŵ① the① plaŶe① of① the①
porphyrin ring from 0.30 Å to 0.44 Å, known as out-of-plane structure.[51] The iron 
is therefore located slightly above the heme so that the coordination sphere of 
the metal is modified. This modification induces a change in the redox potential of 
the iron center by increasing it from -300 to -170 mV. With this increased 
reduction potential the heme is a better electron sink and the subsequent single 
electron transfer resulting in the corresponding FeII ༅①is① the① iŶitial① step① iŶ① the①
process of oxygen activation.[51] The FeII-complex binds then to molecular 
dioxygen and an initial dioxygen-adduct, the superoxo-Đoŵpleǆ①༆① Fe3+OO- is 
foƌŵed.①This①iŶteƌŵediate①༆①is①the①last①ƌelatiǀelǇ①staďle①ĐoŵpouŶd①iŶ①this①Đycle. 
The subsequent transfer of the second electron is relatively slow and therefore 
the rate determining step in many CYPs.[51] The①ƌeduĐtioŶ①of①༆①as①a①ĐoŶseƋueŶĐe①
thereof gives the ferric peroxo-anion Fe3+OO2- ༇① ǁhiĐh① is① theŶ① ƋuiĐklǇ①
protonated to give the hydroperoxo-feƌƌiĐ①iŶteƌŵediate①༈.①②①seĐoŶd①pƌotoŶatioŶ①
at the distal oxygen-atom induces a subsequent elimination of water via the 
heterolytic cleavage of the O-O-ďoŶd① to① giǀe① the① high① ǀaleŶt① iƌoŶ① speĐies①༉①
which is thought to be the active entity in most CYP-catalyzed oxidations. This 
foƌŵeƌ① ͞ŵǇsteƌiĐ① aĐtiǀated① oǆǇgeŶ① speĐies͟[49] was characterized by RITTLE and 
GREEN in 2010.[53] This high valent iron-(IV)-oxo species ༉ is sometimes simplified 
to an iron-(V)-oxo species for the iron charge is +4 and additionally the porphyrine 
ring is a positively charged radical cation.[51]  
 
The insertion of oxygen to the substrate - the alkane hydroxylation - was 
described by GROVES et al. in a so-Đalled①͞ƌeďouŶd①ŵeĐhaŶisŵ͟①ǁhiĐh①is①shoǁŶ①iŶ①
Scheme 10, path a.[54-56] After elimination of the monooxygenated substrate, the 
resting form is reconstructed by rebinding the sixth aqua ligand.[50] This consensus 
oxygen rebound mechanism is postulating that one hydrogen atom from the 
suďstƌate①is①aďstƌaĐted①ďǇ①༉①to①foƌŵ①the radical substrate intermediate. Then the 
hǇdƌoǆǇl① gƌoup① is① tƌaŶsfeƌƌed① to①༉∙ and the catalytic cycle is completed by 
releasing the alcohol and restoring the resting state.[54-56] Although this 
mechanism was accepted for many years it is discussed controversially since 
NEWCOMB et al. took advantage of radical clocks to point out that a cationic 
reaction pathway is easily conceivable (Scheme 10, path b).[57-59] 
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Scheme 10. Insertion of one oxygen atom into the C-H-bond of the substrate in 
one (concerted)[57-59] or two (oxygen rebound)[54-56] steps (adapted from MEUNIER 
et al.[51]) 
Apart from the insertion of one oxygen atom into the C-H-bond of the substrate 
(v.s., main pathway) there are three additional pathways described in literature 
and depicted in Scheme 9. All shuntways lead to the formation of the five-
coordinate high spin (hs) FeIII ༄: the①͞peƌoǆide①shuŶt͟①desĐƌiďes①the①dissoĐiatioŶ①
of the hydrogen peroxide ligand from the hydroperoxo-ferric intermediate ༈①
and is the most detailed investigated side pathway. In case of the high valent iron 
speĐies①༉① is① usiŶg① tǁo① additioŶal① eleĐtƌoŶs① iŶ order to eliminate water, this 
pathǁaǇ① is① Đalled① ͞oǆidatioŶ① shuŶt͟.① IŶ① a① so-Đalled① ͞autooǆidatioŶ① shuŶt͟①
superoxide is dissociated from the superoxo-Đoŵpleǆ① ༆① to① foƌŵ① the① fiǀe-
coordinate high spin (hs) FeIII ༄① ďǇ① ƌetuƌŶ.[50] All three additional pathways 
(shunts) have in common that the consumption of the cofactor is decoupled from 
the substrate oxidation as such, since the electrons are used elsewhere. One 
consequence of this uncoupling is that the precious cofactor is misspent. Another 
effect is that the formation of reactive species like hydrogen peroxide will lead to 
an (irreversible) inactivation of the enzyme.[60,61]  
 
In numerous natural P450 monooxygenases like the camphor hydroxylase from 
Pseudomonas putida (CYP CAM) or the cytochrome P450 monooxygenase from 
Bacillus megaterium (CYP BM-3), the oxidation of the physiological substrate is 
highly coupled to the consumption of cofactor and excellent coupling efficiencies 
are obtained.[62] The coupling efficiency for the hydroxylation of camphor (26) by 
CYP CAM is stated in literature to be 95-100% under optimal conditions[62,63] while 
the hydroxylation of linear and branched C12−C20 fatty acids at subterminal (ω-1, 
ω-2, ω-3) positions - catalyzed by CYP BM-3 - is as well excellent coupled to the 
consumption of cofactor (88-98%).[62] However, this highly efficient but sensitive 
coupling is easily disrupted when amino acids are substituted or the enzyme is 
faced with non-natural substrates. This phenomenon is the consequence of a 
reduced interaction between substrate and enzyme since an enzymes binding 
pocket is optimized for the respective physiological substrate.[62] Almost complete 
coupling efficiencies of up to 100% are often decreased to less than 10%, when 
cytochrome P450 monooxygenases are applied for the biotransformation of non-
physiological substrates.[64,65] 
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This problem can be addressed by protein engineering. For example, BELL et al. 
showed that the wildtype camphor hydroxylase from Pseudomonas putida (CYP 
CAM) converts butane (27) with a coupling efficiency of 4% while a quadruple 
mutant obtained 95%. The same enzyme oxidizes propane (28) with a coupling 
efficiency of 0.9% while a double mutant achieves 39%.[66] The wildtype 
cytochrome P450 monooxygenase from Bacillus megaterium (CYP BM-3) achieved 
only a coupling efficiency of 20% for the oxidation of n-heptane (29) while the 
double mutant R255P-P329H increases the coupling efficiency up to 45%.[32] 
Similar results were found for cyclic alkanes 1 by MAURER in 2005 when identifying 
mutants able to hydroxylate cyclohexane (1a). The CYP BM-3 double mutant R47L, 
Y51F revealed coupling efficiencies of 25% while only 6% were found for the 
wildtype CYP BM-3.[67] Another solution to the problem investigated by WATANABE 
et al. is the application of perfluorocarboxylic acids as decoy molecules which 
force long-alkyl-chain fatty acid hydroxylases to generate the active species and to 
catalyze oxidation of various non-natural substrates.[68,69] Using the decoy 
molecule perfluorooctanoic acid (30), a coupling efficiency of 45% was found for 
the hydroxylation of cyclohexane (1a).[68-69] 
 
4.1.2 Cytochrome P450 monooxygenases (CYPs): Key role in the drug 
metabolism and structure of CYP BM-3 
 
Cytochrome P450 monooxygenases play a key role in the drug metabolism and for 
this reason they are one of the best studied enzyme families. Exogenous unpolar 
compounds e.g. drugs as well as endogenous structures like hormones are made 
excretable by means of biotransformation. These biotransformations are mainly 
located in the liver and are subdivided into phase-I and phase-II-reactions: within 
a phase-I-reaction the structure of the drug is modified by different 
functionalization reactions (oxidation, reduction or hydrolysis). For most drugs, 
oxidation via cytochrome P450 monooxygenases plays the decisive role. The 
subsequent phase-II-reactions are conjugation reactions aiming to enhance the 
water solubility and therefore the renal elimination of the drug.[70,5] An everyday 
example of why drug metabolism studies with cytochrome P450 monooxygenases 
are essential and indispensable is revealed by the analgesic and antipyretic over-
the-counter (OTC) drug paracetamol (31):[71-73]  
 
Paracetamol (31) is almost exclusively metabolized in the liver. As the large part is 
converted into easily excretable compounds, a smaller part undergoes a cyto-
chrome P450 monooxygenase catalyzed breakdown yielding N-acetyl-p-benzo-
quinone imine (NAPQI) (32). NAPQI 32 is highly reactive, able to link the hepatic 
proteins and therefore severe cellular damage is caused. This will lead to death 
within few days via complete liver failure, if untreated. Usually NAPQI 32 is 
rendered harmless by the tripeptide glutathione (33) and excreted renally. But 
excessive amounts of paracetamol (31) will lead to a rapid exhaustion of endo-
genous glutathione (33) and the reactive metabolite NAPQI 32 will accumulate in 
the liver to cause the harms outlined above.  
HYDROXYLATION WITH CYTOCHROME P450 MONOOXYGENASES FROM B. MEGATERIUM | 27 
 
The antidote of choice to treat paracetamol poisoning is N-acetylcystein (34). 34 
replenishes the hepatic reservoir of glutathione (33) that is depleted in case of a 
paracetamol overdose by providing cysteine (35) which is essential for the 
formation of glutathione (33) (Scheme 11).
[71-73]
  
 
 
Scheme 11. Pharmacokinetics of paracetamol (31), summarized according to 
various authors
[71-73]
 
More than 90% of all oxidative drug reactions in humans are catalyzed by a quite 
small number of cytochrome P450 enzymes, like CYP1A2, CYP2C9, CYP2D6, 
CYP2E1 and CYP3A4 whereby the enzyme CYP3A4 is involved in the metabolism of 
more than 50% of all drugs.
[74] 
But P450 enzymes can be found in all domains of 
life: besides the already mentioned human resp. mammalian CYPs these enzymes 
are as well found in e.g. bacteria, fungi, plants and insects.
[75]
 
 
 
However, not only for metabolism studies in drug discovery processes 
cytochrome P450 monooxygenases are of enormous interest. The ability of these 
enzymes to oxyfunctionalize C-H-bonds under mild conditions and the numerous 
applications of these oxidation products arouse the interest of the scientific 
community and industry. Actually, the non-activated C-H-bond is quite strong (ca. 
400 kJ mol
-1
) and consequently graded as inert at mild temperatures and towards 
mild oxidants.
[41,42,76] 
 
Some examples of successful syntheses of fine chemicals using these enzymes are 
given below: due to the large variety of this field of research in 
oxyfunctionalization it is not possible to report on all P450 families and this work 
is in large parts restricted to the CYP102A1 monooxygenase used for the 
preparative experiments of this work. The cytochrome P450 monooxygenase from 
the soil bacterium Bacillus megaterium (CYP BM-3/CYP102A1/EC 1.14.14.1) resp. 
its activity as fatty acid hydroxylase was described for the first time in 1974 by 
MIURA and FULCO.
[77-79]
 The common term “BM-3” is attributed to the fact that CYP 
BM-3 was the third monooxygenase isolated and characterized from this 
organism at all.
[52,80]
 In the 1980s CYP BM-3 was found to show an unusual 
attribute:  
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This completely soluble enzyme with a molecular weight of 119 kDa is a fusion of 
the heme containing hydroxylase domain (55 kDa) and the reductase domain 
(65 kDa, containing FAD and FMN in equimolar ratio) connected via a short 
protein linker into one single polypeptide chain (Figure 5).[52,80,81] 
 
 
Figure 5. Schematic structure of CYP BM-3[52,80,81] 
CYP BM-3 comprises an unequivocal N-terminal sequence and this is considered 
as a confirmatory evidence that not a very stable complex of several proteins but 
rather a single polypeptide chain exists.[80] In 1987 WEN and FULCO expressed the 
complete CYP BM-3 gene in E. coli and characterized it.[82] Sequence homology 
compared with eukaryotic monooxygenases makes it an excellent model system 
for this class of enzyme with the advantage that this soluble enzyme can be 
produced in recombinant form. While other CYPs require additional redox 
proteins, CYP BM-3 is catalytically self-sufficient and requires merely the reduced 
nicotinamide adenine dinucleotide phosphate (NADPH) and oxygen to catalyze 
the hydroxylation of long chain fatty acids.[82] Until today, the exact biological 
function of CYP BM-3 is unknown[83,84] but it hydroxylates primarily linear and 
branched medium- and long-chain fatty acids at the subterminal ω-1, ω-2 and ω-3 
positions.[77-88] 
 
Only the option of expression and purification paved the way for crystal structures 
of the heme containing hydrolase domain in substrate-free and substrate-bound 
form and therefore the way for rational protein design with this enzyme. On this 
basis, several amino acid hotspots with significant influence on binding resp. 
transformation of different substrates were identified. For example, a positively 
charged arginine residue (Arg47) is located at the entrance of the long, 
hydrophobic substrate access channel. The replacement of Arg47 by a negatively 
charged glutamic acid residue (Glu47) led to a catalytically inactive mutant. This 
result is probably referable to an interaction between Arg47 and the carboxyl 
group of the fatty acid neccessary for the conversion.[89] By mutation of certain 
amino acids the substrate spectrum of CYP BM-3 can be expanded enormously: 
phenylalanine at position 87 (Phe87) for example is located above the heme and 
therefore controlling the access of a substrate to the active site of the enzyme. 
This access can be facilitated by the mutation of Phe87 to the smaller amino acid 
valine (F87V). Another hotspot was found in position 328 which is predicted to 
interact with all substrates during the oxidation process.[48,89-92]  
 
4.1.3 Cytochrome P450 monooxygenases (CYPs): Hydroxylation of different 
substrate classes 
 
Besides its natural substrates, the fatty acids, bacterial CYPs are used to 
hydroxylate different substrate classes: the biotransformation of steroids, for 
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example, is well studied for human CYPs[93] and moreover industrially applied for 
fungal CYPs.[94-97] Due to biotechnological advantages of bacterial CYPs, these 
enzymes arouse the interest of academia and industry.[98-103] One example of a 
bacterial P450 monooxygenase which is able to hydroxylate steroids is CYP106A2 
from B. megaterium ATCC 13368[98-101], that moreover can be coexpressed 
together with bovine AdR and Adx in E. coli to improve activity and stability 
(Scheme 12).[102]  
 
 
Scheme 12. ϭϱβ-hydroxylation of the steroid 11-deoxycorticosterone (36) to 
ϭϱβ-hydroxy-11-deoxycorticosterone (37) by CYP106A2[102] 
Another hydroxylating bacterium, Bacillus stearothermophilus, has been found to 
produce 20α-, 6β- and 6α-hydroxyprogesterone from progesterone (38).[103]  
 
 
Figure 6. Structure of progesterone (38) 
Furthermore hydrocarbons as terpenes and their oxyfunctionalized derivatives, 
the terpenoids[104] can be hydroxylated and make this enzymatic access to the 
higher-valued, oxidized compounds attractive. The scope of applications for 
terpenoids shows a very high diversity for it is used as flavour and fragrance but 
also as a builing block for pharmaceuticals. Using quite affordable bulk terpenes 
as limonene (39) or pinene (40) as precursors (Figure 7), most of the required 
terpenoids are synthesized chemically.[105] The isolation of these compounds resp. 
the essential oils from natural resources is unattractive from an economic point of 
view: the yield referred to the starting plant material is at best only few 
percent.[106] 
 
Figure 7. The terpenes limonene (39) or pinene (40) are used as precursors for the 
chemical synthesis of the required terpenoids[105] 
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The oxidation of alkanes is of particular importance for this work. And even 
though the CYP BM-3 catalyzed oxidation of medium to long chained linear and 
branched alkanes is well described in literature[77-88], this chapter will restrict its 
focus to the biotransformation of cyclic alkanes 1. Only few enzymes are known 
that catalyze the biotransformation of cyclohexane (1a) and the breakdown of 
longer chained cyclic alkanes is yet scarcely analyzed.[107,108] While in the middle of 
the 1990s it was stated that CYP BM-3 is showing no activity referring to 
cyclohexane (1a)[109] more recent findings have led to a revision of this opinion:  
 
ADAM et al. pioneered in 2000, that the cyclic alkanes cyclohexane (1a) and 
cyclooctane (1d) can be hydroxylated by living cells of Bacillus megaterium giving 
the corresponding cycloalcohols cyclohexanol (2a) and cyclooctanol (2d). In this 
study it was also found that overoxidation to the corresponding ketones 3a and 
3d occurs. The influence of the ring size on the oxidative activity was conspicuous, 
since 65% cyclooctanone (3d) were yielded while only 21% cyclohexanone (3a) 
were formed.[110] 
 
In 2002 the ARNOLD group found a CYP BM-3 mutant (139-3) hydroxylating 
cyclohexane (1a) with a maximum turnover rate (mol substrate/min/mol enzyme) 
of 3910 for the mutant CYP BM-3 139-3, which was excellent compared to the 
wild type rate of 151.[111] Even though cyclohexanol (2a) was reported to be the 
sole product of the hydroxylation of cyclohexane (1a) the enzyme activity towards 
the oxidation product cyclohexanol (2a) was analyzed with regard to multiple 
oxidations when oxygen is not limiting. It was found to be 7% relative to 
cyclohexane (1a).[111] In a subsequent work by MAURER et al. in 2005 it was as well 
reported that cyclohexanol (2a) was the single product of all measured mutants in 
a biphasic reaction system, consisting of cyclohexane (1a as substrate and solvent) 
and buffer. In this study a set of CYP 102A1 mutants were screened for activity 
towards cyclohexane (1a) and the highest TTN of 12850 was detected for the 
CYP102A1 mutant R47L Y51F [67] It was as well in the year 2005, when KUBOTA et 
al. published the gene P450balk from the n-alkane-degrading bacterium 
Alcanivorax borkumensis SK2. This gene was fused to the reductase domain of the 
self-sufficient P450 monooxygenase (P450RhF) at the C-terminus and expressed in 
Escherichia coli with the aid of the vector pRED. Living cells of E. coli carrying 
P450balk produced 453 µg/mL cyclohexanol (2a) from cyclohexane (1a).[112] In 
2011, DRONE and co-workers reported for the first time an efficiently coupled 
alkane ω-hydroxylase: CYP153A13a from Alcanivorax borkumensis SK2 artificially 
fused to RhFred and to a histidine affinity tag. In this way the P450 unit is 
equipped with a catalytic efficiency comparable to the construction of CYP BM-3. 
This self-sufficient and soluble enzyme A13red was cloned, expressed in E. coli, 
purified and characterized and then applied among others for the oxidation of 
cyclohexane (1a) with a TTN of 20.[113] In the URLACHER group notable oxidation 
rates (nmol product/nmol P450/min) were obtained with selected CYP BM-3 
mutants determined via GC/MS after 15 min:[108]  
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The double mutant F87A A328V was shown to accept cyclooctane (1d) (oxidation 
rate: 87; conversion: 80%) and the mutant F87V A328F converted cyclooctane 
(1d) as well (oxidation rate: 230; conversion: 75%) as the single mutant A328V 
(oxidation rate: 200; conversion: 87%). Furthermore, for the first time also longer 
chained cyclic alkanes 1 were accepted by these mutants: cyclodecane (1b) was 
oxydized by applying the mutant A328V (oxidation rate: 106; conversion: 53%) 
and even cyclododecane (1c) was converted by the mutant F87A A328V (oxidation 
rate: 18; conversion: 46%) a reaction that is not catalyzed by the wild type CYP 
BM-3 at all.[48,108]  
 
4.1.4 Alternative biocatalysts for the oxyfunctionalization of (cyclic) alkanes 
 
Another group of biocatalyst that is able to oxyfunctionalize alkanes are heme 
peroxydases. One oxygen from H2O2 is used for the oxidation of the substrate and 
water is formed during the reaction (Scheme 13). Most of the peroxydases 
perform a one-electron-transfer instead of a two-electron-transfer and the active 
site is sterically hindered.[104] For that reason only few peroxydases are relevant 
for the oxyfunctionalization of the inert C-H-bond of alkanes but should 
nevertheless not be ignored in a chapter focussing on the biocatalytic oxidation of 
(cyclic) alkanes:[104] 
 
 
Scheme 13. General reaction scheme of heme peroxydases[104] 
For example, an enzyme reviewed by BORDEAUX et al. iŶ①ϮϬϭϮ①as①„the closest to 
ideal biocatalyst for (sub)terminal hydroxylation of short- and medium-chain 
alkaŶes①uŶdeƌ①ŵild①ĐoŶditioŶs①to①date͞[114] was published one year before: [115] In 
2011, PETER et al. reported an extracellular fungal peroxygenase secreted by 
Agrocybe aegerita (AaeUPO) that catalyzes the H2O2-dependent monooxygena-
tion of short chained cyclic alkanes 1 (C5-C8) into the corresponding hydroxylated 
products with a total turnover number of 4501 (Scheme 14).[115]  
 
 
Scheme 14. Hydroxylation catalyzed by the peroxygenase from A. aegerita[115] 
On the one hand this result is markedly below the results found by MAURER et al. 
in 2005 (In this study a set of CYP 102A1 mutants was screened for activity 
towards cyclohexane (1a) and the highest TTN of 12850 was detected for the 
CYP102A1 mutant R47L Y51F[67]). On the other hand the enzyme is incapable of 
hydroxylating the longer chained cyclodecane (1b) - a reaction catalyzed easily by 
different mutants of the CYP BM-3.[108] 
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4.1.5 Application of cofactors regeneration systems 
 
With regard to industrial applications it is important to mention, that 
monooxygenases indeed depend on expensive cofactors like NAD(P)H as electron 
donors which are consumed during the reaction. To avoid the uneconomic and 
stoichiometric application of these cofactors, regeneration systems are employed 
to enable an enzymatic transformation with catalytic amounts of the cofactor. The 
application of a formate dehydrogenase (FDH) represents one of the best and 
most widely used enzyme coupled regeneration systems. Besides this another 
attractive and well known system is the regeneration of the cofactor via a glucose 
dehydrogenase coupled regeneration system (Scheme 15).[28] 
 
 
Scheme 15. Cofactor recycling by the coupled enzyme method with glucose 
dehydrogenase (GDH)[28] 
D-glucose (22) is oxidized by the GDH and D-gluconolactone (23) is formed which is 
spontaneously hydrolyzed whereupon gluconic acid (24) is formed. A subsequent 
neutralization with e.g. sodium hydroxyde forms the corresponding sodium salt of 
the D-gluconic acid (24) and the equilibrium is shifted irreversibly towards the 
product. As a consequence the back reaction can not take place.[28]  
 
 
4.1.6 Spectrophotometric enzyme activity assays with substrates of interest 
 
Prior to a preparative biotransformation it is recommendable to determine the 
enzyme activities of the available enzymes with regard to the substrates of 
interest. Based on an established procedure the enzyme activities are determined 
via an UV/VIS-spectrophotometric assay for NAD(P)H is used as cofactor.[116] 
Herein the consumption of the cofactor NAD(P)H through oxidation to NAD(P)+ 
during the course of the reaction is recorded. The time dependent measurements 
are performed at a wavelength of 340 nm allowing to detect NAD(P)H only. The 
decline in absorption in the presence of the tested enzyme and the substrate of 
interest is plotted as a function of time. By means of the initial slope of the 
absorption curve and the following formula the volumetric enzyme activity can be 
determined.  
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With U/mL = volumetric enzyme activity; ΔE340nm/t = initial slope of the absorption curve, Vt = total 
volume [mL]; f = dilution factor; ɸ = molar extinction coefficient for NAD(P)H [6.3 mL*μmol-1*cm-1]; 
VS = sample volume [mL]; d = path length of the cuvette [cm] 
 
 
This method of measurement is also useful to investigate the kinetics according to 
MICHAELIS-MENTEN of a biotransformation. By means of the MICHAELIS-MENTEN-
equation it is specified, to what extent the reaction rate depends on the substrate 
concentration. Therefore the initial slope v0 of the absorption curve is plotted 
against the various substrate concentrations [S] in mM. In Figure 8, an idealized 
MICHAELIS-MENTEN diagram is shown that can be subdivided into three areas.[117] 
 
 
Figure 8. MICHAELIS-MENTEN diagram subdivided into three areas 
 low substrate concentration: Every substrate molecule can easily bind to an 
enzyme and the reaction rate increases (quasi) linearly by increasing the substrate 
concentration. The reaction rate depends on the substrate concentration.  medium substrate concentration: The substrate molecules start to compete for 
free enzyme.  high substrate concentration: Addition of more substrate has no effect on the 
reaction rate since the enzyme is saturated with substrate. The reaction rate 
depends on the enzyme concentration.  
 
The information derived from the kinetics according to MICHAELIS-MENTEN is of 
particular importance if substrates are poorly soluble in the aqueous reaction 
medium. If, for example, substrate A is highly soluble, the maximum reaction rate 
is approximately reached since the enzyme is saturated with substrate. In 
contrast, a poor water soluble substrate B provides not enough substrate 
molecules in solution to saturate the available enzyme with substrate. The 
approximate maximum reaction rate remains inaccessible (Figure 9).[118] 
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Figure 9. Exemplary MICHAELIS-MENTEN diagram of a highly soluble substrate A 
(left) and a poorly soluble substrate B (right) 
UV/VIS-spectroscopy is a helpful tool to determine the enzyme activity for a 
certain substrate. Especially when substrates are applied that tend to be poorly 
water soluble, this analysis method can be used to analyze if the solubility of a 
certain substrate is high enough to set up an efficient biotransformation. 
 
A preliminary selection of substrates - for various reasons attractive to be 
hydroxylated by cytochrome P450 monooxygenases from Bacillus megaterium 
(CYP BM-3) - is investigated via UV/VIS-spectroscopy to find suitable substrate-
enzyme combinations for subsequent preparative experiments. This preliminary 
selection is explained in the following. From the category monounsaturated cyclic 
hydrocarbons, cyclooctyne (17) and cyclododecene (18) are choosen as possible 
substrates. Cyclooctyne (17) is the smallest cyclic alkyne that is stable at room 
temperature. Since the triple bond shows a severe deformation from the linear 
geometry, cyclooctynes are highly reactive and therefore established as tools in 
bioconjugations. This potential was found by BERTOZZI and coworkers who used 
functionalized cycloalkynes in the strain-promoted alkyne azide cycloaddition 
(SPAAC, the so-called ͞copper-free click chemistry͟Ϳ.[23,24] Various cyclooctyne 
reagents have been designed that react selectively with azide-modified 
biomolecules, consequently probing biomolecules in living systems.[23,24] The 
general principle is shown in Scheme 16. 
 
 
Scheme 16. Reaction of a target protein ● (azide modified) with a cyclooctyne 
derivative (linked to a reporter molecule ●) to lable the target protein 
The oxyfunctionalization of cyclooctyne (17) is therefore preferable. Since the 
biocatalytic oxidation of short chained linear alkynes (C6 and C8) has already been 
reported in literature with productive outcomes,[119] it can be supposed that cyclic 
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alkynes are as well accepted as substrates. Cyclododecene (18), the second 
chosen monounsaturated cyclic hydrocarbon is a versatile chemical intermediate 
for organic synthesis in general and for that reason it is aligned in the array of 
products at EVONIK.[120] Compounds with a wood-like scent are synthesized from 
18, making this intermediate interesting for the fragrance industry. Quite often 
the desired target molecules are obtained by the oxidation of 18 making a 
biocatalytic oxidation to an attractive alternative synthesis route.[120] 
 
Furthermore, different cytochrome P450 monooxygenases from Bacillus 
megaterium (CYP BM-3) are analyzed with regard to their capability to convert 
pentanal (19). The aldehyde 19 can be synthesized from easily available 1-butene 
(41) via hydroformylation and therefore is an easily accessible starting material 
for the synthesis of valuable specialty chemicals.[121] In this work, the 
hydroxylation of pentanal (19) is supposed to be realized by a monooxygenase-
catalyzed functionalization using molecular oxygen as oxidant to give the 
corresponding hydroxypentanals 42 resp. 43, that should readily cyclize yielding 
the corresponding lactols 44 resp. 45. The subsequent oxidation of the lactols 44 
and 45 to synthesize the desired lactones, -valerolactone (20) and 
ɷ-valerolactone (21) should be performed by a dehydrogenase since this type of 
reaction is already reported in literature.[122,123] The planned synthesis of -valero-
lactone (20) and ɷ-valerolactone (21) from pentanal (19) is shown in Scheme 17.  
 
 
Scheme 17. Planned synthesis of -valerolactone (20) and ɷ-valerolactone (21) 
from pentanal (19) 
Due to its olfactory qualities, -valerolactone (20) is used in the flavour and 
fragrance industry.[26] ɷ-Valerolactone (21) in contrast is applied in the synthesis 
of polymers (polyesters) and therefore for the production of lacquers and 
colours.[27] Altogether it is worthwhile to investigate pentanal (19) with respect to 
a biotransformation to gain access to valuable precursors.  
 
The last category to be tested is the class of cyclic alkanes 1 which play an 
extraordinary role as feedstock for the production of polyamides. Cycloalkanes 1 
from petroleum are oxidized to a mixture of corresponding cycloalkanols 2 and 
cycloalkanones 3.  
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This procedure is of particular economic importance since these compounds serve 
as industrial feedstock for the synthesis of bulk products. Cyclohexanone (3a) for 
example serves as starting compound for the sǇŶthesis①of①ɛ-caprolactam (46) that 
is applied for the synthesis of the polyamide nylon-6 (5) (Scheme 18). In 2010, the 
ǁoƌldǁide① pƌoduĐtioŶ① of① ɛ-caprolactam (46) was 4 million metric tons per year 
(Mt/a),[124] making the enzymatic synthesis of cyclohexanone (3a) attractive with 
regard to alternative synthesis routes. 
 
 
Scheme 18. Synthesis of the polyamide nylon-6 (5) from cyclohexanone (3a) 
Higher homologue cycloalkanes 1 are oxidized in the presence of boric acid and 
molecular oxygen - a process called BASHKIROV process - and a subsequent catalytic 
dehydration provides access to the corresponding cycloalkanones 3.[7-12] An 
industrial important cycloalkanone which is widely used in industry is cyclodode-
canone (3c), that is applied for the synthesis of nylon-12 (7) via laurinlactam (47) 
and the synthesis of nylon-6,12 (48) via dodecanedioic acid (49). Besides its role 
as feedstock for the polyamide production, cyclododecanone (3c) is applied in 
syntheses of musk fragrances (Scheme 19).[106,120] 
 
 
Scheme 19. Cyclododecanone (3c) is a versatile starting material for the synthesis 
of valuable products 
It is generally known that cyclic alkanes 1 are accepted and converted by 
cytochrome P450 monooxygenases yielding the corresponding oxidation 
products.[67,107-113] Recently, in the interesting field of cycloalkane oxidation a 
pioneering enzymatic two-step one-pot process was described by BURDA that 
basically can be applied for the synthesis of cyclic ketones 3. The direct synthesis 
of cycloalkanones 3 from the corresponding cycloalkanes 1 is based on the 
cooperation of two enzymes: The introductory step of this process is the CYP 
BM 3 catalyzed hydroxylation reaction followed by an alcohol dehydrogenase 
catalyzed oxidation of the in situ formed alkanol 2 giving the corresponding 
alkanone 3. The general reaction scheme is shown below.[20]  
 
HYDROXYLATION WITH CYTOCHROME P450 MONOOXYGENASES FROM B. MEGATERIUM | 37 
 
 
Scheme 20. General reaction scheme of the biocatalyzed double oxidation 
Furthermore STAUDT analyzed mixtures of the substrate cyclooctane (1d) and the 
product cyclooctanone (3d) in the aqueous reaction medium and established a 
working up procedure based on the removal of the solvent in vacuo (900 mbar) 
and the determination of the absolute amount of the cycloalkanone 3 as 
productivity (g/L) of the reaction. Pyridine (25) was applied as external standard 
to analyze the crude product via 1H-NMR-spectroscopy.[21,22] Both, BURDA and 
STAUDT used catalytic amounts of 2-propanol as additive to increase the 
productivity and enable the application of the more cost-effective cofactor in its 
oxidized form (NADP+) since the required reduced form of the cofactor (NADPH) is 
generated in the course of the ADH-catalyzed oxidation of 2-propanol yielding 
acetone.[20-22] A productivity of 0.80 g/L cyclooctanone (3d) was obtained by using 
the mutant CYP BM-3 19A12 in combination with the above-mentioned ADH from 
Lactobacillus kefir (LK-ADH) for the conversion of 100 mM cyclooctane (1d) in 
phosphate buffer.[22] 
 
Due to the qualities as building blocks for the synthesis of variable products, the 
oxyfunctionalization of further cycloalkanes 1 is highly preferable. Since this 
biocatalyzed double oxidation was analyzed for cyclooctane (1d) by STAUDT, the 
transfer of this procedure should be realized applying the substrates cyclohexane 
(1a), cyclodecane (1b) and cyclododecane (1c). Moreover, the challenge is to 
investigate more potentially active mutants of the cytochrome P450 monooxy-
genase (CYP BM-3) from Bacillus megaterium for this worthwhile hydroxylation of 
cyclic alkanes 1. In order to avoid the application of pyridine (25) as external 
standard, the removal of the solvent at exact 900 mbar and the analysis via 
1H-NMR-spectroscopy, a GC-based analysis is planned to be established since this 
method is more reliable and even more economic.  
 
4.2 Results and discussion 
4.2.1 Spectrophotometric enzyme activity studies 
 
Spectrophotometric assays were conducted since this is a current method to 
determine the specific activity in U/g lyophilized crude extract for the respective 
enzyme-substrate combinations. However, in the case of cytochrome P450 
monooxygenases this practice provides indications but can not be used to derive 
absolute data concerning the product formation.  
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The reason is that these enzymes have a reputation for showing deviation 
between the consumption of the cofactor NAD(P)H and formation of the product 
or more precisely, consuming cofactor without oxidizing the substrate.[62-65] 
Altogether three additional shunt pathways are known to occur at different 
moments of the catalytic cycle and all three additional pathways (shunts) have in 
common that the consumption of the cofactor is decoupled from the substrate 
oxidation as such, since the electrons are used elsewhere. This phenomenon of 
uncoupling was described in detail earlier (4.1.1). 
 
The measurements to determine the enzyme activities with an UV/VIS-
spectrophotometer were conducted always at least in a twofold determination 
with the result that for every measurement the average of a twofold dataset is 
calculated. The content of CYP [nmol resp. µmol/g lyophilized crude extract] was 
determined via CO-difference spectroscopy by the research group Prof. Dr. U. 
Schwaneberg (RWTH Aachen) and is summarized in Table 9.  
 
Table 9. Content of CYP BM-3 determined via CO-difference spectroscopy 
Entry 
Enzyme lot  
of the cytochrome P450 
monooxygenase from Bacillus 
megaterium
a)
  
Content of CYP  
[μmol/g lyophilized crude extract] 
1 CYP BM-3 19A12 (0) 0.123  
2 CYP BM-3 19A12 (1) 0.060  
3  CYP BM-3 19A12 (2) 0.120  
4 CYP BM-3 19A12 (3) 0.115  
5 CYP BM-3 F87A A328V (1) 0.480 
6 CYP BM-3 F87A A328V (2) 0.989 
7 CYP BM-3 F87P (1) 0.235 
8 CYP BM-3 F87P (2) 0.223 
9 CYP BM-3 R255P-P329H 0.220  
10 CYP BM-3 F87V 0.525 
11 CYP BM-3 WT 1.260  
a)In parentheses the different enzyme formulations are given. 
 
On the basis of this data, the content of CYP [µmol/g lyophilized crude extract] 
and the subsequent determined specific activity [U/g lyophilized crude extract], 
the turnover frequency (TOF) [min-1] is calculated according to the following 
formula. 
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Cyclododecene (18) was analyzed as a possible substrate from the category 
monounsaturated cyclic hydrocarbons in an enzyme activity test. The following 
mutants of the cytochrome P450 monooxygenase from Bacillus megaterium 
(CYP BM-3) were tested: CYP BM-3 19A12 (1), CYP BM-3 F87P (2), CYP BM-3 F87V, 
CYP BM-3 F87A A328V (2), CYP BM-3 WT and CYP BM-3 R255P-P329H (SOP 4). In 
Figure 10, the specific activity in U/g lyophilized crude extract is plotted against 
the respective mutant.  
 
 
Figure 10. Results of the enzyme activity test with cyclododecene (18) as 
substrate 
As apparent from Figure 10, the mutants CYP BM-3 F87P (2) and CYP BM-3 F87A 
A328V (2) turned out to be most promising for preparative biotransformations. 
For the mutant CYP BM-3 F87P a specific activity of 40 U/g was found and with 
the CYP-content of 0.223 µmol/g in the lyophilized crude extract, a TOF of 
179 min-1 was calculated. For CYP BM-3 F87A A328V, as well a specific activity of 
40 U/g was found and with the CYP-content of 0.989 µmol/g in the lyophilized 
crude extract, a TOF of 40 min-1 was obtained. 
 
The next substrate, cyclooctyne (17) was first synthesized from cyclooctene (50) 
according to a two-stage procedure reported in literature[125] via the intermediate 
1-bromocyclooctene (51).[125-126] Then it was analyzed as a second possible 
substrate from the category monounsaturated cyclic hydrocarbons in an enzyme 
activity test with the mutants CYP BM-3 F87P (2) and CYP BM-3 F87A A328V (2) of 
the cytochrome P450 monooxygenase from Bacillus megaterium (SOP 4). Both 
mutants showed no activity and therefore the intention to apply cyclooctyne (17) 
in a preparative biotransformation was dropped. 
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Furthermore, different cytochrome P450 monooxygenases from Bacillus 
megaterium (CYP BM-3) were analyzed with regard to their capability to convert 
pentanal (19). Since the tendency of aldehydes to undergo oxidation by simply 
stirring their aqueous emulsions in air to give the corresponding carboxylic acids 
in high yields recently was described in literature[127] the stability of pentanal (19) 
in water was investigated over the time. Therefore a mixture of pentanal (19) in 
D2O was stirred for 0 - 24 h and analyzed via 
1H-NMR-spectroscopy at different 
reaction times. The formation of the corresponding carboxylic acid was found to 
be very small at an extent of 5.4% on average, identified on the basis of the 
characteristic triplet caused by the two Cα-protons at 2.2 ppm. The following 
mutants of a cytochrome P450 monooxygenase from Bacillus megaterium 
(CYP BM-3) were tested: CYP BM-3 F87A A328V (2), CYP BM-3 F87P (2), CYP BM-3 
19A12 (2), CYP BM-3 F87V, CYP BM-3 R255P P329H and CYP BM-3 WT (SOP 4). In 
Figure 11, the specific activity in U/g lyophilized crude extract is plotted against 
the respective mutant. 
 
 
 
 
Figure 11. Results of the enzyme activity test with CYP BM-3 and pentanal (19) 
As apparent from Figure 11, the mutants CYP BM-3 F87P (2) and CYP BM-3 19A12 
(2) are most promising for a preparative biotransformation. For the mutant CYP 
BM-3 F87P a specific activity of 21 U/g was found and with the CYP-content of 
0.223 µmol/g in the lyophilized crude extract, a TOF of 94 min-1 was calculated.  
For CYP BM-3 19A12 (2), a specific activity of 29 U/g was found and with the CYP-
content of 0.120 µmol/g in the lyophilized crude extract, a TOF of 242 min-1 was 
calculated. 
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Different mutants of the cytochrome P450 monooxygenase from Bacillus 
megaterium (CYP BM-3 19A12 (formulation 0-3), CYP BM-3 F87P (1-2), CYP BM-3  
F87V, CYP BM-3  WT, CYP BM-3  R255P-P329H, CYP BM-3 F87A A328V (1-2)) were 
analyzed at different times to transform cyclododecane (1c) into the 
corresponding cyclododecanol (2c) (SOP 4). In Figure 12, the specific activity in 
U/g lyophilized crude extract is plotted against the respective mutant. 
 
 
 
Figure 12. Results of the enzyme activity test with cyclododecane (1c) as 
substrate. Repetitions are referred to multiple measurements of individual 
enzyme lots during the project term. In that case, the more recent the measured 
value, the further right it is placed on the x-axis. A decrease in activity over the 
course of time can be ascribed to a loss in stability of the enzyme lot during long-
term storage. 
It is noticable from Figure 12, that only the mutants CYP BM-3 F87P and CYP BM-3 
F87A A328V showed an activity in converting the substrate 1c, while all other 
mutants showed no or only poor activity. Therefore these mutants are most 
promising for a preparative biotransformation. For the mutant CYP BM-3 F87P a 
specific activity of 52 U/g and later 34 U/g was found and with the CYP-content of 
0.235 µmol/g in the lyophilized crude extract, a TOF of 221 resp. 145 min-1 was 
calculated. For CYP BM-3 F87A A328V (1), a specific activity of 15 U/g was found 
and with the CYP-content of 0.480 µmol/g in the lyophilized crude extract, a TOF 
of 31 min-1 was calculated. With a new formulation of CYP BM-3 F87A A328V (2), 
27 U/g and a TOF of 27 min-1 was obtained. However, in the presence of higher 
concentrations of DMSO (F87A A328V (2)* in Figure 12) the specific activity and 
therefore the turn over frequency (TOF) is lowered noticable.  
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Different mutants of the cytochrome P450 monooxygenase from Bacillus 
megaterium (CYP BM-3 19A12 (formulation 0-3), CYP BM-3 F87P (1), CYP BM-3 
F87V, CYP BM-3 WT, CYP BM-3 R255P-P329H, CYP BM-3  F87A A328V (1)) and 
empty vector E.coli BL21 as blank were analyzed at different times in the course of 
this project with respect to their ability to transform cyclodecane (1b) into the 
corresponding cyclodecanol (2b) (SOP 4). In Figure 13, the specific activity in U/g 
lyophilized crude extract is plotted against the respective mutant. 
 
 
 
 
Figure 13. Results of the enzyme activity test with cyclodecane (1b) as substrate. 
Repetitions are referred to multiple measurements of individual enzyme lots 
during the project term. In that case, the more recent the measured value, the 
further right it is placed on the x-axis. A decrease in activity over the course of 
time can be ascribed to a loss in stability of the enzyme lot during long-term 
storage. 
It is noticable from Figure 13, that all available formulations of the mutant CYP 
BM-3 19A12 showed the best specific activity for cyclodecane (1b) by far (39-
56 U/g; TOFs of 317-850 min-1) and therefore this mutant was preferred for 
preparative experiments with this substrate. One of the later performed tests 
manifests the mutant CYP BM-3 F87P (1) as well as a promising mutant for the 
conversion of cyclodecane (1b). A specific activity of 76 U/g was found but with 
the CYP-content of 0.235 µmol/g in the lyophilized crude extract, a turn over 
frequency of 323 min-1 was calculated. 
 
Different mutants of the cytochrome P450 monooxygenase from Bacillus 
megaterium (CYP BM-3 19A12 (formulation 0-3), CYP BM-3 F87P (1), CYP BM-3 
F87V, CYP BM-3 WT, CYP BM-3 R255P-P329H, CYP BM-3 F87A A328V (1)) and 
empty vector E.coli BL21 as blank were analyzed at different times in the course of 
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this project with respect to their ability to transform cyclohexane (1a) into the 
corresponding cyclohexanol (1b). In Figure 14, the specific activity in U/g 
lyophilized crude extract is plotted against the respective mutant. 
 
 
 
 
 
Figure 14. Results of the enzyme activity test with cyclohexane (1a) as substrate. 
Repetitions are referred to multiple measurements of individual enzyme lots 
during the project term. In that case, the more recent the measured value, the 
further right it is placed on the x-axis. A decrease in activity over the course of 
time can be ascribed to a loss in stability of the enzyme lot during long-term 
storage. 
As already with the substrate cyclodecane (1b), the mutant CYP BM-3 19A12 was 
by far the best enzyme to catalyze the oxidation of cyclohexane (1a). Moreover, 
this mutant emerged to be the one of choice for the whole project. Without 
exception, all other tested enzymes lag far behind this remarkable activity. For the 
formulation CYP BM-3 19A12 (0), a specific activity of 146 U/g was found and with 
the CYP-content of 0.123 µmol/g in the lyophilized crude extract, a TOF of 
1187 min-1 was calculated. The formulations CYP BM-3 19A12 (1) (131 U/g; TOF = 
2183 min-1), CYP BM-3 19A12 (2) (161 U/g; TOF = 1342 min-1) and CYP BM-3 19A12 
(3) (134 U/g; TOF = 1165 min-1) were at the same promising range and therefore 
CYP BM-3 19A12 was used extensively for preparative experiments. 
 
Moreover, UV/VIS-spectroscopy was used to investigate the kinetics according to 
MICHAELIS-MENTEN of a biotransformation and by the MICHAELIS-MENTEN-equation it 
was specified, to what extent the reaction rate depends on the substrate 
concentration. This information is of particular importance if substrates are poorly 
soluble in the aqueous reaction medium.  
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Since the log P value of cyclododecane (1c) is 6.6[128] - exemplarily for the higher 
homologue cycloalkanes - this compound is known to show a very poor solubility 
in water. Therefore it has to be analyzed if the effective solubility of a certain 
substrate, e.g. cyclododecane (1c) is high enough for an efficient 
biotransformation: if not enough substrate molecules are in solution to saturate 
the available enzyme with substrate, the approximate maximum reaction rate 
remains inaccessible. To analyze this parameter, a serial dilution of 1c in DMSO 
was prepared from a stock solution (0.5-16 mM). The concentration of the 
saturated solution (~16 mM) was identified via 1H-NMR-spectroscopy using pivalic 
acid (52) as standard. A set of serial dilution (16 mM, 12 mM, 8 mM, 4 mM, 2 mM, 
1 mM, 0.5 mM) was prepared to measure the following absolute concentrations 
in a photometric assay: 160 µM, 120 µM, 80 µM, 40 µM, 20 µM, 10 µM and 5 µM. 
A 0.6 mM solution of NAD(P)H was used for the measurements (SOP 5). In this 
way the kinetics according to MICHAELIS-MENTEN of the cyclododecanol (2c)-
formation were determined via an enzyme activity test with the cytochrome P450 
monooxygenase mutant from Bacillus megaterium (CYP BM-3 F87A A328V) 
(solution of the lyophilisate: 10 mg/mL, NAD(P)H-dependent, phosphate buffer: 
pH 7.0, 50 mM) and cyclododecane (1c) as substrate (Figure 15). 
 
 
 
 
 
Figure 15. Results of the enzyme activity test with cyclododecane (1c) as substrate 
combined in a MICHAELIS-MENTEN diagram of the biocatalyzed hydroxylation 
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As it is apparent from Figure 15, the substrate molecules in solution are entirely 
sufficient so that the enzyme is working at full capacity. Adding more substrate 
would not affect the reaction rate since the enzyme is already saturated with 
substrate at the given concentration.  
 
To make a statement about the stability of CYP BM-3 F87A A328V, the enzyme 
activity of CYP BM-3 F87A A328V to convert the substrate 1c to the corresponding 
product 2c is investigated as a function of time. Therefore the cytochrome P450 
monooxygenase mutant from Bacillus megaterium (CYP BM-3 F87A A328V) was 
stirred in the presence of 0.02 mmol D-glucose (22) and DMSO (10% v/v) in 
phosphate buffer (pH 7.0, 50 mM) and samples are taken at (regular) intervals 
over a period of 28h (SOP 6). These samples were analyzed via UV/VIS-
spectroscopy and the initial slope of the absorption curve v0 [1/min] was plotted 
against the time [h] (Figure 16). 
 
 
 
Figure 16. Stability of CYP BM-3 F87A A328V as a function of time 
It is apparent from Figure 16 that a reaction time of 28h and even the presence of 
DMSO (10% v/v) in the reaction mixture have no severe negative effect on the 
stability and therefore the enzyme activity of mutant CYP BM-3 F87A A328V. Of 
course a theoretical inhibition of the enzyme by product formation or 
denaturation of the enzyme through long contact with the substrate or product is 
not considered with this test.  
 
0
0.01
0.02
0.03
0.04
0.05
0.06
0.07
0.08
0.09
0.1
0 5 10 15 20 25 30
In
it
ia
l s
lo
p
e 
v 0
 [
1/
m
in
] 
time [h] 
Initial slope V0 [E/min]
Linear (Initial slope V0 [E/min])
I itial slope v  [1/ i ] 
 
i r (I itial sl pe v  [1/ i ]) 
46 | HYDROXYLATION WITH CYTOCHROME P450 MONOOXYGENASES FROM B. MEGATERIUM 
 
4.2.2 Biocatalyzed oxidation of monounsaturated cyclic hydrocarbons with 
different CYP BM-3 and glucose dehydrogenase (GDH) 
 
Cyclododecene (18) 
  
C-C multiple bonds in unsaturated hydrocarbons lag far behind the single bonds in 
saturated hydrocarbons regarding stability and are therefore more easily 
attacked.[76] Cyclododecene (18), a valuable intermediate for e.g. the synthesis of 
parfumes and fragrances,[25] was tested as agent of this class of substrates with 
different mutants of the cytochrome P450 monooxygenases from Bacillus 
megaterium.  
 
 
Scheme 21. Anticipated enzymatic oxidation of Cyclododecene (18) 
The promising mutants which were detected in the enzyme activity test with the 
unsaturated cyclic hydrocarbon cyclododecene (18) as substrate were the 
mutants CYP BM-3 F87P (2) and CYP BM-3 F87A A328V (2) (SOP 4). The specific 
activities of CYP BM-3 F87P (40 U/g) and CYP BM-3 F87A A328V (40 U/g) are in a 
range worthy to test and therefore those two mutants are applied in a 
preparative biocatalyzed oxidation. The formation of an oxidation product was 
not detected via 1H-NMR-spectroscopy, neither with CYP BM-3 F87P nor with 
CYP BM-3 F87A A328V (by comparison with the 1H-NMR-spectra of 18), that 
means that cyclododedene (18) was neither converted by CYP BM-3 F87P nor by 
CYP BM-3 F87A A328V. The activity detected in the enzyme activity test can be 
attributed to an undefined background reaction consuming the cofactor NADPH 
resp. uncoupling in general.  
 
4.2.3 Biocatalyzed oxidation of pentanal (19) with different CYP BM-3 and 
glucose dehydrogenase (GDH) 
 
 
Scheme 22. Anticipated enzymatic oxidation of pentanal (19) 
HYDROXYLATION WITH CYTOCHROME P450 MONOOXYGENASES FROM B. MEGATERIUM | 47 
 
The cytochrome P450 monooxygenase from Bacillus megaterium CYP BM-3 19A12 
(2) was expected to be suitable for an enzymatic oxidation of pentanal (19) 
because its specific activity (29 U/g) was the highest activity found in these 
enzyme activity tests (SOP 4). Therefore this mutant is applied in a preparative 
enzymatic transformation (Scheme 22). 
 
 
Scheme 23. Biocatalyzed reduction of pentanal (19) yielding 1-pentanol (53) 
 
 
Figure 17. Results of the enzymatic oxidation of pentanal (19) (red, above), 
biotransformation of pentanal (19) (blue, middle) and biotransformation sample 
after addition of the assumed product 1-pentanol (53) 
Compared to the 1H-NMR spectrum of pentanal (19) (red, above), the 1H-NMR 
spectrum of the biocatalytic transformation with CYP BM-3 19A12 (blue, middle) 
showed a clear modification (Figure 17). Especially the triplet that appears at 
3.58 ppm indicates the formation of a new compound. The addition of the 
assumed product 1-pentanol (53) to the biotransformation sample (1H-NMR 
spectrum in green, below) confirms the assumption, that not the oxidation 
reaction takes place but the reduction of pentanal (19) to the corresponding 
alcohol 53 occurs (Figure 17). The most obvious explanation for this phenomenon 
is an undesired background activity caused by an alcohol dehydrogenase from the 
host organism E. coli, operating in the reductive direction (Scheme 23). 
19 
53 
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4.2.4 Biocatalyzed hydroxylation of higher homologous cycloalkanes with 
different CYP BM-3 and glucose dehydrogenase (GDH) 
 
Cyclododecane (1c)  
 
The mutants CYP BM-3 F87P and CYP BM-3 F87A A328V seemed to be very 
promising for the conversion of the substrate cyclododecane (1c) (TOF of 145 
resp. 31 min-1) in an initial enzyme activity test (SOP 4). Therefore the preparative 
hydroxylation of 1c with 0.762 U of the mutant CYP BM-3 F87A A328V was carried 
out first. All experiments were conducted by varying the following parameters: 
Concentration of the substrate 1c, concentration of the cofactor, volume of the 
cosolvent DMSO and reaction time. In addition, the absence of the cofactor 
regeneration system was analyzed (Scheme 24). Despite a scientifically supported 
confidence especially for the double mutant CYP BM-3 F87A A328V, which is 
known to convert even the long chained cyclic alkane cyclododecane (1c),[108] in 
most experiments the conversion of cyclododecane (1c) to cyclododecanol (2c) 
was below 1% and the results could not be reproduced (SOP 9). Probably one of 
the most obvious reasons why WEBER et al. found conversion in their experiments 
is the comparatively low substrate concentration of 200 µM while in the 
experiments shown below substrate concentrations up to 0.1 M were applied.[108] 
 
 
Scheme 24. Biocatalyzed hydroxylation of cyclododecane (1c) 
A series of experiments with different CYP BM-3, mainly CYP BM-3 F87P was 
conducted with the result that the formation of cyclododecanol 2c was below 
5 mg/L and conversion could not be determined. For the sake of completeness 
experiments with all spectrophotometrically inactive mutants were carried out 
with exemplarily 50 mg of the respective mutant to ensure that no active mutant 
is missed. But in all experiments the formation of cyclododecanol 2c was below 
5 mg/L and conversion was always below 1% (SOP 9). 
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In summary it can be stated that there was a very low acceptance of all tested 
mutants towards the substrate cyclododecane (1c) in the preparative experiments 
although activity was shown in an initial enzyme activity test. This activity may be 
caused from another NADPH-consuming background reaction because crude 
extract is used for both, the enzyme activity test and the preparative experiments. 
The fact that cyclododecane (1c) is hardly soluble in the aqueous phase could be 
another reason for the biotransformation did not work. Compared to other 
analyzed liquid substrates the additional lattice energy of the molecular crystal 
has to be overcome in that case and it is not surprising that the solubility of the 
unpolar 1c in the aqueous phase is quite poor.  
 
The corresponding alcohols 2 formed during the biotransformation are 
notoriously not as stable and inert as the substrate alkanes 1[76] and for this 
reason the further oxidation of the alcohol 2 can not be excluded. For example, it 
is supposed that the sesquiterpene (+)-valencene (54) has multiple binding 
orientations in CYP BM-3 and therefore - besides the favoured (+)-nootkatone 
(55) - several further oxidation products are formed.[129] In 2000, ADAM et al. 
showed, that cyclohexane (1a) and cyclooctane (1d) can be hydroxylated by living 
cells of Bacillus megaterium giving the corresponding cycloalcohols cyclohexanol 
(2a) and cyclooctanol (2d). In this study it was additionally found that 
overoxidation to the corresponding ketones 3a and 3d takes place. The influence 
of the ring size on the oxidative activity was conspicuous, since 65% 
cyclooctanone (3d) were yielded while only 21% cyclohexanone (3a) were 
formed.[110] Therefore the hydroxylation of cyclohexane (1a) and cyclodecane (1b) 
is realized and for that reason analyzed with regard to a possible further 
oxidation. 
 
Cyclodecane (1b)  
 
Scheme 25. Results of the oxidation of cyclodecane (1b) with CYP BM-3 19A12 
(SOP 10) 
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The cytochrome P450 monooxygenase from Bacillus megaterium CYP BM-3 19A12 
is expected to be suitable for an enzymatic oxidation of 1b. The specific activity of 
CYP BM-3 19A12 was significantly higher than all other mutants (39-56 U/g; TOFs 
of 317-850 min-1, SOP 4) and therefore this mutant is applied in a preparative 
enzymatic transformation (Scheme 25). The content of CYP BM-3 19A12 (2) 
amounts to 0.120 μmol/g lyophilized crude extract. 
 
In the experiment shown in Scheme 25, 7.65 mg of the substrate 1b were 
recovered and as a product of further oxidation cyclodecanone (3b) was found 
(0.08 mg). The product formation of 2b was 0.15 mg. 
 
Cyclohexane (1a)  
 
The cytochrome P450 monooxygenase from Bacillus megaterium CYP BM-3 19A12 
was by far the best enzyme to catalyze the oxidation of cyclohexane (1a) and 
specific activities up to 161 U/g were found.  Therefore this mutant is applied in a 
preparative enzymatic transformation (Scheme 26). The content of CYP BM-3 
19A12 (2) amounts to 0.120 μmol/g lyophilized crude extract. 
 
Scheme 26. Results of the oxidation of cyclohexane (1a) with CYP BM-3 19A12 
(SOP 10) 
In the experiment shown in Scheme 26, 0.89 mg substrate 1a were recovered and 
as a product of further oxidation cyclohexanone (3a) was found (0.08 mg). In all, 
1.33 mg of the product 2a were formed. It can be summarized that the double 
oxidation induced by CYP BM-3 can be detected for both substrates, cyclohexane 
(1a) and cyclodecane (1b). However, it plays a major role for cyclodecane( 1b).  
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5 Double oxidation combining a cytochrome P450 
monooxygenase from B. megaterium and an 
alcohol dehydrogenase from L. kefir in an one-
pot process 
5.1 Introduction, state of the art, and aim of this section 
 
Since a whole chapter is already focused on the first step of the planned double 
oxidation, namely the cytochrome P450 monooxygenase catalyzed hydroxylation 
(chapter 4), the key aspect of this chapter is the oxidation of the alcohol 2 to the 
corres-ponding ketone 3, catalyzed by an alcohol dehydrogenase from 
Lactobacillus kefir, which is highlighted in Scheme 27. 
 
 
Scheme 27. Double oxidation of cycloalkanes 1 with ADH-catalyzed step 
Alcohol dehydrogenases (ADHs) occur in all domains of life.[19] In humans, for 
example, ADHs are found in high concentrations in liver and stomach, catalyzing 
the oxidative degradation of toxic alcohols (Scheme 28, left).[130] In yeast, the last 
step of the alcoholic fermentation is the ADH-mediated transformation of 
acetaldehyd (56) yielding ethanol (57) (Scheme 28, right).[131] 
 
 
Scheme 28. Details of A) the degradation of alcohol in humans[130] and B) the 
alcoholic fermentation in yeast cells[131] 
In the field of organic chemistry, the ketoreductase function of alcohol 
dehydrogenases is often used to generate a stereogenic center and therefore a 
valuable structural motif. Three impressive examples for the application of ADHs 
on an industrial scale are shown below:[132] 
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The first example is the synthesis of the (4S,6S)-hydroxysulfone ((4S,6S)-58) 
performed at AstraZeneca which serves as an intermediate in the synthesis of 
Tƌusopt™,① a① dƌug① foƌ① the① tƌeatŵeŶt① of① glauĐoŵa.① “uspeŶded① ǁhole① Đells① aƌe①
applied in aqueous medium to produce (4S,6S)-58 from the methyl ketosulfone 
((6S)-59) on a multi ton scale with a yield of >85% and >98% ee (Scheme 29).[132]  
 
 
Scheme 29. Selected step of the synthesis①ƌoute①foƌ①the①dƌug①Tƌusopt™ 
A further example is a selected step in the synthesis of LY 300164, an orally 
administered benzodiazepine produced by Eli Lilly and Company. Suspended 
whole cells are applied in aqueous medium to produce the precursor (S)-60 from 
3,4-methylenedioxyphenylacetone (61) on a kilogram scale with a yield of 96% 
and >99.9% ee (Scheme 30).[132] 
 
 
Scheme 30. Selected step of the synthesis route for the drug LY 300164 
The next biocatalytic synthesis is performed at Wacker Chemie. A crude enzyme 
solution of alcohol dehydrogenase from Lactobacillus brevis is applied in aqueous 
medium to produce (R)-ethyl-3-hydroxybutyrate ((R)-62) from ethyl acetoacetate 
(63) on a scale of 35 t/a with a yield of 96% and >99.8% ee. The coproduct 
acetone which is formed during the regeneration of the cofactor is continuously 
stripped to shift the reactions equilibrium to the product site. (Scheme 31).[132] 
 
 
Scheme 31. Selected step of the synthesis route of (R)-62 
 
As apparent from the example shown in Scheme 31, one single enzyme (alcohol 
dehydrogenase from Lactobacillus brevis) catalyzes both, the desired biotrans-
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formation as well as the biotransformation of the auxiliary substrate 2-propanol. 
This coupled substrate process is one possibility for the recycling of the high 
priced cofactor to its reduced form.  
 
Another approach is a coupled enzyme method where two different enzymes (E1 
and E2) are applied, one (E1) for the formation of the product of interest and 
another (E2) for the recycling of the cofactor (Scheme 32).[28]  
 
 
Scheme 32. Coupled-enzyme method for cofactor recycling 
The application of ADHs is described in literature for the transformation of the 
main product[133] but also for its function in cofactor recycling: besides other well-
known systems for recycling of the cofactor (E2 = Formate dehydrogenase (FDH); 
AS = formate; SSP = CO2 resp. E2 = Glucose dehydrogenase (GDH); AS = glucose; 
SSP = gluconic acid), alcohol dehydrogenases are as well established in the 
coupled method for cofactor recycling.[28] These applications make clear that the 
oxidative direction of ADHs is as well important for designing enzyme reactions 
and should not be disregarded. Nevertheless, the capability of these enzymes to 
catalyze oxidation reactions as well is often outshined by the corresponding and 
above-mentioned reduction reactions.[28,104] 
 
Some generally accepted reasons for the fact that dehydrogenase-mediated 
oxidation reactions attach less importance than the corresponding reduction 
reactions are outlined below. In the course of oxidation of an unsymmetric 
secondary alcohol a chiral center - generally valuable for synthetic applications - is 
destroyed.[28] Furthermore, aldehydes and ketones tend to bind more tightly to 
the hydrophobic active site of the dehydrogenase than the employed alcohols and 
product inhibition might be a result hereof.[28] In addition, oxidation reactions  of 
primary and secondary alcohols that depend on the cofactor NAD(P)+ are 
thermodynamically unfavoured (ethanol/acetaldehyde: -199 mV; 2-propanol/ace-
tone: -286 mV) since the redox couple NAD(P)H/NAD(P)+ has a redox potential 
of -320 mV.[28,104] Despite these drawbacks, alcohol dehydrogenases are the most 
popular biocatalysts for the oxidation of alcohol substrates (Scheme 33).[19,104] 
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Scheme 33. General reaction equation of the ADH-catalyzed oxidation of 
alcohols[19,104] 
The alcohol dehydrogenase isolated from horse liver (HLADH) for example is one 
of the first enzymes applied in organic syntheses and therefore very well 
characterized.[134] HLADH shows an (S)-enantioselectivity and is successfully 
applied in oxidation reactions for enzymatic kinetic resolution of alcohols. A 
prominent example is the HLADH-catalyzed enantioselective dehydrogenation of 
racemic β-hydroxysilanes (rac)-64. One enantiomer (R)-64 remains untouched 
while the other is converted into the corresponding β-ketosilane (S)-65, that 
hydrolyzes spontaneously and promotes the regeneration of the cofactor 
(Scheme 34).[135] 
 
 
Scheme 34. KinetiĐ①ƌesolutioŶ①of①ƌaĐeŵiĐ①β-hydroxysilane (rac)-64 [135] 
A further example was reported in 2006 when a secondary ADH from 
Rhodococcus ruber DSM 44541 (ADH-A) was found to catalyze the desymmet-
risation of meso-2,5-hexanediol (66) yielding (R)-5-hydroxy-2-hexanone ((R)-67) 
(Scheme 35).[19,136] 
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Scheme 35. ADH-A catalyzed desymmetrisation of meso-2,5-hexanediol (66) 
yielding (R)-5-hydroxy-2-hexanone ((R)-67)[19,136] 
The simplified mechanism of oxidations catalyzed by NADP(P)+-dependent ADHs is 
depicted in Scheme 36.[104,130] The cofactor NAD(P)+ binds to the protein by 
coordinating zinc at the ADHs active site. After the dissociation of water, the 
alcohol substrate is as well coordinated to the zinc of the ADH-NAD(P)+-complex. 
A conformation change effects, that the catalytic domain moves closer to the 
cofactor to easify the hydride transfer. The first step in the redox reaction is the 
deprotonation of the alcohol. The resulting alkoxide ion is complexed by the 
active-site zinc to stabilize it and prevent extraction of an adjacent proton forming 
the alcohol substrate again (b). The second step is the hydride transfer from the 
alkoxide ion to NAD(P)+. Simultaneously the double bond is formed (c). The 
release of the oxidized ketone is forced by the - at this point favored - 
recoordination of water to zinc (d). Finally the reduced cofactor NAD(P)H 
dissociates and the catalytic cycle is ready to restart from (a)( Scheme 36)[104,130] 
 
 
Scheme 36. Simplified mechanism of the ADH-catalyzed oxidation[104]  
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Aim of this section is to realize the second, ADH-catalyzed oxidation step 
simultaneously to the first CYP BM-3 catalyzed oxidation step in a one pot process 
to synthesize the cyclic ketones 3 directly from the corresponding cycloalkanes 1. 
 
In the previous chapter 4, the first hydroxylation step, which is catalyzed by a 
cytochrome P450 monooxygenase (CYP BM-3), was investigated in detail. In order 
to complete the enzymatic two-step one-pot process that is based on the 
cooperation of two enzymes, a second alcohol dehydrogenase catalyzed oxidation 
step has to be implemented. In this way the oxidized form of the cofactor NADP+, 
which is generated in the first CYP BM-3 catalyzed hydroxylation step, is retrans-
formed into the reduced form NAD(P)H by the alcohol dehydrogenase. By this 
means the application of a further cosubstrate becomes redundant. Using this 
process, cyclic ketones 3 can be synthesized directly from the corresponding 
cycloalkanes 1. BURDA applied the (R)-enantioselective alcohol dehydrogenase 
from Lactobacillus kefir (LK-ADH) for the direct oxidation of cycloalkanes 1 to 
cycloalkanones 3 with oxygen in water and STAUDT extensively analyzed the 
synthesis of cyclooctanone (3d) in an aqueous reaction medium while using this 
system.[20-22] On the basis of these results, the application of this (R)-enantio-
selective alcohol dehydrogenase from Lactobacillus kefir (LK-ADH) for the second 
oxidation step was adopted to complete the double oxidation sequence as well 
for the synthesis of further homologue cycloalkanones 3. 
 
With intent to make enzymatic applications even more attractive, the conversion 
in relation to the catalyst can be enormously enhanced by using the catalyst more 
often than once. In literature, several methods of enzyme immobilization are 
reported aiming to overcome general limitations of enzyme applications like the 
difficult recovery of the biocatalyst or low stability in organic syntheses.[137] In this 
way, the recycling of the (to some extent) costly biocatalysts is possible. According 
to SHELDON, the immobilization of enzymes can be distinguished into three groups, 
abridged in Figure 18.  
 
 
 
Figure 18. Three methods to immobilize enzymes (enzyme: ●; carrier: ●):              
A) Cross-Linking B) Entrapment C) Binding to a support [137] 
While cross-linking (method A) is a carrier-free approach, encapsulation in a 
support (method B) resp. binding on a support (method C) is a carrier-based 
procedure. If covalent binding is used to attach the enzyme to a support, enzyme 
leaching from the surface of the carrier is prevented.[138] However it is a drawback 
of this generally robust method that the cofactor is not co-immobilized[139] and if 
the enzyme is deactivated, the whole system (biocatalyst and support) is use-
less.[137]  
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In 2009 it was reported by JEROMIN, that an entrapment of an ADH in a hydrogel 
matrix (superabsorbent polymer Favor SXM 9155) was accomplished, in which the 
required cofactor was co-immobilized. The application of this system in aqueous 
medium enabled a recyclization of the immobilized enzyme over five cycles, 
providing constantly high substrate conversion. The main disadvantage of this 
approach is the very high excess enzyme loading, that renders the application 
unattractive.[139] Recently RULLI et al. presented a further development of this 
encapsulation system for the synthesis of different 1,3-diols with drastically 
reduced enzyme loading (LK- resp. Rsp.-ADH). However, under these conditions 
no conversion was detected after the third cycle. These results emphasized that 
leaching in aqueous media is a problem to consider.[140] This problem was 
adressed by a most recent publication, describing the application of a co-immo-
bilized, superabsorbed ADH in organic media (Scheme 37). In this way, the 
enzyme can be removed from its natural aqueous environment into a biphasic 
system with the result that leaching is suppressed and extraction of the product is 
redundant.[141]  
 
 
Scheme 37. Synthesis of the 1,3-diol (1R,3S)-68 from (R)-69 with high conversion 
and ee over five cycles[141] 
The aim of this section is to analyze, if the recently presented achievement of 
HEIDLINDEMANN et al. can be generally transferred to the above described double 
oxidation system. For this purpose a co-immobilisate of enzymes, hereinafter 
ƌefeƌƌed①to①as①͚supeƌaďsoƌďed①eŶzǇŵe①taŶdeŵ͚,①consisting of a cytochrome P450 
monooxygenase from Bacillus megaterium (CYP BM-3 19A12) and an alcohol 
dehydrogenase from Lactobacillus kefir (LK-ADH) together with the cofactor 
NADPH is prepared and applied for the enzymatic two-step one-pot process.  
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5.2 Results and discussion 
5.2.1 Photometric assay to determine the enzyme activity of the alcohol 
dehydrogenase from Lactobacillus kefir (LK-ADH) 
 
The recombinant ADH from Lactobacillus kefir (LK-ADH) turned out to be a 
suitable catalyst for the oxidation of cyclohexanol (2a) yielding cyclohexanone 
(3a). Very recently, in 2013, STAUDT et al. presented a proof of concept for the 
sǇŶthesis① of① the① ďulk① ĐheŵiĐal① ɸ-caprolactone (70) in a biocatalytic one-pot 
process. This process is based on a double oxidation starting from cyclohexanol 
(2a), which is oxidized by an LK-ADH to provide cyclohexanone (3a). This key 
intermediate 3a is then directly transformed into the desired product 
ɸ-caprolactone (70) with up to 97% conversion in a second oxidation step, 
catalyzed by a Baeyer-Villiger monooxygenase.[142] Based on these positive 
findings this ADH from Lactobacillus kefir (LK-ADH) was chosen for the second 
step of the double oxidation of cycloalkanes 1 shown in Scheme 38. 
 
 
Scheme 38. Double oxidation of cycloalkanes 1 (n = 1, 3, 5) 
Prior to a preparative biotransformation it is essential to determine the enzyme 
activities with regard to the selected substrates. The enzyme activities can be 
determined with an UV/VIS-spectrophotometer for NADP+ is used as cofactor. The 
formation of NADPH through reduction of NADP+ is measured spectrophoto-
metrically at a wavelength of 340 nm in the presence of the LK-ADH and the 
respective substrate. This increase in extinction is recorded time-dependent by a 
spectrophotometer and is schematically shown in Scheme 39 on the right side. By 
means of the initial slope of the absorption curve and the following formula, the 
volumetric enzyme activity can be determined.  
 
 
 
With U/mL = volumetric enzyme activity; ΔE340nm/t = initial slope of the absorption curve, Vt = total 
volume [mL]; f = dilution factor; ɸ = molar extinction coefficient for NAD(P)H [6.3 mL*μmol-1*cm-1]; 
VS = sample volume [mL]; d = path length of the cuvette [cm] 
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Scheme 39. General reaction scheme of the photometric assay applying LK-ADH 
(left) and schematically plotted increase of NADPH over the course of the enzyme 
activity test (right) 
Additionally to the respective substrates a reference compound is measured and 
its activity is defined as 100% in order to make a relative statement on the 
enzyme activities. The specific activities of the substrates are related to this value. 
Over the course of time, the reference compound 1-phenylethanol (71) as well as 
the substrates cyclohexanol (2a) and cyclodecanol (2b) were repeatedly measured 
and the results of the measurements were of the same order of magnitude 
(SOP 11). It is noticable that the substrate cyclodecanol (2b) is accepted 3 to 6 
times better by the LK-ADH than the substrate cyclohexanol (2a), which is shown 
clearly in Figure 19.  
 
 
Figure 19. Relative activities of reference compound 1-phenylethanol (71) and the 
substrates cyclohexanol (2a) and cyclodecanol (2b) with LK-ADH, measured at 
different times (n.d. not determined) 
An explanation can be found in the log-P-values of the substrate alcohols 2a and 
2b. The octanol-water partition coefficient is a non-dimensional partition 
coefficient (log P) that describes the ratio of the concentrations of a compound in 
a biphasic system, containing of water and 1-octanol. By means of log P, the 
hydrophobicity of a compound can be deduced. While a high log P-value indicates 
for a hydrophobic compound, a low log P-value describes a more hydrophilic 
substance.[143,128] As apparent from Figure 20, cyclodecanol (2b) is composed of a 
larger cyclic alkyl chain than cyclohexanol (2a), making this substrate 2b 
considerably more hydrophobic.  
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Figure 20. Cyclohexanol (2a) and cyclodecanol (2b) with differently sized 
hydrophobic areas (⃝: hydrophobic, ⃝: hydrophilic)[128] 
A substrate has to pass a hydrophobic tunnel-like region[130] to reach the as well 
hydrophobic active site.[130,28] Therefore it seems to be obvious that the more 
hydrophilic substrate 2a is accepted to a lesser extent. 
 
5.2.2 Biocatalyzed oxidation of cyclododecanol (2c) with different alcohol 
dehydrogenases 
 
Since the main focus of this thesis was on the first oxidation step catalyzed by a 
cytochrome P450 monooxygenase from Bacillus megaterium (CYP BM-3) (chapter 
4), comparatively few experiments were conducted to oxidize cyclododecanol (2c) 
to cyclododecanone (3c) with alcohol dehydrogenases (Scheme 40). 
 
 
Scheme 40. ADH-catalyzed oxidation of cyclododecanol (2c) 
Despite knowing that only the alcohol dehydrogenase from Lactobacillus kefir 
(LK-ADH) is a suitable catalyst for the double oxidation as it is NADPH-dependent, 
two more NADH-dependent alcohol dehydrogenases, namely an alcohol dehydro-
genase from Rhodococcus species (Rsp.-ADH) and the ADH evo-1.1.200 were 
tested in preparative experiments (SOP 12). The conversion was determined by 
comparison of the GC-areas of the substrate 2c and the product 3c. In order to 
verify this method, the simulated conversion is related to the actually measured 
conversion. The simulated conversion is obtained by weighting in the substrate 2c 
and the product 3c and is calculated to be 50.22%. The conversion determined by 
means of gas chromatography, 49.99%, is obtained by comparing the substance-
specific surface integrals of 2c and 3c (SOP 12). The results are summarized in 
Table 10.  
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Table 10. Results of the ADH-catalyzed oxidation of cyclododecanol (2c) according 
to Scheme 40 
Entry 
ADH/µL or mL  
resp. mg 
Activityb) 
[U/mmol] 
Cofactor 
Substrate 
[mmol] 
Conversion 
[%] 
1 LK-ADH/32.4 µLa) 100 NADP+ 0.5 2 
2 Rsp.-ADH/2.5 mLa) 100 NAD+ 0.5 1 
3 
ADH evo-
1.1.200/11.1 mg 
100 NAD+ 0.5 2 
4 LK-ADH/64.8 µLa) 1000 NADP+ 0.1 10 
5 
ADH evo-
1.1.200/22.2 mg 
1000 NAD+ 0.1 5 
a)diluted 1:1 in glycerol; b)referred to the respective standard substrate (LK-ADH: acetophenone (72) 
(1544 U/mLa)); Rsp.-ADH: p-chloroacetophenone (73) (49 U/mLa)); ADH evo-1.1.200: ethyl 
acetoacetate (63) (4.5 U/mg)). 
 
These preliminary experiments were performed in order to generally analyze if 
cyclododecanol (2c) is a substrate for the available alcohol dehydrogenases. 
However, the activities applied were referred to the oxidized form of the 
respective standard substrate (LK-ADH: acetophenone (72); Rsp.-ADH: p-chloro-
acetophenone (73); ADH evo-1.1.200: ethyl acetoacetate (63) (Figure 21). 
 
 
Figure 21. Structures of the standard substrates acetophenone (72) (LK-ADH), 
p-chloro-acetophenone (73) (Rsp.-ADH) and ethyl acetoacetate (63) (ADH evo-
1.1.200) as well as the corresponding reduced forms 1-phenylethanol (71), 
p-chloro-1-phenylethanol (74) and ethyl 3-hydroxybutyrate (62) 
For the performed oxidation reaction, which is not favoured compared to the 
reduction reaction, higher amounts of enzyme need to be applied, as an enzyme 
activity test has to be done with the reduced form of the standard substrates 
1-phenylethanol (71), p-chloro-1-phenylethanol (74) and ethyl 3-hydroxy-
butyrate (62) (Figure 21). Therefore, even better results can be expected if the 
experiments are repeated with redefined amounts of ADHs.  
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5.2.3 Biocatalyzed double oxidation of cyclododecane (1c) with CYP BM-3 
and LK-ADH 
 
The double oxidation with cyclododecane (1c) as substrate was performed twice 
and as no product formation was detected, the first oxidation step catalyzed by a 
cytochrome P450 monooxygenase from Bacillus megaterium (CYP BM-3) was 
focused for the main part. Nevertheless an important discovery was made 
performing these experiments, based on the varying recovery of the substrate 1c 
(SOP 13)(Table 11).  
 
Table 11. Results of the double oxidation of cyclododecane (1c) 
 
 
Entry 
CYP BM-3 
(biomass) 
IPA Cofactor 
Cyclododecanone 
(3c) [g/l]] 
Recovery of 
substrate 1c [%] 
1 
19A12 
(19.6 mg)a) 
 NADP+ 0 92 
2 
F87V 
(127.0 mg)b) 
- NADPH 0 83 
a)The content of CYP BM-3 19A12 (0) amounts to 0.123 μmol/g lyophilized crude extract; b)The con-
tent of CYP BM-3 F87V amounts to 0.525 μmol/g lyophilized crude extract. 
 
As already described detailed in chapter 3, high recovery rates in the presence of 
biomass are not something that can be taken for granted and require an 
appropriate working up procedure. This correlation, namely the decreasing of the 
recovery rate with increasing biomass applied in an experiment, can be seen from 
both preparative double oxidations of cyclododecane (1c) summarized in Table 
11. No product 3c was detected and although same amounts of 1c were applied, 
the recovery of 1c deviated enormously. The explanation for this phenomenon is 
that for the biotransformation with the mutant CYP BM-3 19A12 only 19.6 mg 
protein contained the required activity (0.762 U referred to 1b), whereas in 
contrast it was necessary to apply a more than sixfold higher amount of biomass, 
namely 127.0 mg protein by using the mutant CYP BM-3 F87V, in order to obtain 
the same activity.  
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This considerably increased amount of biomass manifests itself by the recovery 
rate of the substrate 1c: while in the small enzyme pellet only traces of the 
substance 1c are restrained, the more voluminous pellet is able to hold back 
higher amounts. A one-time extraction of the pellet (later mentioned as SOP A) is 
therefore insufficient to isolate the absorbed compounds completely (Figure 22).  
 
 
Figure 22. Enzyme pellet from 19.6 mg biomass (CYP BM-3 19A12) (left) and 
enzyme pellet from 127.0 mg biomass (CYP BM-3 F87V) (right) 
Taking this into account and aiming to further improve the recovery rate, the 
working up process of the reaction mixture was optimized to the effect 
that - likewise the aqueous phase - the enzyme pellet is extracted three times 
(later mentioned as SOP B). This optimized extractive working up of the reaction 
mixture ensures a high recovery rate both, in presence and absence of an enzyme 
pellet.  
 
5.2.4 Biocatalyzed double oxidation of cycloalkanes 1 with different CYP 
BM 3 and LK-ADH 
 
The double oxidation of cyclohexane (1a) and cyclodecane (1b) was realized in the 
presence of a cytochrome P450 monooxygenase from Bacillus megaterium (CYP 
BM-3) and the alcohol dehydrogenase from Lactobacillus kefir (LK-ADH) in 
phosphate buffer. To start the reaction, cofactor NADPH is added (SOP 14). The 
results of the oxidation of 1a are summarized in Table 12, whereby it is 
unmissable, that two experiments (entry 1-2) yield 0.41 g/L while two further 
experiments, that were conducted about one year later (entry 3-4) yield 0.98 g/L 
on an average.  
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Table 12. Results of the double oxidation of cyclohexane (1a) with CYP 
BM-3 19A12 
 
 
En- 
try 
Activity 
19A12 
[U]/[mg] 
LK-ADH 
[U/mmol]/[µL] 
NADPH 
[mol%] 
Recovery/formationd) [g/L] 
of 
…1a …2a …3a 
1 0.762/5.2a) 200/326 10 1.01 0.43 0.41 
2 0.762/5.2a) 200/326 10 1.05 n.d.e) 0.40 
3 0.762/10.3b) 200/1057 10 0.61 0.53 0.96 
4 0.762/10.3b) 200/528c) 10 1.61 0.16 0.99 
a)The content of CYP BM-3 19A12 (0) amounts to 0.123 μmol/g lyophilized crude extract; b)The con-
tent of CYP BM-3 19A12 (2) amounts to 0.120 μmol/g lyophilized crude extract; c)Addition of LK-ADH 
without dilution in glycerol; d)The① teƌŵ① ͞ƌeĐoǀeƌǇ͞① desĐƌiďes① the① ŵass① ĐoŶĐeŶtƌatioŶ① iŶ① g/L① of① a①
compound initially added to the reaction, that is recovered after workup, here cycloalkane 1. The 
teƌŵ①͞foƌŵatioŶ͞①desĐƌiďes① the①ŵass①ĐoŶĐeŶtƌatioŶ① iŶ① g/L①of①a①ĐoŵpouŶd①ǁhiĐh① is① foƌŵed①duƌiŶg①
the reaction and isolated while workup (product formation of cycloalkanol 2 and cycloalkanone 3). 
All mass concentrations in g/L were determined via gas chromatography; e)n.d.: not determined, no 
clear assignment possible.. 
 
An explanation for this is the protein concentration of CYP BM-3 19A12, which 
was twice as high (entry 3-4: 10.3 mg) as in the previously conducted experiments 
(entry 1-2: 5.2 mg) and additionally, the amount of LK-ADH (528 µL crude extract 
resp. 1057 µL crude extract dil. 1:1 in glycerol instead of 326 µL crude extract dil. 
1:1 in glycerol) was increased. This pheŶoŵeŶoŶ① is① kŶoǁŶ① as① ͚MaĐƌoŵoleĐulaƌ①
CƌoǁdiŶg͛,① desĐƌiďiŶg① the① eŶhaŶĐed① staďilitǇ① of① aŶ① eŶzǇŵe① iŶ① the① pƌeseŶĐe① of①
higher total protein concentration.[144] For this purpose bovine serum albumin 
(BSA) is applied to stabilize proteins resp. enzymes and ranks among the most 
commonly used stabilizers in buffer solutions.[145]  
 
The double oxidation of cyclodecane (1b) with CYP BM 3- F87V and LK-ADH 
yielded 0.20 g/L cyclodecanone (1b) but since slightly better results were reached 
for this substrate by adding an 2-propanol-starter, the biotransformation was 
generally conducted in the presence of 2-propanol. 
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5.2.5 Biocatalyzed double oxidation of cycloalkanes 1 with different CYP BM-
3 and LK-ADH and addition of 2-propanol 
 
By adding 2-propanol, the reduced cofactor form NADPH which is required for the 
initial hydroxylation step, is generated in situ from NADP+. This approach is 
preferable for NADP+ is more cost-effective than the reduced NADPH.[146,147] In 
Table 13 the results of the double oxidation of 0.1mmol 1a with addition of 
2-pƌopaŶol①;Ϯ.ϱ‰①;ǀ/ǀͿͿ①aƌe①suŵŵaƌized (SOP 15). 
 
Table 13. Results of the double oxidation of 1a with addition of 2-propanol 
 
 
Entry 
Activity CYP 
BM-3 
[U]/[mg] 
LK-ADH 
[U/mmol]/[µL] 
NADP+ 
[mol%] 
Recovery/formationc) [g/L] 
of 
…1a …2a …3a 
1 
WT 
0.762/109.2a) 
200/326 10 0.75 0.25 0.35 
2 
19A12 
0.762/5.2b) 
200/326 10 1.39 0.68 0.19 
3 
19A12 
0.762/5.2b) 
200/326 10 0.91 0.40 0.18 
a)The content of CYP BM-3 WT amounts to 1.260 μmol/g lyophilized crude extract; b)The content of 
CYP BM-3 19A12 (0) amounts to 0.123 μmol/g lyophilized crude extract; c)The① teƌŵ① ͞ƌeĐoǀeƌǇ͞①
describes the mass concentration in g/L of a compound initially added to the reaction, that is 
recovered after workup, here cycloalkane 1.①The①teƌŵ①͞foƌŵatioŶ͞①desĐƌiďes①the①ŵass①ĐoŶĐeŶtƌatioŶ①
in g/L of a compound which is formed during the reaction and isolated while workup (product 
formation of cycloalkanol 2 and cycloalkanone 3). All mass concentrations in g/L were determined 
via gas chromatography. 
 
Higher product amounts (0.35 g/L) were obtained by applying the wildtype 
enzyme, probably due to the high protein loading and the associated 
macromolecular crowding. However, this extremely increased need for biomass 
renders this enzyme unattractive for further applications. The experiments with 
the mutant CYP BM-3 19A12 showed a product formation of 0.18 resp. 0.19 g/L 
that lag far behind the product formations without 2-propanol-starter 
(0.41 g/L)(5.2.4). This is the reason why this type of biotransformation was 
generally conducted in the absence of 2-propanol.  
66 | DOUBLE OXIDATION COMBINING A CYTOCHROME P450 MONOOXYGENASE FROM B. 
MEGATERIUM AND AN ALCOHOL DEHYDROGENASE FROM L. KEFIR IN AN ONE-POT PROCESS 
 
In Table 14 the results of the double oxidation of 0.1 mmol 1b with addition of 
2-pƌopaŶol①;Ϯ.ϱ‰①;ǀ/ǀͿͿ①aƌe①suŵŵaƌized (SOP 15). 
 
Table 14. Results of the double oxidation of cyclodecane (1b) with CYP 
BM-3 19A12 
 
 
Entry 
Activity 
19A12 
[U]/[mg] 
LK-ADH 
[U/mmol]/[µL] 
NADP+ 
[mol%] 
Recovery/formationc) [g/L] 
of 
…1b …2b …3b 
1 0.762/19.6a) 200/91 10 7.92 0.00 0.24 
2 0.762/14.9b) 200/166 10 9.66 0.00 0.27 
3 0.762/14.9b) 200/166 10 9.38 0.00 0.27 
4 0.762/14.9b) 200/166 10 10.28 0.00 0.25 
a)The content of CYP BM-3 19A12 (0) amounts to 0.123 μmol/g lyophilized crude extract; b)The 
content of CYP BM-3 19A12 (2) amounts to 0.120 μmol/g lyophilized crude extract; c)The term 
͞ƌeĐoǀeƌǇ͞①desĐƌiďes①the①ŵass①ĐoŶĐeŶtƌatioŶ① iŶ①g/L①of①a①ĐoŵpouŶd① iŶitiallǇ①added①to①the① ƌeaĐtioŶ,①
that is recovered after workup, here cycloalkane 1.① The① teƌŵ① ͞foƌŵatioŶ͞① desĐƌiďes① the① ŵass①
concentration in g/L of a compound which is formed during the reaction and isolated while workup 
(product formation of cycloalkanol 2 and cycloalkanone 3). All mass concentrations in g/L were 
determined via gas chromatography. 
 
Entry 1 shows one of the early experiments of the double oxidation of 
cyclodecane (1b) with CYP BM-3 19A12 and LK-ADH, in which a product formation 
of 0.24 g/L cyclodecanone (1b) was detected. Since the double oxidation of 1b 
without the 2-propanol-starter gave slightly poorer results (0.20 g/L) this type of 
biotransformation was generally conducted in the presence of 2-propanol. A 
reason for this phenomenon, namely the slightly higher product formation in the 
presence of low concentrations of 2-propanol (2.5‰ (v/v)) could be the following: 
Not only the amount of NADPH, necessary to start the first step of the 
biotransformation is generated by this system. Also the wastage of NADPH, an 
undesired result from three possible additional shunt pathways consuming 
NADPH decoupled from the substrate oxidation, is compensated by the 
regeneration of NADPH with 2-propanol. The experiments shown in entry 2-4, 
were conducted one year after the experiment shown in entry 1 and the obtained 
result of entry 1 could be reproduced precisely accurate for three times.  
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Like in the experiments without 2-propanol-starter (5.2.4) no intermediate was 
detected in contrast to the conversion of 1a. But if the result of the enzyme 
activity test is regarded (5.2.1), where it is shown that the substrate cyclodecanol 
(2b) is accepted 3 to 6 times better by the LK-ADH than the substrate 
cyclohexanol (2a), it becomes clear that 2b is quickly converted into 3b and 
therefore did not accumulate. 
 
5.2.6 Biocatalyzed double oxidation of cycloalkanes 1 with different CYP 
BM-3 and LK-ADH with reduced amount of cofactor 
 
Aiming to find out if an economically profitable reduction of the high-priced 
cofactor quantity - and therefore a notable decrease of the total turn over 
number (TTN) - is possible, several experiments are conducted with reduced 
amount of cofactor. Compared to the experiments described so far in which 
generally 10 mol% of cofactor were applied, the input of only 1 or 2 mol% 
cofactor was analyzed (SOP 16). The results of the double oxidation of 0.1 mmol 
1a with addition of only 1 or 2 mol% cofactor are summarized in Table 15.  
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Table 15. Results of the double oxidation of cyclohexane (1a) with different 
concentrations of cofactor NADPH 
 
En- 
try 
Activity 
19A12 
[U]/[mg] 
LK-ADH 
[U/mmol]/[µL] 
NADP(H) 
Recovery/formatione) [g/L] 
of 
…1a …2a …3a 
1 0.762/5.2a) 200/825 1 mol% 0.42 0.09 0.08 
2 0.762/5.2a) 200/825 1 mol% 1.04 0.09 0.10 
3 0.762/5.2a) 200/825 2 mol% 1.07 0.11 0.11 
4 0.762/5.2a) 200/825 2 mol%d) 0.98 0.09 0.10 
5 0.762/10.3b) 200/528c) 1 mol% 0.31 0.19 0.28 
6 0.762/10.3b) 200/528c) 10 mol% 1.61 0.16 0.99 
a)The content of CYP BM-3 19A12 (0) amounts to 0.123 μmol/g lyophilized crude extract; b)The 
content of CYP BM-3 19A12 (2) amounts to 0.120 μmol/g lyophilized crude extract; c)Addition of LK-
ADH without dilution in glycerol; d)each 1 mol% cofactor in oxidized + reduced form; e)The term 
͞ƌeĐoǀeƌǇ͞①desĐƌiďes the mass concentration in g/L of a compound initially added to the reaction, 
that is recovered after workup, here cycloalkane 1.① The① teƌŵ① ͞foƌŵatioŶ͞① desĐƌiďes① the① ŵass①
concentration in g/L of a compound which is formed during the reaction and isolated while workup 
(product formation of cycloalkanol 2 and cycloalkanone 3). All mass concentrations in g/L were 
determined via gas chromatography. 
 
For the experiments shown in entry 1-4, always the same amount of both 
enzymes (CYP BM-3 and LK-ADH) was applied to obtain comparable results. The 
product formation is pretty much the same employing 1 or 2 mol% of NADPH. 
Also the application of both, each 1 mol % of the reduced as well as of the 
oxidized form of cofactor gave no notable increase on the product formation. This 
is not surprising for the initially necessary NADPH in den comparative tests is not 
formed via a 2-propanol-starter. In entry 5, the amount of CYP BM-3 19A12 was 
twice as high (10.3 mg) as in the previously conducted experiments (entry 1-4; 
5.2 mg) and additionally the amount of LK-ADH (528 µL crude extract instead of 
825 µL crude extract diluted 1:1 in glycerol) is increased. As already depicted in 
5.2.4, macromolecular crowding is, besides an optimized work up, hence the 
explanation for this threefold higher product formation.  
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Comparing the experiments in entry 5 and 6, that differ only in the amount of 
ĐofaĐtoƌ,① it① is①appaƌeŶt① that①sĐaƌĐelǇ①⅓①of①the①ďeŶĐhŵaƌk①pƌoduĐt① foƌŵatioŶ①ĐaŶ①
ďe①aĐĐoŵplished①ǁith①⅟10 amount of cofactor. The results of the double oxidation 
of 0.1mmol 1b with addition of only 1 or 2 mol% cofactor are summarized in Table 
16.  
 
Table 16. Results of the double oxidation of cyclodecane (1b) with different 
concentrations of cofactor NADP+ 
 
 
En- 
try 
Activity 
19A12 
[U]/[mg] 
LK-ADH 
[U/mmol]/[µL] 
NADP+ 
Recovery/formatione) [g/L] 
of 
…1b …2b …3b 
1 0.762/19.6a) 200/241 1 mol% 7.34 n.d.f) 0.26 
2 0.762/19.6a) 200/241 1 mol% 3.25 n.d.f) 0.29 
3 0.762/19.6a) 200/241 2 mol% 7.08 n.d.f) 0.25 
4 0.762/19.6a) 200/241 2 mol%d) 4.23 n.d.f) 0.35 
5 0.762/14.9b) 200/83c) 1 mol% 7.88 n.d.f) 0.22 
6 0.762/14.9b) 200/166 10 mol% 9.38 n.d.f) 0.27 
a)The content of CYP BM-3 19A12 (0) amounts to 0.123 μmol/g lyophilized crude extract; b)The 
content of CYP BM-3 19A12 (2) amounts to 0.120 μmol/g lyophilized crude extract; c)Addition of LK-
ADH without dilution in glycerol; d)each 1 mol% cofactor in oxidized + reduced form; e)The term 
͞ƌeĐoǀeƌǇ͞①desĐƌiďes①the①ŵass①ĐoŶĐeŶtƌatioŶ① iŶ①g/L①of①a①ĐoŵpouŶd① iŶitiallǇ①added①to the reaction, 
that is recovered after workup, here cycloalkane 1.① The① teƌŵ① ͞foƌŵatioŶ͞① desĐƌiďes① the① ŵass①
concentration in g/L of a compound which is formed during the reaction and isolated while workup 
(product formation of cycloalkanol 2 and cycloalkanone 3). All mass concentrations in g/L were 
determined via gas chromatography; f)not detected. 
 
Entry 6 shows the benchmark experiment with a product formation of 0.27 g/L. 
The biotransformations applying only 1-2 mol% NADP+ gave nearly the same 
product formation which was 0.26 g/L on an average (entry 1-3, 5). A slightly 
higher product formation was realized when using each 1 mol% of the reduced as 
well as of the oxidized form of cofactor (entry 4). This is not surprising since only 
half of the amount of the cofactor NADPH has to be produced in situ and the 
reaction could start immediately without waiting for the starter-step. 
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5.2.7 Biocatalyzed double oxidation of cycloalkanes 1 with different CYP 
BM-3 and LK-ADH with reduction of the reaction time 
 
Since a shortened reaction time enables the performance of more experiments 
and decreases the consumption of resources, the biotransformationes with 
cyclohexane (1a) as well as with cyclodecane (1b) as substrates were analyzed 
with regard to this parameter (SOP 17). The results of the biotransformation of 
cyclohexane (1a) are summarized in Table 17 and can be compared easily to the 
benchmark experiment (entry 3), for the same amounts of both enzymes (CYP 
BM-3 19A12 and LK-ADH) were applied. 
 
Table 17. Results of the double oxidation of cyclohexane (1a) with shortened 
reaction time 
 
 
Entry 
Activity 
19A12 
[U]/[mg] 
LK-ADH 
[U/mmol]/[µL] 
Time 
[h] 
Recovery/formationc) [g/L] 
of 
…1a …2a …3a 
1 0.762/10.3a) 200/528b) 2 1.09 0.22 0.37 
2 0.762/10.3a) 200/528b) 4 0.66 0.23 0.51 
3 0.762/10.3a) 200/528b) 24 1.61 0.16 0.99 
a)The content of CYP BM-3 19A12 (2) amounts to 0.120 μmol/g lyophilized crude extract; b)Addition 
of LK-ADH without dilution in glycerol; c)The①teƌŵ①͞ƌeĐoǀeƌǇ͞①desĐƌiďes①the①ŵass①ĐoŶĐeŶtƌatioŶ①iŶ①g/L①
of a compound initially added to the reaction, that is recovered after workup, here cycloalkane 1. 
The① teƌŵ① ͞foƌŵatioŶ͞① desĐƌiďes① the① ŵass① ĐoŶĐeŶtƌatioŶ① iŶ① g/L① of① a① ĐoŵpouŶd① ǁhiĐh① is① foƌŵed①
during the reaction and isolated while workup (product formation of cycloalkanol 2 and 
cycloalkanone 3). All mass concentrations in g/L were determined via gas chromatography. 
 
After 4 h, which is one sixth of the generally used reaction time of 24 h, the 
product formation was already at 0.51 g/L, therefore the half of 0.99 g/L. The 
results of the biotransformation of cyclodecane (1b) are summarized in Table 18. 
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Table 18. Results of the double oxidation of cyclodecane (1b) with shortened 
reaction time 
 
 
 
Entry 
Activity 
19A12 
[U]/[mg] 
LK-ADH 
[U/mmol]/[µL] 
Time 
[h] 
Recovery/formationb) [g/L] 
of 
…1a …2a …3a 
1 0.762/14.9a) 200/166 2 11.81 0.00 0.21 
2 0.762/14.9a) 200/166 4 10.98 0.00 0.23 
3 0.762/14.9a) 200/166 24 9.38 0.00 0.27 
a)The content of CYP BM-3 19A12 (2) amounts to 0.120 μmol/g lyophilized crude extract; b)The term 
͞ƌeĐoǀeƌǇ͞①desĐƌiďes①the①ŵass①ĐoŶĐeŶtƌatioŶ① iŶ①g/L①of①a①ĐoŵpouŶd① iŶitiallǇ①added①to①the① ƌeaĐtioŶ,①
that is recovered after workup, here cycloalkane 1.① The① teƌŵ① ͞foƌŵatioŶ͞① desĐƌiďes① the① ŵass①
concentration in g/L of a compound which is formed during the reaction and isolated while workup 
(product formation of cycloalkanol 2 and cycloalkanone 3). All mass concentrations in g/L were 
determined via gas chromatography. 
 
The experiments using cyclodecane (1b) as substrate are - in contrast - more easy 
to abbreviate, for the shortening of the reaction time brought along only a 
marginal decrease of the product formation. The reason for this divergence - 
namely the different product formation of 3a and 3b at shortened reaction times 
of the double oxidation - can be found in the fact that the biotransformation of 1b 
is faster compared to the biotransformation of 1a. Cyclodecanol (2b) is accepted 3 
to 6 times better by the LK-ADH than cyclohexanol (2a) what makes the reaction 
faster and provides the reduced form of the cofactor more quickly to the first 
oxidation step.  
 
5.2.8 Biocatalyzed double oxidation of cyclodecane (1b) with increased 
initial substrate concentration 
 
To compare the influence of the substrate concentration on the product 
formation, one experiment with fivefold substrate concentration was conducted 
(SOP 18). The results are summarized in Table 19.  
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Table 19. Results of the double oxidation of cyclodecane (1b) with increased 
substrate concentration 
 
 
Entry 
Activity 
19A12 
[U]/[mg] 
LK-ADH 
[U/mmol]/[µL] 
1b 
[mmol] 
Recovery/formationb) [g/L] 
of 
…1a …2a …3a 
1 0.762/14.9a) 200/166 0.1 10.28 0.00 0.25 
2 0.762/14.9a) 200/166 0.5 64.32 0.00 0.82 
a)The content of CYP BM-3 19A12 (2) amounts to 0.120 μmol/g lyophilized crude extract; b)The term 
͞ƌeĐoǀeƌǇ͞①desĐƌiďes①the①ŵass①ĐoŶĐeŶtƌatioŶ① iŶ①g/L①of①a①ĐoŵpouŶd① iŶitiallǇ①added①to①the① ƌeaĐtioŶ,①
that is recovered after workup, here cycloalkane 1.① The① teƌŵ① ͞foƌŵatioŶ͞① desĐƌiďes① the① ŵass①
concentration in g/L of a compound which is formed during the reaction and isolated while workup 
(product formation of cycloalkanol 2 and cycloalkanone 3). All mass concentrations in g/L were 
determined via gas chromatography. 
 
The increase of the substrate concentration leads to higher product formations, 
but the correlation is not linear. However, this slightly more than three-times 
higher product formation can easify the analytic that is quite complex at low 
product formations. 
 
5.2.9 Double oxidation of cyclohexane (1a) using a superabsorbed enzyme 
tandem 
 
Aiming to make the presented biotransformation even more attractive by 
enhancing the conversion in relation to the catalysts by using the catalysts more 
often than once, a co-immobilisate of enzymes, hereinafter referred to as 
͚supeƌaďsoƌďed① eŶzǇŵe① taŶdeŵ͚,① was prepared (SOP 19). This superabsorbed 
enzyme tandem consisted of a cytochrome P450 monooxygenase from Bacillus 
megaterium (CYP BM-3 19A12) and an alcohol dehydrogenase from Lactobacillus 
kefir (LK-ADH) together with the cofactor NADPH and was applied for the 
enzymatic two-step one-pot process. To obtain this hydrogel matrix, the 
superabsorbent polymer Favor SXM 9155 was employed. The results of the 
biotransformation are summarized in Table 20 (SOP 20).  
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Table 20. Double oxidation of cyclohexane (1a) using the superabsorbed enzyme 
tandem 
 
 
 
Entrya) 
Method 
(SOP 19) 
Flask 
Cyclohexane 
(1a) [g/L] 
Cyclohexanol 
(2a) [g/L] 
Cyclohexanone 
(3a) [g/L] 
1 A 10 mL -- d) 0.00 0.15 
2 B 50 mLc) -- d) 0.00 0.16 
3b) B 50 mLc) -- d) 0.00 0.18 
a)GC-measurements are conducted in a twofold determination; b)Extraction as described in SOP 20, 
but instead of dichloromethane, 1a (saturated with water to avoid the unwanted reduction of the 
aqueous quantity) was used; c)Enlargement of the air volume in the flask to rule out the deficiency of 
molecular oxygen; d)Concentration of 1a is higher than the detection limit of the straight calibration 
line. 
 
As apparent from Table 20, the product formation was five to six times lower than 
in the benchmark experiment using non-immobilized free catalysts, where 
0.99 g/L of 3a were formed (5.2.4). Even in the experiments shown in entry 2-3, in 
which the immobilisate contained twice the amount of all components (SOP 19) 
no increase was observed. The reason for this phenomenon is most likely to be 
found in the course of process engineering. The preparation of the heterogenized 
enzyme tandem was performed according to HEIDLINDEMANN et al.[141], keeping the 
ratio aqueous phase/superabsorbent polymer constant with the result that a 
quite voluminous hydrogel was formed. It is easy conceivable that the reaction 
proceeds mainly on the surface of the immobilisate while the inlying enzymes are 
passive. Additionally, the proteins on the surface might be denaturated due to the 
contact with organic solvent. The extraction of the hydrogel by gently swirling 
might be not enough to isolate the product completely. The addition of 5 mL 
cyclohexane (1a) were necessary to surround the voluminous hydrogel with 
solvent. The decision to use the substrate as solvent arose from the fact that 
many common solvents are as well accepted as substrates by the cytochrome 
P450 monooxygenase. This increases the over-all substrate concentration 
enormously. Despite the increased substrate concentration and the complete 
missing of a further solvent, the reaction takes place and a proof of concept for 
the co-immobilization of two enzymes and the cofactor to realize the above 
presented double oxidation of cycloalkanes 1 was given. Also the recycling of the 
co-immobilisate was analyzed (SOP 20). However, the system showed no 
conversion after the second cycle and could be optimized (Table 21). 
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Table 21. Double oxidation of cyclohexane (1a) using the superabsorbed enzyme 
tandem for 1-3 cycles 
 
 
EŶtƌǇaͿ CǇĐle CǇĐloheǆaŶe①;ϭaͿ①[g/L] 
CǇĐloheǆaŶol①
;ϮaͿ①[g/L] 
CǇĐloheǆaŶoŶe①;ϯaͿ 
[g/L①iŵŵoďilized①
aƋueous①phase] 
ϭ ϭ --①ďͿ Ϭ.ϬϬ Ϭ.ϭϴ 
Ϯ Ϯ --①ďͿ Ϭ.ϬϬ Ϭ.Ϭϰ 
ϯ ϯ --①ďͿ Ϭ.ϬϬ <①Ϭ.Ϭϭ 
a)GC-measurements are conducted in a twofold determination with the result that for each reaction 
the average of a twofold dataset is calculated; b)Concentration of 1a over the detection limit of the 
straight calibration line. 
 
A possible explanation why the system shows no conversion after the second 
cycle is the denaturation of the biocatalyst on the outer shell of the immobilisate. 
Furthermore the incomplete extraction after the first (and every following 
reaction cycle) leads to the accumulation of organic materials in the hydrogel 
compartiment, causing a destabilization of the biocatalyst.  
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6 Biocatalyzed double oxidation of cycloalkanes 1 
via whole cell catalysis 
6.1 Introduction, state of the art and aim of this section 
 
Already in ancient times, mankind employed microorganisms - and therefore 
catalytically active whole cells - within daily life. Completely unaware of their tiny 
assistants the Sumerians from Mesopotamia started to brew beer since 6000 BC. 
Today it`s known that for the activation of the fermentation process the dominant 
operating organism is Saccharomyces cerevisiae, already present on the barley. 
The situation is equal to the wine: Squashed berry juice was fermented yielding 
alcohol by yeast growing on the berries. As well as the production of these 
fermented beverages, the manufacturing of bread and cheese is based on the 
application of living microorganisms.[148,149]  
 
For preparative and scientific purposes, microorganisms were applied 1858 for 
the first time by L. PASTEUR when he realized the first microbial kinetic resolution 
with the fungus Penicillium glaucum. This fungus is converting exclusively the 
(R,R)-tartaric acid ((R,R)-75) of racemic ammonium tartrate (rac-75), not touching 
the (S,S)-tartaric acid ((S,S)-75). The non-metabolizable enantiomer is accumulating 
to an excess amount of (S,S)-tartaric acid ((S,S)-75) (Scheme 41).[132,150,] 
 
 
Scheme 41. Kinetic resolution of racemic tartaric acid (rac-75) yielding 
(S,S)-tartaric acid ((S,S)-75) 
But not only on a laboratory scale whole cell biotransformations are highly 
successful. One of the first biocatalytic reactions using whole cells as catalysts for 
the industrial synthesis of considerable intermediates is shown in Scheme 42 and 
further outstanding processes shoud be developed.[151] In 1921, NEUBERG and 
HIRSCH published a procedure in which benzaldehyde (76) and pyruvate (77) 
undergo C-C bond formation in the presence of Saccharomyces cerevisiae, 
yielding the optically active key intermediate (R)-phenyl-acetylcarbinol 
((R)-78).[152] Applying two further chemical steps, the nearly enantiomerically pure 
L-ephedrine ((1R,2S)-79) is easily synthesized from the precursor (R)-78 (Scheme 
42). 
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Scheme 42. L-Ephedrine production in the presence of yeast and two further 
chemical steps, since 1930 by Knoll-AG, Ludwigshafen (Germany)[8,151-154] 
For the purpose of cost- and atom efficiency, acetaldehyde (80) can be employed 
in preference to pyruvate (77).[8] This is one of the oldest biocatalytic processes 
still applied, for ephedrine 79 is synthesized until today following this 
procedure.[154]  
 
Another important process based on whole cell catalysis, the synthesis of 
acrylamide (81) from acrylonitrile (82), is often serving as prime example to 
demonstrate the commercial relevance of biocatalysis in industry. Acrylamide (81) 
ranks among the most significant chemical commodities for it is applied as 
versatile starting material for polymers. This importance is mirrored by the global 
consumption of about 200 000 tons per year worldwide.[132] Quite recently, in the 
year 2013, it was published that the reaction shown in Scheme 43 is now 
performed on a scale of > 40 ϬϬϬ①toŶs①peƌ①Ǉeaƌ,①ǁhiĐh①ƌepƌeseŶts①⅕①of①the①gloďal①
demand.[155] 
 
 
Scheme 43. Acrylamide-Process based on immobilized whole cells, since 1985 by 
Nitto Chemical Ltd (Japan) 
The last example that should emphasize the enormous significance of whole cells 
in biocatalysis is the hydantoinase process. The D-hydantoinase process (Scheme 
44, above) is applied since the 1970s, providing a direct access to D-amino acids 
(D-83) and in this particular case to D-phenylglycine (D-83a) and p-hydroxyphenyl-
glycine (D-83b). Nowadays, more than 1000 tons per year of D-83a and D-83b are 
produced as these compounds serve as side chain building blocks for the β-lactam 
antibiotics ampicillin 84 and amoxicilin 85.[156] A process of highest importance is 
without doubt the L-hydantoinase process (Scheme 44, below), producing L-amino 
acids (L-83) with the aid of a tailor-made recombinant whole-cell biocatalyst 
(Scheme 45).[156]  
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Scheme 44. Reaction scheme of the D-hydantoinase process (above) and the 
L-hydantoinase process (below) for the production of D- resp. L-amino acids (D-83 
resp. L-83), starting from D- resp. L-hydantoin (D-86 resp. L-86) via the 
corresponding D- resp. L-carbamoyl amino acid (D-87 resp. L-87) [156] 
 
 
Scheme 45. Reaction scheme of the L-hydantoinase process yielding L-amino acids 
(L-83) [156] 
As pointed out above, there are several processes that are based on whole cell 
biocatalysts and their application is known to have clear advantages. There is no 
universal answer to the question if a certain reaction should be conducted in the 
presence of whole cells or isolated enzymes. Some criterions helpful to balance 
the pros and cons are - without raising a claim to completeness - summarized in 
Table 22.[18] 
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Table 22. Pros and cons of non-recombinant whole cells and isolated enzymes as 
catalysts according to JEROMIN[18] 
Non-recombinant whole cells as catalyst Isolated enzymes as catalyst 
Cofactor recycling occurs in the cell 
 
Demand for expensive  cofactors in 
stoichiometric amounts or need for 
an external cofactor regeneration 
system 
 
Side reactions are characteristic for a 
multi-enzyme system, a previous 
statement concerning the selectivities is 
difficult 
 
Side reactions are rare for this highly 
selective and definable system what 
makes the reaction good manageable 
and a process more controllable 
 
Biotransformations with extracellularly 
not stable or applicable enzymes are 
possible. However, the substrate has to 
overcome the cell membrane to enter 
the cytosol 
 
Absence of a protective cell 
membrane requires suitable reaction 
conditions to avoid the denaturation 
or the complete loss of activity of the 
enzyme 
 
 
Working up might cause difficulties as a 
result of the biomass 
 
Working up is traditionally rather easy 
 
Due to these advantages, especially with regard to the process management, it is 
worthy to analyze if results that are obtained with isolated enzymes as catalysts 
can be reproduced in a comparative whole cell biotransfomation. In particular 
problems like side reactions, catalyzed by other enzymes in the wildtype cells, can 
be avoided by using recombinant whole cell catalysts. 
 
In the case of cytochrome P450 monooxygenases (CYPs), this approach is 
promising for there are already several whole cell biotransformations with this 
class of enzymes. Indeed, the technical application of these enzymes is still 
constrained to a limited number of whole cell processes[67], recently reviewed by 
BERNHARDT and URLACHER.[157] The reason behind this fact is that isolated enzymes 
are considered to be inappropriate basically because of their low stability, their 
stoichiometric demand for the high priced cofactors NAD(P)H and the low 
solubility of many substrates in aqueous reaction media.[67] Indeed it is not 
necessary to add stoichiometric amounts of cofactor if a regeneration system is 
applied. However, additional cofactor has to be regenerated to compensate the 
losses within the shunt pathways.  
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Microbial oxidations of steroids are good examples of commercial applications of 
cytochrome P450 monooxygenases. 11-Deoxycortisol (88) for example can be 
transformed into hydrocortisone (89) via hydroxylation catalyzed by a CYP from 
Curvularia sp. This process is applied by Schering AG (in 2006 acquired by Merck, 
Germany) and performed on an industrial large scale of about 100 tons per year 
(Scheme 46).[94,157,158 ] 
 
 
Scheme 46. Reaction scheme of the hydroxylation of 11-deoxycortisol (88) 
A further example already established in the 1950s is the application of Rhizopus 
sp. for the regioselective hydroxylation of progesterone (38) yielding cortisone 
(90) (Scheme 47) conducted by Pharmacia & Upjohn (meanwhile acquired by 
Pfizer Inc., USA).[157,159] 
 
 
Scheme 47. Reaction scheme of the regioselective hydroxylation of progesterone 
(38) yielding cortisone (90) 
But also in the particular case of CYP-based whole cell biotransformations with 
(cyclic) alkanes as substrates researchers already started their investigations.[31,32] 
Taking their results into consideration, there is a reasonably confidence for the 
quite similar substrates cyclohexane (1a) and cyclodecane (1b) applied in this 
work. The first whole cell double oxidation of n-heptane (29) was recently 
reported by MÜLLER et al.[31,32] and is shown in Scheme 48. While the two-enzyme 
system (consisting of CYP BM-3 and one ADH) enables the chiral resolution of the 
(R)- resp. (S)-heptanols ((R)- resp. (S)-91) (RE-ADH: (S)-selective; LB-ADH: 
(R)-selective), the three-enzyme system converts the alcohols 91 completely into 
the corresponding ketones 92.[31,32] 
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Scheme 48. Reaction scheme of the whole cell double oxidation of n-heptane (29) 
with a three-enzyme catalyst, converting the intermediates (R)- resp. (S)-
heptanols ((R)- resp. (S)-91) completely into the corresponding ketones 92[31,32] 
This concept was furthermore successfully adapted to cyclooctane (1d) and the 
application of the three-enzyme system CYP BM-3 19A12NADH-RE-ADH-LB-ADH 
yielded 94% cyclooctanone (3d) (652 mg/l). With the two-enzyme system 
containing CYP BM-3 19A12-LB-ADH the third highest TTN of 23700 for CYP BM-3 
was achieved (Scheme 49).[32] 
 
 
Scheme 49. Reaction scheme of the whole cell double oxidation of cyclooctane 
(1d) yielding the corresponding ketone 3d[32] 
Cyclohexane (1a) and cyclodecane (1b) turned out to be the most promising 
substrates in both, the monohydroxylation experiments and the double oxidation 
approaches. In this section it is analyzed if the cyclic alkanes cyclohexane (1a) and 
cyclodecane (1b) can be applied as substrates in a whole cell biotransformation as 
good as the encouraging substrate cyclooctane (1d).[32] 
 
6.2 Results and discussion 
6.2.1 Cultivation of the recombinant cells 
 
To investigate cyclohexane (1a) and cyclodecane (1b) in a whole cell 
biotransformation two different constructs were applied. These two constructs 
(E. coli BL21 (DE3) Gold LacIQ1 pALXtreme-1a P450 BM-3 19A12NADPH(KanR) + pKA1 
LB-ADH (CmR) and E. coli BL21 (DE3) Gold LacIQ1 pALXtreme-1a P450 BM-3 
19A12NADH::RE-ADH (KanR) + pKA1 LB-ADH (CmR)) were previously used in the 
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above-mentioned biotransformation of cyclooctane (1d).[31,32] In both cases 
recombinant cells from E. coli are used in which the respective enzymes were 
coexpressed. At one point, the monooxygenase and the LB-ADH were coex-
pressed on two different plasmids while the other time, the RE-ADH was coex-
pressed on the same plasmid with the monooxygenase while the LB-ADH was 
coexpressed on a second plasmid. The strains were cultivated according to SOP 21 
and for the whole cell experiments the cells were defrosted and suspended in 
buffer.  
 
6.2.2 Oxidation of cyclohexane (1a) using a two- and a three-enzyme system 
 
In this section the whole cell biotransformation of cyclohexane (1a) is described 
which was carried out according to SOP 22. The reaction scheme is shown in Table 
23 - Table 24 and the model reaction was studied at different reaction times. The 
concentration of the substrate 1a, the intermediate 2a and the product 3a was 
analyzed via gas chromatography and the results are summarized in Figure 23 - 
Figure 24.  
 
Table 23. Oxidation of cyclohexane (1a) using construct A, BL21 (DE3) Gold LacIQ1 
pALXtreme-1a P450 BM-3 19A12NADPH(KanR) + pKA1 LB-ADH (CmR); OD600 = 40.2, 
CDW = 8.7 (cell dry weight; in gCDW L
-1)  
 
Entrya) 
Time 
[h] 
1a [g/L] 2a [g/L] 3a [g/L] 
Σ2a+3a 
[g/L] 
Product yield  on 
catalystb) 
[mgproduct/gCDW] 
1 0.5 0.06 0.10 0.02 0.12 14 
2 1 0.01 0.16 0.08 0.24 28 
3 2 0.02 0.21 0.14 0.35 40 
4 4 0.03 0.26 0.15 0.41 94 
5 18 0.02 0.36 0.04 0.40 47 
6 24 0.02 0.38 0.04 0.42 48 
a)Both, experiments and GC-measurements are conducted in a twofold determination with the 
result that for each reaction the average of a fourfold dataset is calculated; b)Product yield on 
catalyst describes the ratio between the sum of products mass concentrations (Σ2+3) in mg/L and 
the amount of catalyst as cell dry weight in gCDW L
-1. 
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Figure 23. Oxidation of cyclohexane (1a) using construct A, BL21 (DE3) Gold LacIQ1 
pALXtreme-1a P450 BM-3 19A12NADPH(KanR) + pKA1 LB-ADH (CmR) over the course 
of time 
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Table 24. Oxidation of cyclohexane (1a) using construct B, BL21 (DE3) Gold LacIQ1 
pALXtreme-1a P450 BM-3 19A12NADH::RE-ADH (KanR) + pKA1 LB-ADH (CmR);      
OD600 = 39.0; CDW = 5.0 (cell dry weight; in gCDW L
-1) 
 
Entrya) 
Time 
[h] 
1a [g/L] 2a [g/L] 3a [g/L] 
Σ2a+3a 
[g/L] 
Product yield  on 
catalystb) 
[mgproduct/gCDW] 
1 0.5 0.05 0.08 0.03 0.11 22 
2 1 0.03 0.14 0.09 0.23 46 
3 2 0.02 0.18 0.15 0.33 66 
4 4 0.01 0.25 0.21 0.46 92 
5 18 0.01 0.41 0.06 0.47 94 
6 24 0.01 0.43 0.08 0.51 102 
a)Both, experiments and GC-measurements are conducted in a twofold determination with the 
result that for each reaction the average of a fourfold dataset is calculated; b)Product yield on 
catalyst describes the ratio between the sum of products mass concentrations (Σ2+3) in mg/L and 
the amount of catalyst as cell dry weight in gCDW L
-1. 
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Figure 24. Oxidation of cyclohexane (1a) using construct B, BL21 (DE3) Gold LacIQ1 
pALXtreme-1a P450 BM-3 19A12NADH::RE-ADH (KanR) + pKA1 LB-ADH (CmR) over 
the course of time 
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Both, the series of experiments with the two-enzyme system (consisting of CYP 
BM-3 19A12NADPH and LB-ADH) and the three-enzyme system (consisting of CYP 
BM-3 19A12NADH, RE-ADH and LB-ADH) (Scheme 48 - Scheme 49 and Figure 23 - 
Figure 24) showed a very similar progress: in the beginning of the whole cell 
catalyzed reaction, the concentration of the substrate cyclohexane (1a) is 
continually decreasing. At about the same time, the concentration of the 
intermediate cyclohexanol (2a) and the product cyclohexanone (3a) is continually 
increasing. After the 4 initial hours of the reaction, the equilibrium is strongly 
shifted from the product cyclohexanone (3a) towards the intermediate 
cyclohexanol (2a). A conceivable explanation for this phenomenon is the low 
stability of the cytochrome P450 monooxygenase and the associated, 
chronological following disruption of the first oxidation step. As a consequence, 
the reduced form of the cofactor NAD(P)H accumulates within the cells. This 
excess causes the increased activity of the alcohol dehydrogenase in the reductive 
direction.  
 
The experiments with the three-enzyme system (CYP BM-3 19A12NADH+ RE-ADH + 
LB-ADH) showed a tendentially higher product formation (up to 0.51 g/l 2a and 
3a) than the experiments with the two-enzyme system (CYP BM-3 19A12NADPH+ 
LB-ADH) where up to 0.42 g/l 2a and 3a are produced. An explanation for these 
findings is the varying intracellular concentration of CYP BM-3 that can be 
ascribed to a varying expression level of the recombinant protein in the cells. This 
value, specified as mgP450/gCDW, is generally determined via CO-difference 
spectroscopy. For the experiments described in this chapter, the intracellular 
concentration of CYP BM-3 was not determined. Nevertheless, it is published by 
MÜLLER et al. that the cells containing three enzymes (CYP BM-3 19A12NADH+ 
RE-ADH + LB-ADH) include a fourfold higher concentration of the monooxygenase 
(12 mgP450/gCDW) than the cells containing only two enzymes (3 mgP450/gCDW with 
CYP BM-3 19A12NADPH+ LB-ADH). Within the whole cell double oxidation of 
n-heptane, this considerably increased content of CYP BM-3 causes an 
improvement in product formation.[31,32] Assuming that this a general tendency, 
this makes the increased formation of the oxidation products 2a and 3a with the 
three-enzyme system (CYP BM-3 19A12NADH+ RE-ADH + LB-ADH)  more 
comprehensible. 
 
6.2.3 Oxidation of cyclodecane (1b) using a two- and a three-enzyme system 
 
In this section the whole cell biotransformation of cyclodecane (1b) is described 
which was carried out according to SOP 23. The reaction scheme is shown in Table 
25 - Table 26 and the model reaction was studied at different reaction times. The 
concentration of the substrate 1b, the intermediate 2b and the product 3b was 
analyzed via gas chromatography and the results are summarized in Figure 25 - 
Figure 26.  
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Table 25. Oxidation of cyclodecane (1b) using construct A, BL21 (DE3) Gold LacIQ1 
pALXtreme-1a P450 BM-3 19A12NADPH(KanR) + pKA1 LB-ADH (CmR);                     
OD600 = 39.4; CDW = 14.9 (cell dry weight; in gCDW L
-1) 
 
Entrya) 
Time 
[h] 
1b [g/L] 2b [g/L] 3b [g/L] 
Σ2b+3b 
[g/L] 
Product yield  on 
catalystb) 
[mgproduct/gCDW] 
1 1 8.00 -- 0.06 0.06 4 
2 4.5 6.42 -- 0.10 0.10 7 
3 20 1.99 -- 0.06 0.06 4 
a)Both, experiments and GC-measurements are conducted in a twofold determination with the 
result that for each reaction the average of a fourfold dataset is calculated; b)Product yield on 
catalyst describes the ratio between the sum of products mass concentrations (Σ2+3) in mg/L and 
the amount of catalyst as cell dry weight in gCDW L
-1. 
 
 
1h 
4,5h 
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Figure 25. Oxidation of cyclodecane (1b) using construct A, BL21 (DE3) Gold LacIQ1 
pALXtreme-1a P450 BM-3 19A12NADPH(KanR) + pKA1 LB-ADH (CmR)                       
over the course of time 
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Table 26. Oxidation of cyclodecane (1b) using construct B, BL21 (DE3) Gold LacIQ1 
pALXtreme-1a P450 BM-3 19A12NADH::RE-ADH (KanR) + pKA1 LB-ADH (CmR);      
OD600 = 33.6; CDW = 10.4 (cell dry weight; in gCDW L
-1) 
 
Entrya) time [h] 
1b 
[g/L] 
2b 
[g/L] 
3b 
[g/L] 
Σ2b+3b 
[g/L] 
Product yield  on 
catalystb) 
[mgproduct/gCDW] 
1 1 7.97 -- 0.12 0.12 12 
2 4.5 7.17 -- 0.12 0.12 12 
3 20 4.95 -- 0.12 0.12 12 
a)Both, experiments and GC-measurements are conducted in a twofold determination with the 
result that for each reaction the average of a fourfold dataset is calculated; b)Product yield on 
catalyst describes the ratio between the sum of products mass concentrations (Σ2+3) in mg/L and 
the amount of catalyst as cell dry weight in gCDW L
-1. 
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Figure 26. Oxidation of cyclodecane (1b) using construct B, BL21 (DE3) Gold LacIQ1 
pALXtreme-1a P450 BM-3 19A12NADH::RE-ADH (KanR) + pKA1 LB-ADH (CmR) over 
the course of time 
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Both, the series of experiments with the two-enzyme system (consisting of CYP 
BM-3 19A12NADPH and LB-ADH) and the three-enzyme system (consisting of CYP 
BM-3 19A12NADH, RE-ADH and LB-ADH) (Table 25 - Table 26 and Figure 25 - Figure 
26) show a very similar progress: over the course of time the concentration of the 
substrate cyclodecane (1b) is continually decreasing. On the other hand, the 
concentration of the product cyclodecanone (3b) remains constant (disregarding 
one deviation of measurement, Table 25, entry 2). For the intermediate cyclo-
decanol (2b) is not detected at any time, a reasonable explanation for the 
decreasing concentration of 1b might be a further- or multiple oxidation. Gas 
chromatography was used as analytical method for the absolute and 
simultaneous quantification of all cycloalkanes 1, cycloalkanols 2 and cycloalka-
nones 3 by a straight calibration line. Multiple oxidation products would give 
signals at higher retention times than the analyzed cycloalkanes 1, cycloalkanols 2 
and cycloalkanones 3. Therefore it is conceivable that multiple oxidation products 
of cyclodecane (1b) are not detected by the time-optimized method of 
measurement which was designed for quantification of the oxidation products 
cyclodecanol (2b) and cyclodecanone (3b) only. This approach can serve as 
starting point for further investigation on this topic.  
 
As already described for the substrate cyclohexane (1a), the formation of the 
oxidation products 2b and 3b with the three-enzyme system (CYP BM-3 
19A12NADH+ RE-ADH + LB-ADH) is increased compared to the whole cell catalysis 
with the two-enzyme system (CYP BM-3 19A12NADPH+ LB-ADH). This is the result of 
the tendential higher intracellular concentration of CYP BM-3 within the three-
enzyme system.[31,32] 
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7 Summary 
 
The aim of this thesis was predominantly to develop a more contemporary and 
green procedure for the direct functionalization of cycloalkanes 1 to cycloalkano-
nes 3, theoretically able to substitute traditionally applied oxidation procedures. 
The concept was a biotechnological approach, in which the desired cycloalkanone 
3 is obtained directly by a one-pot process starting from the corresponding cyclo-
alkane 1 and using atmospheric oxygen as oxidizing agent (Scheme 50).  
 
 
Scheme 50. Double oxidation of cycloalkanes 1 (n = 1, 3)  
Besides the cycloalkanes 1 mentioned above, a range of substrates, for various 
reasons attractive to be hydroxylated by cytochrome P450 monooxygenases from 
Bacillus megaterium (CYP BM-3), was analyzed in this context. Cyclooctyne (17) 
was accepted by none of the tested mutants while two mutants showed activity 
with cyclododecene (18). However, the formation of an oxidation product was not 
detected and the previously measured activity towards 18 was attributed to an 
undefined background reaction consuming the cofactor NADPH resp. uncoupling 
in general. The substrate pentanal (19) was expected to be suitable for an 
enzymatic oxidation since a specific activity of 29 U/g towards this compound was 
found with the mutant CYP BM-3 19A12. Nevertheless, the precisely identified 
new compound was not the product of an oxidation reaction but the 
corresponding alcohol 53, a product of the reduction of pentanal (19). Probably 
this was the result of an undesired background activity caused by an alcohol 
dehydrogenase from the host organism E. coli, operating in reductive direction.  
 
Prior to preparative oxidation experiments with cycloalkanes 1, preliminary 
studies like the simulation of the reaction conditions and the working up were 
conducted to develop an overall process that is only marginal error-prone under 
realistic conditions. Taking sources of error like the presence of biomass into 
consideration, an efficiently optimized reaction progress and working up led to a 
likewise high isolation rate of 94% cyclododecanone (3c) after 24 h, when 100 mM 
of 3c were applied in a simulated reaction. Even concentrations down to 10 mM 
of the substrate cyclododecane (1c) and the intermediate cyclododecanol (2c) 
showed a constant deviation of < 10% and mostly far below, based on an ideal 
recovery of 100%.  
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To facilitate the simultaneous quantification of the particular cycloalkanes 1, 
cycloalkanols 2 and cycloalkanones 3 from the extraction mixture via gas chroma-
tography, multipoint calibration lines were acquired. Additionally, the methods 
detection limit (MDL) was investigated to ensure quantitatively correct results and 
guarantee the reproducibility of the measurements. The C12-compounds 1-3c can 
be detected in concentrations down to 0.005 g/L, covering the relevant concen-
tration range of interest. Also the quantification of the C10-compounds 1-3b is 
realized and valid results are obtained in microgram quantities. Even at a concen-
tration of 0.025 g/L, the deviation was not exceeding more than 10% of the ideal 
recovery (100%) at any time. For the C6-compounds 1-3a the simultaneous and 
reliable quantification can be realized in a concentration range down to 0.1 g/L, a 
result that is entirely sufficient for the planned syntheses.  
 
In preliminary stages prior to the preparative biotransformations, the enzyme 
activities of selected mutants were determined via UV/VIS-spectrophotometric 
assays. The most promising substrates that came out of these enzyme activity 
studies with the cycloalkanes 1 were then applied in preparative biotransforma-
tions. For the not readily soluble substrate cyclododecane (1c), the kinetics 
according to MICHAELIS-MENTEN were investigated to ensure that the biotransfor-
mation can be conducted at maximum reaction rate. Since the enzyme is already 
saturated with substrate at a substrate concentration of 50 µM, addition of more 
substrate would not affect the reaction rate and under the standard reaction 
conditions the maximum reaction rate is reached.  
 
Since only the mutants CYP BM-3 F87A A328V and CYP BM-3 F87P seemed to be 
promising for the conversion of the substrate cyclododecane (1c) (15-34 U/mg; 
TOFs of 31 resp. 145 min-1) while all other mutants showed no or only poor 
activity, these mutants were used for the preparative biotransformations of 1c. In 
summary it can be stated that all tested mutants showed a low acceptance 
towards 1c in the preparative experiments although activity was shown in 
preliminary enzyme activity tests. 
 
The highest specific activity for the oxidation of cyclodecane (1b) by far (39-
56 U/g; TOFs of 317-850 min-1) was shown by the mutant CYP BM-3 19A12 and 
therefore it was preferred for preparative experiments with this substrate. In 
order to consider the hydroxylation of the cycloalkane 1 in isolation, a cofactor 
regeneration system using glucose dehydrogenase (GDH) was applied. In an 
experimentally performed hydroxylation of cyclodecane (1b) (100 mM) with CYP 
BM-3 19A12, 0.15 g/L of the desired product cyclodecanol (2b) were formed. 
Therefore 1b turned out to be a suitable substrate for the planned double 
oxidation. Just as with the substrate cyclodecane (1b), the mutant CYP BM-3 
19A12 turned out to be as well by far the best recombinant enzyme to catalyze 
the oxidation of cyclohexane (1a) and without exception, all other tested enzymes 
lag far behind this remarkable activity. In summary, specific activities from 
131 U/g through to 161 U/g and TOFs from 1165 to 2183 min-1 were found for the 
different formulations.  
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Therefore, CYP BM-3 19A12 was used extensively for preparative experiments. In 
the following hydroxylation experiment, remarkable 1.33 g/L of the product 2a 
were formed while as a product of further oxidation 0.08 g/L 3a were detected 
(Scheme 51). Keeping the synthetic concept - namely the intention to synthesize 
cycloalkanones 3 from cycloalkanes 1 - in mind, the further oxidation is supporting 
the LK-ADH-catalyzed reaction step (Scheme 50) by enhancing the desired 
product quantity.  
 
Scheme 51. Oxidation of cyclohexane (1a) with CYP BM-3 19A12  
This successful P450 monooxygenase-catalyzed hydroxylation using and consu-
ming molecular oxygen (O2) represents the initial step of the planned two step 
one-pot process starting from a cycloalkane 1 and aiming to directly synthesize 
the desired cycloalkanone 3. For the realization, a further alcohol dehydrogenase-
catalyzed oxidation of the cycloalkanol 2 into the desired cycloalkanone 3 was 
planned, which proceeds in situ and transforms the oxidized form of the cofactor 
resulting from the initial hydroxylation back to the reduced form NAD(P)H 
(Scheme 52). 
 
 
Scheme 52. Double oxidation of cycloalkanes 1 (n = 1, 3) focussing the second 
LK-ADH-catalyzed oxidation step 
Spectrophotometric assays were performed to determine the enzyme activity of 
the alcohol dehydrogenase from Lactobacillus kefir (LK-ADH) towards the sub-
strates of most interest, cyclohexanol (2a) and cyclodecanol (2b). Average relative 
activities up to 42% referred to 1-phenylethanol (71) were determined for the 
transformation of 2a. The enzyme activity studies with 2b in contrast revealed 1.5 
times higher relative activities of Ø 155% referred to the reference compound 71. 
The double oxidations of cyclohexane (1a) and cyclodecane (1b) were realized in 
the presence of a cytochrome P450 monooxygenase from Bacillus megaterium 
(CYP BM-3) and the alcohol dehydrogenase from Lactobacillus kefir (LK-ADH) in 
phosphate buffer.  
92 | SUMMARY 
 
To oxidize 1a, the cofactor NADPH was added directly to start the reaction. The 
approach of adding 2-propanol to generate the reduced cofactor form NADPH - 
that is required for the initial hydroxylation step - in situ from NADP+ was 
discarded since in experiments with the mutant CYP BM-3 19A12 the product 
formation of 0.19 g/L was lower by half of the product formations without 
2-propanol (0.41 g/L). Using the subsequent system the best results were 
obtained whereby it was notable that early experiments yielded 0.41 g/L while 
later conducted experiments gave 0.98 g/L on an average (Scheme 53). Since 
quantitatively more biomass, nearly the double amount, was applied in the later 
experiments, ͚MaĐƌoŵoleĐulaƌ①CƌoǁdiŶg͛①- caused by an increased overall protein 
loading - is hence, besides the optimized work up, an explanation for the more 
than twofold higher productivity. 
 
 
Scheme 53. Double oxidation of cyclohexane (1a) with CYP BM-3 19A12 
The formation of cyclohexanone (3a) on a gram scale constitutes an excellent 
productivity for this type of reaction. In comparison to cyclohexane (1a), slightly 
better results were achieved for the double oxidation of cyclodecane (1b) by 
adding the 2-propanol-starter. An average product formation of 0.26 g/L was 
obtained by admixing NADP+ and 2-propanol (Scheme 54). The intermediate 2b 
was not detected at any time in contrast to intermediate 2a. This is owed to a fact 
clarified by the enzyme activity assays: cyclodecanol (2b) revealed 1.5 times 
higher relative activities of Ø 155% referred to the reference compound 71, 
compared to cyclohexanol (2a) with only 42%. Therefore 2b is quickly converted 
into 3b and was not accumulated. 
 
 
Scheme 54. Double oxidation of cyclodecane (1b) with CYP BM-3 19A12 
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Furthermore the shift in product formation caused by a shortened reaction time 
was investigated. The double oxidation of cyclohexane (1a) was performed under 
constant conditions with constant amounts of both enzymes (CYP BM-3 19A12 
and LK-ADH) and various reaction times. After 4 h the product formation was 
already 0.51 g/L and therefore half the benchmark product formation after 24 h, 
which was 0.99 g/L. Even more easy to abbreviate were the experiments using 
cyclodecane (1b) as substrate, since a shorter reaction time brought along only a 
marginal decrease of product formation: After 2 h it was 0.21 g/L and after 4 h it 
was 0.23 g/L while 24 h gave 0.27 g/L of cyclodecanone (3b). The reason for this 
divergence - namely the different product formation of 3a and 3b at shortened 
reaction times of the double oxidation - can be found in the fact that the 
biotransformation of 1b is faster compared to the biotransformation of 1a. 
Cyclodecanol (2b) is accepted 3 to 6 times better by the LK-ADH than cyclohexanol 
(2a) what makes the reaction faster and provides the reduced form of the 
cofactor more quickly to the first oxidation step.  
  
Moreover the effect of decreasing the usually applied concentration of cofactor 
NADP+/NADPH (10 mol%) was investigated. Under constant conditions, the 
double oxidation of cyclohexane (1a) yielded a product formation that remained 
unchanged employing 1 or 2 mol% of NADPH (Ø 0.10 g/L) and also the application 
of both, each 1 mol % of the reduced as well as of the oxidized form of cofactor 
resulted in the same productivity. This was not surprising because the initially 
necessary NADPH in den comparative tests had as well not to be formed via a 
2-propanol-starter and the reaction could start immediately in any case. By 
directly comparing experiments that differ only in the amount of cofactor it was 
fouŶd①that①sĐaƌĐelǇ①⅓①of①the①ďeŶĐhŵaƌk①pƌoduĐt①foƌŵatioŶ①ĐaŶ①ďe①aĐĐoŵplished①
ǁith①⅟10 amount of cofactor: The application of 10 mol% cofactor led to a product 
formation of 0.99 g/L while using only 1 mol% cofactor effected a product 
formation of 0.28 g/L. 
 
With cyclodecane (1b) as substrate, the biotransformations applying only 
1-2 mol% NADP+ resulted in a nearly unchanged product formation, which was 
0.26 g/L on an average, compared to a benchmark product formation of 0.27 g/L. 
However, a slight but noteworthy increased product formation of 0.35 g/L was 
obtained when each 1 mol% of the reduced as well as of the oxidized form of 
cofactor were added. This can be attributed to the fact that 1 mol% of the 
reduced cofactor was provided directly to start the reaction and only half of the 
amount of the cofactor NADPH had to be produced in situ from NADP+. The direct 
comparison of the experiments that differ only in the amount of cofactor showed 
that the benchmark product formation (0.27 g/L at 10 mol% cofactor) can be 
aĐhieǀed①ǁith①⅟10 amount of cofactor (Ø 0.26 g/L at 1 mol% cofactor).  
 
A shortened reaction time - explained in the section above - illustrated that the 
enzyme catalyzed formation of cyclodecanone (3b) proceeds faster than the 
formation of cyclohexanone (3a), probably due to a higher acceptance of 
cyclodecanol (2b) by the LK-ADH.  
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Therefore the considerably reduced cofactor quantity is more quickly provided to 
the first hydroxylation step in the oxidation of cyclodecane (1b) whereas the 
double oxidation of cyclohexane (1a) is not fast enough to compensate the 
reduced amount of cofactor. To investigate the impact of substrate concentration 
on product formation, an experiment with fivefold substrate concentration was 
performed. The increase of the substrate concentration led to higher product 
formations, but the correlation was not linear: Applying 100 mM 1b in a 
biotransformation, the product formation was 0.25 g/L of 3b. A fivefold higher 
substrate concentration, namely 500 mM resulted in a product formation of 
0.82 g/L 3b.  
 
An extended aim was to test a co-immobilisate of enzymes, hereinafter referred 
to①as①͚supeƌaďsoƌďed①eŶzǇŵe①taŶdeŵ͚, that would render the presented biotrans-
formation even more attractive by reusing the catalysts. This tandem consisted of 
a cytochrome P450 monooxygenase from Bacillus megaterium (CYP BM-3 19A12) 
and an alcohol dehydrogenase from Lactobacillus kefir (LK-ADH) together with the 
cofactor NADPH and was applied for the enzymatic two-step one-pot process 
(Scheme 55). 
 
 
 
Scheme 55. Double oxidation of cyclohexane (1a) using the superabsorbed 
enzyme tandem 
To obtain this hydrogel matrix, the superabsorbent polymer Favor SXM 9155 was 
employed. On an average, the product formation was about six times lower using 
this not optimized system than in the benchmark experiment using non-
immobilized free catalysts, where 0.99 g/L of 3a were formed. Moreover, the 
system showed no conversion after the second cycle.  
 
Finally the biocatalyzed double oxidation via whole cell catalysis was investigated 
for cyclohexane (1a) and cyclodecane (1b) and two different constructs were used 
for this project. At one point, monooxygenase and LB-ADH were coexpressed on 
two different plasmids while the other time, an RE-ADH was coexpressed on the 
same plasmid with the monooxygenase while the LB-ADH was coexpressed on a 
second plasmid. The oxidation of 1a was performed using the two- and the three-
enzyme system and the model reaction was studied at different reaction times. 
The series of experiments with the two-enzyme system (consisting of CYP BM-3 
19A12NADPH and LB-ADH) and the three-enzyme system (consisting of CYP BM-3 
19A12NADH, RE-ADH and LB-ADH) showed a very similar progress and one selected 
reaction scheme is shown exemplarily in Scheme 56. 
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Scheme 56. Oxidation of cyclohexane (1a) using the three-enzyme system 
(consisting of CYP BM-3 19A12NADH, RE-ADH and LB-ADH) 
At the beginning of the whole cell biotransformation the concentration of 1a was 
continually decreasing while the amount of the intermediate 2a and the product 
3a increased significantly. Following this trend for 4 hours, the equilibrium was 
then strongly shifted from the product 3a towards the intermediate 2a. A disrup-
tion of the first step might cause the accumulation of the reduced form of the 
cofactor NAD(P)H within the cells and this excess effects the increased activity of 
the alcohol dehydrogenase in reductive direction. Conceivable due to the varying 
expression level of the recombinant protein in the cells, the experiments with the 
three-enzyme system showed a slightly higher product formation (up to 0.51 g/L 
2a and 3a after 24 h) than the experiments with the two-enzyme system where 
up to 0.42 g/L 2a and 3a were produced after 24 h.  
The oxidation of 1b was also analyzed using the two- and the three-enzyme 
system over the time and with the two-enzyme system, 0.10 g/L 3b were obtained 
after 4.5 h. As well as with 1a as substrate, the experiments with the two- and the 
three-enzyme system showed an almost identical progression. The concentration 
of the substrate 1b was decreasing while the concentration of 3b remained most 
widely constant. The intermediate cyclodecanol (2b) was not detected at any 
time. A reasonable explanation for the decreasing concentration of 1b - without 
visible product formation - might be the formation of multiple oxidation products 
which are not detected by the time-optimized method of measurement which 
was designed for the quantification of the oxidation products 2b and 3b only.  
In summary a biotechnological process was developed in which the desired cyclo-
alkanones 3, namely cyclohexanone (3a) and cyclodecanone (3b), were obtained 
in a one-pot process starting from the corresponding cycloalkane 1. This system, 
in which the reaction takes place in water, atmospheric oxygen is used as 
oxidation agent and no further co-substrate is required, renders the necessity of 
interim stages with isolation of intermediates obsolete. Furthermore this 
technology was successful performed in a superabsorbed enzyme tandem consis-
ting of both enzymes as well as the cofactor NADPH. Equally this type of reaction 
can be realized using whole cell catalysis.  
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8 Experimental Section 
8.1 Materials, instruments and methods 
 
Chemicals:  
The commercially available chemicals used for this project were purchased from 
Acros Organics®, Sigma-Aldrich®, ABCR®, Thermo Fisher Scientific®, TCI Europe® 
or Fluka® and except as noted otherwise used without further purification. The 
supeƌaďsoƌďeŶt①polǇŵeƌ①„Faǀoƌ①“XMϵϭϱϱ͞①is①Đoŵŵercially available from Evonik 
Industries, Stockhausen. 
 
Enzymes and cofactors: 
The cytochrome P450 monooxygenases (CYP BM-3) used for this project (CYP 
BM-3 WT[81], CYP BM-3 19A12[160,161], CYP BM-3 F87V[89,161], CYP BM-3 F87A 
A328V[92,162], CYP BM-3 R255P-P329H[32,163], CYP BM-3 F87P[164]) were made avail-
able through the courtesy of the research group Prof. Dr. U. Schwaneberg (RWTH 
Aachen). The alcohol dehydrogenases from Lactobacillus kefir (LK-ADH) and 
Rhodococcus sp. (Rsp.-ADH)[165-167] were made available through the courtesy of 
the research group Prof. Dr. W. Hummel (Research Centre Jülich). The ADH-200 is 
commercially available from evocatal[168] (catalogue entry evo-1.1.200, CAS: 9031-
72-5). The glucose dehydrogenase from Bacillus sp. (Amano 2) was purchased 
from Amano Enzyme Inc. (Nagoya, Japan). The cofactors NADPH and NADP+ were 
purchased from Oriental Yeast Co. Ltd., Japan.  
 
Buffer and media: 
Buffer solutions were prepared from sodium dihydrogenphosphate and 
equilibrated by adding sodium hydroxide until the desired pH was reached. 1 l LB-
medium is prepared by dissolving 10 g peptone, 5 g yeast extract and 10 g NaCl in 
deionized water and filling up to a final volume of 1 l. The medium is autoclaved. 
1 l TB-medium is mixed on demand from 800 mL solution A and 200 mL solution 
B. For the preparation of solution A, 12 g peptone, 24 g yeast extract und 4 g 
glycerol are dissolved in deionized water, filled up to 800 mL and autoclaved. For 
the preparation of solution B, KH2PO4 (2.31 g) und K2HPO4 (12.54 g) are dissolved 
in deionized water, filled up to 200 mL and autoclaved. 
 
The following instruments have been used for analytic and preparative works: 
 
NMR-spectroscopy: 
1H and 13C NMR spectra were recorded on an Avance DRX 500 spectrometer 
(Bruker) in deuterochloroform (CDCl3), deuteriumoxide (D2O), dimethylsulfoxide-
d6 (DMSO-d6) or deuterodichloromethane (CD2Cl2) on a 500 MHz instrument. 
Chemical shifts were reported in parts per million (ppm, ɷ) downfield from 
residual solvent signals: CHCl3: ɷ(1H), 7.26 ppm; ɷ(13C), 77.16 ppm. D2O: ɷ(1H), 
4.79 ppm. CD2Cl2: ɷ(1H), 5.32 ppm; ɷ(13C), 53.84 ppm. DMSO-d6: ɷ(1H), 2.50 ppm; 
ɷ(13C), 39.52 ppm. Proton coupling patterns are described as singlet (s), doublet 
(d), triplet (t), doublet of triplet (dt), quartet (q) and multiplet (m). 
98 | EXPERIMENTAL SECTION 
 
Spectrophotometer:  
The data for activity determination of the enzymes was recorded with a UV/VIS-
spectrophotometer V-630 from Jasco. 
 
Thermomixer: 
Extractions under constant shaking and isothermic conditions were conducted 
using a thermomixer comfort 5355 from Eppendorf. 
 
Centrifuge: 
Phase separations during work-up were achieved using a microliter centrifuge 
(model CT15RE, VWR). Samples were centrifuged for 10 - 30 minutes at 13000 
rpm and room temperature. 
 
Gas chromatography: 
All qualitative and quantitative measurements via gas chromatography were 
performed with a Shimadzu GC 2010 (Autoinjector AOC-20i (Shimadzu)) using a 
Rt-βDEXm (Restek®) column (Length: 30 m; Inner Diameter: 0.25 mm; Film 
Thickness: 0.25 µm) (used for method A) or a Shimadzu GC 2010 Plus 
(Autoinjector AOC-20i (Shimadzu), Autosampler AOC-20s (Shimadzu)) using a Rxi-
5ms (Restek®) column (Length: 25 m; Inner Diameter: 0.2 mm; Film Thickness: 
0.33 µm) (used for method B). Molecular nitrogen (N2) is used as carrier gas at a 
pressure of 100 kPa and as gas chromatographic detector a flame ionization 
detector (FID) is applied. Since technical deviation of the retention times occur to 
a certain degree, the samples are spiked at regular intervals. The measurements 
are conducted according to the following temperature programs: 
 
1-3c:  
Method A (0.1 - 10 g/L): Shimadzu GC 2010: starting at 150°C, heating 10°C/min 
up to 220°C. Old column: tR (1c): 2.5 min; tR (2c): 4.9 min; tR (3c): 4.5 min; new 
column: tR (1c): 2.7 min; tR (2c): 5.2 min; tR (3c): 4.7 min. 
Method B (0.025 - 0.2 g/L): Shimadzu GC 2010 Plus: isotherm at 170°C for 5.5 min. 
tR (1c): 2.7 min; tR (2c): 5.2 min; tR (3c): 4.7 min. 
 
1-3b: 
Method A (0.1 - 10 g/L): Shimadzu GC 2010: starting at 150°C, heating 10°C/min 
up to 220°C. Old column: tR (1b): 1.8 min; tR (2b): 3.4 min; tR (3b): 3.0 min; new 
column: tR (1b): 1.9 min; tR (2b): 3.7 min; tR (3b): 3.2 min. 
Method B (0.025 - 0.80 g/L): Shimadzu GC 2010 Plus: starting at 125°C, heating 
15°C/min up to 185°C. tR (1b): 2.2 min; tR (2b): 3.6 min; tR (3b): 3.3 min. 
 
1-3a:  
Method A (0.15 - 1.5 g/L): Shimadzu GC 2010: starting at 70°C, heating 3.5°C/min 
up to 95°C. Old column: tR (1a): 1.5 min; tR (2a): 5.6 min; tR (3a): 5.1 min; new 
column: tR (1a): 1.6 min; tR (2a): 6.3 min; tR (3a): 5.7 min. 
Method B (0.025 - 0.80 g/L): Shimadzu GC 2010 Plus: isotherm at 70°C for 4.5 min. 
tR (1a): 1.5 min; tR (2a): 3.8 min; tR (3a): 4.0 min 
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General methods for working up: 
 
Standard Operating Procedure A (SOP A): 
After the individual reaction time the aqueous phase is poured into an Eppendorf 
tube and 1 mL dichloromethane is added. The biphasic system is extracted for 
30 min by shaking in a Thermomixer Comfort (type 5355) with 550 rpm at 25°C. In 
order to get a well-defined phase boundary the mixture is centrifuged at 13000 
rpm for 10 min. The supernatant aqueous phase is transferred into another 
Eppendorf tube and the extraction as described above is repeated twice, whereby 
the final phase separation is obtained by centrifugation at 13000 rpm for 30 min. 
The combined organic phases are transferred completely into a 5 mL volumetric 
flask which is filled with dichloromethane. By means of a straight calibration line 
the concentration is analyzed via gas chromatography. 
 
Standard Operating Procedure B (SOP B):  
After the individual reaction time 1 mL dichloromethane is added and the biphasic 
system is poured into an Eppendorf tube. The biphasic system is extracted for 
30 min by shaking in a Thermomixer Comfort (type 5355) with 550 rpm at 25°C. In 
order to get a well-defined phase boundary the mixture is centrifuged at 13000 
rpm for 10 min. After removing the organic phase the extraction as described 
above is repeated twice, whereby the final phase separation is obtained by 
centrifugation at 13000 rpm for 30 min. The combined organic phases are 
transferred completely into a 3 mL volumetric flask which is filled with 
dichloromethane. By means of a straight calibration line the concentration is 
analyzed via gas chromatography.  
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8.2 Syntheses and analytical data 
8.2.1 Standard operation procedure 1 (SOP 1): Biocatalyzed double 
oxidation of cyclododecane (1c) with CYP BM-3 and LK-ADH 
 
In a 25 mL round bottom flask cyclododecane (1c) (16.8 mg, 0.1 mmol) is mixed 
with 1 mL phosphate buffer (pH 7.0, 50 mM, 1 mM MgCl2) resp. 997.5 µL 
phosphate buffer (pH 7.0, 50 mM, 1 mM MgCl2) and 2.5 µL 2-propanol. Then a 
cytochrome P450 monooxygenase from Bacillus megaterium (CYP BM-3) 
(lyophilisate, 0.762 U referred to cyclodecane (1b)) and the alcohol 
dehydrogenase from Lactobacillus kefir (LK-ADH) (crude extract, 200 U/mmol 
referred to cyclodecanol (2b), diluted 1:1 with glycerol) are added. To start the 
reaction cofactor NADPH (8.3 mg, 0.01 mmol) resp. NADP+ (7.9 mg, 0.01 mmol) is 
added. The reaction mixture is stirred for 24 h at room temperature covered with 
a plug and worked up according to SOP A. 
 
Table 27. Results of the double oxidation of cyclododecane (1c) 
 
 
Entry 
CYP BM-3 
(biomass) 
IPA Cofactor 
Cyclododecanone 
(3c) [g/l]] 
Recovery of 
substrate 1c [%] 
1 
CYP BM-3 19A12 (0) 
(19.6 mg)a) 
 NADP+ 0 92 
2 
CYP BM-3 F87V 
(127.0 mg)b) 
- NADPH 0 83 
a)The content of CYP BM-3 19A12 (0) amounts to 0.123 μmol/g lyophilized crude extract; b)The con-
tent of CYP BM-3 F87V amounts to 0.525 μmol/g lyophilized crude extract. 
 
 
8.2.2 Standard operation procedure 2 (SOP 2): Simulation of reaction 
conditions and working up for cyclododecane (1c), cyclododecanol (2c) 
and cyclododecanone (3c) 
 
In a 25 mL round bottom flask cyclododecanone (3c) (18.13 - 18.54 mg, 
0.10 mmol) resp. cyclododecanol (2c) (0.184 -18.72 mg, 0.001 - 0.10 mmol) resp. 
cyclododecane (1c) (0.168 - 16.97 mg, 0.001 - 0.10 mmol) is mixed with 1 mL 
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phosphate buffer (pH 7.0, 50 mM) (3c) or 900 µL phosphate buffer (pH 7.0, 
50 mM) and 100 µL DMSO (1c, 2c). Then 0 - 30 mg of the denaturated (60°C, 20 h) 
cytochrome P450 monooxygenase from Bacillus megaterium (CYP BM-3 19A12, 
lyophilisate) is added and the mixture is stirred for 5 min up to 24 h at room 
temperature, each time covered with a plug. Then 1 mL dichloromethane is added 
and the biphasic system is poured into an Eppendorf tube. The biphasic system is 
extracted for 30 min by shaking in a Thermomixer Comfort (type 5355) with 
550 rpm at 25°C. After removing the organic phase the extraction as described 
above is repeated twice (whereby with 1c and 2c, the third extraction is 
conducted only with 500 µL dichloromethane) and the final phase separation is 
obtained by centrifugation at 13000 rpm for 30 min. The combined organic phases 
are transferred completely into a 2 mL (1c, 2c) resp. 5 mL (3c) volumetric flask 
which is filled with dichloromethane. By means of a straight calibration line the 
concentration is analyzed via gas chromatography.  
 
8.2.2.1 Cyclododecanone (3c) 
 
In a 25 mL round bottom flask cyclododecanone (3c) (18.13 - 18.54 mg, 
0.10 mmol) is mixed with 1 mL phosphate buffer (pH 7.0, 50 mM) and 0 - 20 mg of 
the cytochrome P450 monooxygenase from Bacillus megaterium (CYP BM-3 
19A12, lyophilisate) and stirred for 5 min - 24 h at room temperature covered 
with a plug and worked up according to SOP B, but a 5 mL volumetric flask was 
used instead of a 3 mL volumetric flask. 
 
Table 28. Results of the simulation of reaction conditions and working up for 
cyclododecanone (3c) 
 
 
Entry Time Initial weight [mg] Output weight [mg]b) Recovery [%] 
1 5 min 18.40 17.29 94 
2 24 h 18.13 17.29 95 
3 a) 24 h 18.40 --c) -- 
4 5 min 18.54 17.04 92 
5 24 h 18.15 17.28 95 
6 a) 24 h 18.44 17.32 94 
a)20 mg denaturated CYP BM-3 19A12 are added; b) calculated via GC;  c)lost during working up. 
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8.2.2.2 Cyclododecanol (2c) 
 
In a 25 mL round bottom flask cyclododecanol (2c) (0.184 - 18.72 mg, 0.001 -
 0.10 mmol) is mixed with 900 µL phosphate buffer (pH 7.0, 50 mM) and 100 µL 
DMSO. Then 0 - 30 mg of the denaturated (60°C, 20 h) cytochrome P450 mono-
oxygenase from Bacillus megaterium (CYP BM-3 19A12, lyophilisate) are added. 
The mixture is stirred for 5 min - 2 h at room temperature covered with a plug and 
worked up according to SOP B, but a 2 mL volumetric flask was used instead of a 
3 mL volumetric flask and the third extraction is conducted only with 500 µL 
dichloromethane (Table 29). 
 
Table 29. Results of the simulation of reaction conditions and working up for 
cyclododecanol (2c) 
 
Entrya) 2c [mmol] Time Initial weight [mg] Output weight [mg]d) 
Deviatione) 
[%] 
1 0.1 5 min 18.35 20.04 +9 
2 0.1 2 h 18.72 20.16 +8 
3b) 0.1 2 h 18.35 18.45 +1 
4 0.01 5 min 2.21 2.27 +3 
5 0.01 2 h 2.18 2.19 0 
6b) 0.01 2 h 2.20 2.13 -3 
7 0.001 5 min 0.184c) 0.151 -18 
8 0.001 2 h 0.184c) 0.150 -19 
9b) 0.001 2 h 0.184c) 0.136 -26 
a)All measurements are conducted in a twofold determination; b)30 mg denaturated CYP BM-3 
19A12 are added; c)weigh in via stock solution; d)calculated via GC; e)average deviation from a 
recovery of 100%. 
 
8.2.2.3 Cyclododecane (1c) 
 
In a 25 mL round bottom flask cyclododecane (1c) (0.168 - 16.97 mg, 0.001 -
 0.10 mmol) is mixed with 900 µL phosphate buffer (pH 7.0, 50 mM) and 100 µL 
DMSO. Then 0 - 30 mg of the denaturated (60°C, 20 h) cytochrome P450 mono-
oxygenase from Bacillus megaterium (CYP BM-3 19A12, lyophilisate) are added. 
The mixture is stirred for 5 min - 2 h at room temperature covered with a plug and 
worked up according to SOP B, but a 2 mL volumetric flask was used instead of a 
3 mL volumetric flask and the third extraction is conducted only with 500 µL 
dichloromethane (Table 30). 
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Table 30. Results of the simulation of reaction conditions and working up for 
cyclododecane (1c) 
 
 
Entrya) 1c [mmol] Time Initial weight [mg] Output weight [mg]d) 
Deviationf) 
[%] 
1 0.1 5 min 16.89 18.26 +8 
2 0.1 2 h 16.95 18.35 +8 
3b) 0.1 2 h 16.97 18.03 +6 
4 0.01 5 min 1.80 1.87 +4 
5 0.01 2 h 1.75 1.79 +2 
6b) 0.01 2 h 1.92 1.86e) -3 
7 0.001 5 min 0.168c) 0.162 -4 
8 0.001 2 h 0.168c) 0.106 -37 
9b) 0.001 2 h 0.168c) 0.039 -77 
a)All measurements are conducted in a twofold determination; b)30 mg denaturated CYP BM-3 
19A12 are added; c)weigh in via stock solution; d)calculated via GC; e)loss of one drop during working 
up; f)average deviation from a recovery of 100%. 
 
8.2.3 Standard operation procedure 3 (SOP 3): Simultaneous quantification 
of cycloalkanes 1, cycloalkanols 2 and cycloalkanones 3 via gas 
chromatography 
 
In a 100 mL volumetric flask a stock solution in acetone is prepared containing the 
substrate 1, the intermediate 2 and the product 3, each in a concentration of 
10 g/L (A) resp. 0.2 g/L (B) for the compounds 1-3c; 10 g/L (A) resp. 0.80 g/L (B) for 
the compounds 1-3b; 15 g/L (A) resp. 0.80 g/L (B) for the compounds 1-3a. A serial 
dilution is prepared to measure the following concentrations via gas chromato-
graphy:  
1-3c: Method A (0.1 - 10 g/L): 10 g/L, 5 g/L, 1 g/L, 0.5 g/L, 0.3 g/L, 0.1 g/L; Method 
B (0.025 - 0.2 g/L): 0.2 g/L, 0.1 g/L, 0.05 g/L, 0.025 g/L.  
1-3b: Method A (0.1 - 10 g/L): 10 g/L, 1 g/L, 0.5 g/L, 0.3 g/L, 0.1 g/L; Method B 
(0.025 - 0.80 g/L): 0.80 g/L, 0.40 g/L, 0.20 g/L, 0.10 g/L, 0.05 g/L, 0.025 g/L.  
1-3a: Method A (0.15 - 1.5 g/L): 1.5 g/L, 1.0 g/L, 0.75 g/L, 0.5 g/L, 0.3 g/L, 0.15 g/L; 
Method B (0.025 - 0.80 g/L): 0.80 g/L, 0.40 g/L, 0.20 g/L, 0.10 g/L, 0.05 g/L, 
0.025 g/L.  
 
All measurements are conducted in a sixfold determination and different 
concentrations of 1, 2 and 3 are analyzed to verify the respective method. 
104 | EXPERIMENTAL SECTION 
 
8.2.3.1 Quantification of cyclododecane (1c), cyclododecanol (2c), 
cyclododecanone (3c) 
 
According to SOP 3 a stock solution in acetone is prepared containing the 
substrate cyclododecane (1c), the intermediate cyclododecanol (2c) and the 
product cyclododecanone (3c). A serial dilution is prepared to measure different 
concentrations via gas chromatography. Straight calibration lines are prepared 
from the obtained data and different concentrations are analyzed to verify these 
methods.  
 
8.2.3.2 Definition of the methods detection limit (MDL) 
 
The detection limit of cyclododecane (1c), cyclododecanol (2c) and 
cyclododecanone (3c) is defined via gas chromatography. A stock solution in 
acetone is therefore prepared containing the substrate cyclododecane (1c), the 
intermediate cyclododecanol (2c) and the product cyclodecanone (3c), each in a 
concentration of 0.04 g/L. A serial dilution is prepared to measure the following 
concentrations via gas chromatography: 0.04 g/L, 0.02 g/L, 0.01 g/L, 0.005 g/L, 
0.002 g/L. All measurements are conducted in a twofold determination (Table 31). 
 
Table 31. GC-determined percental deviation from the prepared concentrations 
of cyclododecane (1c), cyclododecanol (2c) and cyclododecanone (3c) (B) 
Entrya) Compound 
Deviationb) at①a①ĐoŶĐeŶtƌatioŶ①of… 
…Ϭ.Ϭϰ g/L …Ϭ.ϬϮ g/L …Ϭ.Ϭϭ g/L …Ϭ.ϬϬϱ g/L …Ϭ.ϬϬϮ g/L 
1 1c +3% -7% -9% -13% -31% 
2 2c -1% -6% -6% -2% +6% 
3  3c -6% -8% -9% -13% -41% 
a)All measurements are conducted in a twofold determination; b)average deviation from a recovery 
of 100%. 
 
8.2.3.3 Quantification of cyclodecane (1b), cyclodecanol (2b), cyclodecanone 
(3b) 
 
According to SOP 3 a stock solution in acetone is prepared containing the 
substrate cyclodecane (1b), the intermediate cyclodecanol (2b) and the product 
cyclodecanone (3b). A serial dilution is prepared to measure different 
concentrations via gas chromatography. Straight calibration lines are prepared 
from the obtained data and different concentrations are analyzed to verify these 
methods (Table 32).  
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Table 32. Results of the verification of the GC-method for 1b, 2b and 3b 
Entrya) 
(method A) 
Compound 
Deviationc) at①a①ĐoŶĐeŶtƌatioŶ①of…  
…ϳ.Ϭ g/L …ϭ.ϰ g/L …Ϭ.Ϯ g/L 
1 1b -1.7% -3.6% 0.0% 
2 2b +2.9% n.d. -5.0% 
3  3b -1.4% -2.7% -8.6% 
Entryb) 
(method B) 
Compound 
Deviationc) at①a①ĐoŶĐeŶtƌatioŶ①of… 
…Ϭ.ϴ g/L …Ϭ.ϭ g/L …Ϭ.ϬϮϱ g/L 
1 1b -1.4% -2.7% -10.0% 
2 2b -0.5% +0.1% +0.8% 
3  3b -1.5% -2.1% -5.0% 
a)All measurements are conducted in a fourfold determination; b)All measurements are conducted in 
a twofold determination; c)average deviation from a recovery of 100%. 
 
8.2.3.4 Quantification of cyclohexane (1a), cyclohexanol (2a), cyclohexanone 
(3a) 
 
According to SOP 3 a stock solution in acetone is prepared containing the 
substrate cyclohexane (1a), the intermediate cyclohexanol (2a) and the product 
cyclohexanone (3a). A serial dilution is prepared to measure different 
concentrations via gas chromatography. Straight calibration lines are prepared 
from the obtained data and different concentrations are analyzed to verify these 
methods (Table 33). 
 
Table 33. Results of the verification of the GC-method for 1a, 2a and 3a 
Entrya) 
(method A) 
Compound 
Deviationc) at①a①ĐoŶĐeŶtƌatioŶ①of… 
…ϭ.ϯ g/L …Ϭ.ϵ g/L …Ϭ.Ϯ g/L 
1 1a +7.8% +12.2% +13.9% 
2 2a -1.3% -10.6%. -4.5% 
3  3a -5.5% -6.9% -6.7% 
Entryb) 
(method B) 
Compound 
Deviationc) at①a①ĐoŶĐeŶtƌatioŶ①of… 
…Ϭ.ϴ g/L …Ϭ.ϭ g/L …Ϭ.ϬϮϱ g/L 
1 1a +5.0% +9.5% +21.4% 
2 2a +4.5% +1.9% +2.1% 
3  3a -1.8% -5.3% -10.8% 
a)All measurements are conducted in a fourfold determination; b)All measurements are conducted in 
a twofold determination; c)average deviation from a recovery of 100%. 
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8.2.4 Standard operation procedure 4 (SOP 4): Photometric assay to 
determine the enzyme activity of different cytochrome P450 
monooxygenases from Bacillus megaterium (CYP BM-3) 
 
The enzyme activities can be determined with an UV/VIS-spectrophotometer for 
NAD(P)H is used as cofactor. The consumption of NAD(P)H through oxidation to 
NAD(P)+ is measured spectrophotometrically at a wavelength of 340 nm in the 
presence of the tested enzyme and one of the following compounds: Cyclohexane 
(1a), cyclodecane (1b), cyclododecane (1c), pentanal (19), cyclooctyne (17) or 
cyclododecene (18). A solution of the respective substrate (12 - 25 mM resp. 0.5 -
16 mM 1c for kinetics, assuming that the substrate will dissolve completely) is 
prepared in DMSO. For this purpose the substrates are weigh in a 5 mL volumetric 
flask which is filled up with DMSO.  
 
A cuvette (1 mL) is filled with 690 μl phosphate buffer (pH 7.0, 50 mM) and 10 µL 
of the substrate solution in DMSO (12 - 25 mM). Then 100 µL of the enzyme 
solution (10 mg/mL) are pipetted in the cuvette and mixed by inversion. After 
5 min, 200 μl of a buffered solution of the cofactor NAD(P)H (NAD(P)H: 
0.6 - 0.8 mM; phosphate buffer: pH 7.0, 50 mM) are pipetted in the cuvette and 
mixed by inversion. Then the measurement is started immediately. 
 
At first a measurement of the blank value (DMSO without substrate) is taken in 
which 690 μl of the phosphate buffer (pH 7.0, 50 mM), 10 μl DMSO and 100 μl of 
the enzyme solution (10 mg/mL) are pipetted in the cuvette and mixed by 
inversion. After 5 min, 200 μl of a buffered solution of the cofactor NAD(P)H 
(NAD(P)H: 0.6-0.8 mM; phosphate buffer: pH 7.0, 50 mM) are pipetted in the 
cuvette and mixed by inversion. Then the measurement is started immediately. 
This blank value is subtracted from the measured values resulting from the 
measurements including the respective substrate solutions. By means of the initial 
slope of the absorption curve and the following formula the volumetric enzyme 
activity resp. the kinetics resp. the stability can be determined. 
 
 
 
8.2.4.1 Enzyme activity towards monounsaturated cyclic hydrocarbons 
8.2.4.1.1 Enzyme activity towards cyclododecene (18) 
 
The measurements are performed as described above (SOP 4) to determine the 
enzyme activity of different cytochrome P450 monooxygenases from Bacillus 
megaterium (CYP BM-3) (solution of the lyophilisate: 10 mg/mL, NAD(P)H- 
dependent, phosphate buffer: pH 7.0, 50 mM) for cyclododecene (18). A solution 
of 18 (12 mM, assuming that 18 will dissolve completely) is prepared in DMSO. 
For this purpose 9.98 mg (0.06 mmol) of 18 are weigh in a 5 mL volumetric flask 
which is filled up with DMSO.  
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A 0.6 mM solution of NAD(P)H is used for the measurements. For all preparative 
experiments 0.762 U relative to 18 are used (Table 34). 
 
Table 34. Results of the enzyme activity test with cyclododecene (18) as substrate 
 
 
Entry CYP BM-3a) 
Specific 
activity 
[U/mg] 
0.762 U 
Content of CYP 
[nmol/g 
lyophilisate]d) 
TOF 
1  19A12 (1) -- -- 60 -- 
2 F87P (2) 0.040 19.05 mg 223 179 
3 F87V -- -- 525 -- 
4 F87A A328V (2) 0.040 19.05 mg 989 40 
5 WT -- -- 1260 -- 
6 R255P-P329Hb) 0.003 254.0 mg 220 14 
Vt = 1 mL, f = 1, ɸ = 6.3 mL*μmol-1*cm-1, Vs = 0.1 mL, d = 1 cm; a)In parentheses the different enzyme 
formulations are given; b)NADH-dependent; c)determined via CO-difference spectroscopy.  
 
1
H-NMR (500 MHz, CD2Cl2):  (ppm) = 5.28-5.39 (2H, m, H-C1,2), 2.04-2.13 (4H, m, H-C3, 
12), 1.25-1.47 (16H, m, H-C4-11).   
 
 
 
 
8.2.4.1.2 Synthesis and enzyme activity towards cyclooctyne (17) 
 
Two-step synthesis: 
1) Synthesis of 1-bromocyclooctene (51) )[125]: 
 
 
Scheme 57. Synthesis of 1-bromocyclooctene (51) according to BRANDSMA et al.[125] 
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The synthesis of 1-bromocyclooctene (51) is carried out 
according to BRANDSMA et al. starting from cyclooctene (50).[125] 
To a solution of cyclooctene (50; 11.02 g, 0.1 mol) in 
dichloromethane (35 mL) bromine (5.15 mL, 0.1 mol) is added 
with cooling at about -40°C until the brown colour persists. 
After removal of the solvent in vacuo the residue is dissolved in 
dry THF (40 mL) and a suspension of potassium t-butoxide (16.85 g, 0.15 mol) in 
50 mL THF is added in 20 min to the vigorously stirred mixture, keeping its 
temperature at 0 °C. After the addition, stirring is continued for 1 h at 15 °C. The 
mixture is then poured into ice/water (50 mL) and the organic products are 
extracted with MTBE. The organic phase is dried over magnesium sulfate. After 
evaporation of the solvent in vacuo the crude product 51 is obtained as pale beige 
oil and purified via fractional distillation. 
 
Yield: 12.90 g (68%) 
 
1
H-NMR (500 MHz, CDCl3):  (ppm) = 6.05 (1H, t, J = 12.5 Hz, H-C2), 2.60-2.62 (2H, m, H-C8), 2.08-2.13 (2H, m, 
H-C3), 1.46-1.66 (8H, m, H-C4-7).   
 
The compound 51 is further confirmed through conversion into the product 17 
and its analytical characterization. 
 
2) Synthesis of cyclooctyne (17) )[125]: 
 
 
Scheme 58. Synthesis of cyclooctyne (17) according to BRANDSMA et al.[125] 
 
The above product (51; 12.90 g, 68.22 mmol) is added at once 
to a solution of lithium diisopropylamide (1.5 M) in THF, cooled 
at -25 °C. The temperature of the reaction mixture is allowed to 
rise gradually over a period of 45 min to 15 °C and is kept at this 
level for another 90 min. It is then poured into a cold solution 
of 3 normal hydrochloric acid. Five extractions with n-heptane 
(5 x 15 mL) are carried out. The combined extracts are washed several times with 
water in order to remove the THF and are then dried over magnesium sulphate. 
The solvents are removed in vacuo keeping the bath temperature at 0 °C. 
Distillation of the crude product by using a vigreux column gives cyclooctyne (17). 
 
Yield: 0.87 g (12%) 
 
1
H-NMR (500 MHz, CDCl3):  (ppm) = 2.15-2.18 (4H, m, H-C4-7), 1.86-1.87 (4H, m, H-C4-7), 1.60-1.64 (4H, m, 
H-C3,8).  
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The spectral data are in accordance with literature.[126] 
 
Enzyme activity: 
The measurements are taken as described above (SOP 4) to determine the 
enzyme activity of different cytochrome P450 monooxygenase from Bacillus 
megaterium (CYP BM-3) (solution of the lyophilisate: 10 mg/mL, NAD(P)H-
dependent, phosphate buffer: pH 7.0, 50 mM) for cyclooctyne (17). A solution of 
17 (12 mM, assuming that 17 will dissolve completely) is prepared in DMSO. For 
this purpose 6.49 mg (0.06 mmol) of 17 are weigh in a 5 mL volumetric flask which 
is filled up with DMSO. A 0.6 mM solution of NAD(P)H is used for the 
measurements (Table 35). 
 
Table 35. Results of the enzyme activity test with CYP BM-3 and cyclooctyne (17) 
 
 
Entry CYP BM-3a) Substrate 
Specific activity 
[U/mg] 
0.762 U 
2 F87A A328V (2) cyclooctyne (17) -- -- 
4 F87P (2) cyclooctyne (17) -- -- 
Vt = 1 mL, f = 1, ɸ = 6.3 mL*μmol-1*cm-1, Vs = 0.1 mL, d = 1 cm a)In parentheses the different enzyme 
formulations are given. 
 
8.2.4.2 Enzyme activity towards pentanal (19)  
 
Stability of pentanal (19) in water over the time: 
The stability of pentanal (19) in water is analyzed over a period of 
24 h in the presence of equimolar amounts sodium acetate as 
external standard. For this purpose pentanal (19) (8.6 mg, 
0.1 mmol) is weigh in a 25 mL round bottom flask and 1 mL D2O is 
added. The mixture is stirred for up to 24 h and then transferred into a NMR-tube 
filled with sodium acetate (8.2 mg, 0.1 mmol). The formation of the corresponding 
carboxylic acid was found only to very small extent of 5.4% on an average, 
identified on the basis of the characteristic triplet caused by the two Cα-protons at 
2.2 ppm. Pentanal (19) is high vacuum distilled prior use and purity is examined 
via 
1H-NMR-spectroscopy. 
 
1
H-NMR (500 MHz, CD2Cl2): 
ɷ①;ppŵͿ①=①ϵ.ϳϯ①;ϭH,①t,①J = 1.8 Hz, H-C1), 2.40 (2H, td, J = 7.4 Hz, 1.8 Hz, H-C2), 1.55-
1.62 (2H, m, H-C3), 1.31-1.38 (2H, m, H-C4), 0.92 (3H, t, J = 7.4 Hz, H-C5)  
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Enzyme activity 
The measurements are performed as described above (SOP 4) to determine the 
enzyme activity of different cytochrome P450 monooxygenases from Bacillus 
megaterium (CYP BM-3) (solution of the lyophilisate: 10 mg/mL, NAD(P)H- 
dependent, phosphate buffer: pH 7.0, 50 mM) for pentanal (19). A solution of 19 
(12 mM, assuming that 19 will dissolve completely) is prepared in DMSO. For this 
purpose 5.17 mg (0.06 mmol) of 19 are weigh in a 5 mL volumetric flask which is 
filled up with DMSO. A 0.6 mM solution of NAD(P)H is used for the 
measurements. For all preparative experiments 0.762 U relative to 19 are used 
(Table 36). 
 
Table 36. Results of the enzyme activity test with CYP BM-3 for pentanal (19) 
 
 
Entry CYP BM-3a) 
Specific 
activity 
[U/mg] 
0.762 U 
Content of CYPd) 
[nmol/g 
lyophilisate] 
TOF [min-1] 
1 
F87A A328V 
(2) 
0.010 76.2 mg 989 10 
2 F87P (2) 0.021 36.3 mg 223 94 
3 19A12 (2) 0.029 26.3 mg 120 242 
4 F87V 0.009 84.7 mg 525 17 
5 R255P P329Hb) -- -- 220 -- 
6 WTc) 0.009 84.7 mg 1260 7 
Vt = 1 mL, f = 1, ɸ = 6.3 mL*μmol-1*cm-1, Vs = 0.1 mL, d = 1 cm; a)In parentheses the different enzyme 
formulations are given; b)NADH-dependent; c)5 mg/mL enzyme; d)determined via CO-difference 
spectroscopy.  
 
8.2.4.3 Enzyme activity towards higher homologous cycloalkanes 
8.2.4.3.1 Enzyme activity towards cyclododecane (1c) 
 
The measurements are performed as described above (SOP 4) to determine the 
enzyme activity of different cytochrome P450 monooxygenase from Bacillus 
megaterium (CYP BM-3) (solution of the lyophilisate: 10 mg/mL, NAD(P)H-
dependent, phosphate buffer: pH 7.0, 50 mM) for cyclododecane (1c). A solution 
of 1c (25 mM: entry 1-10; 12.5 mM: entry 11-13; assuming that 1c will dissolve 
completely) is prepared in DMSO. For this purpose 10.5 mg resp. 21 mg 
(0.06 mmol resp. 0.12 mmol) are weigh in a 5 mL volumetric flask which is filled 
up with DMSO. A 0.8 mM (entry 1-2) resp. 0.6 mM (entry 3-13) solution of 
NAD(P)H was used for the measurements. For all preparative experiments 0.762 U 
relative to 1c are used (Table 37).  
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Table 37. Results of the enzyme activity test with cyclododecane (1c) as substrate 
 
 
Entry CYP BM-3a) 
Specific 
activity 
[U/mg] 
0.762 U 
Content of CYPd) 
[nmol/g 
lyophilisate] 
TOF 
[min-1] 
1 19A12 (0) 0.003 254.0 mg 123 24 
2 F87P (1) 0.052 14.7 mg 235 221 
3 19A12 (1) -- -- 60 -- 
4 19A12 (2) -- -- 120 -- 
5 19A12 (3) 0.001 762 mg 115 9 
6 F87P (1) 0.034 22.4 mg 235 145 
7 F87V 0.001 762 mg 525 2 
8 F87A A328V (1) 0.015 50.8 mg 480 31 
9 WT -- -- 1260 -- 
10 R255P-P329Hb) -- -- 220 -- 
11 F87A A328V (2) 0.027 28.2 mg 989 27 
12 F87A A328V (2)c) 0.005 152.4 mg 989 5 
13 F87A A328V (2) 0.023 33.1 mg 989 23 
Vt = 1 mL, f = 1, ɸ = 6.3 mL*μmol-1*cm-1, Vs = 0.1 mL, d = 1 cm; a)In parentheses the different enzyme 
formulations are given; b)NADH-dependent; c)10% (v/v) DMSO by adding 600 µL phosphate buffer 
(pH 7.0, 50 mM)/ 90 µL DMSO and 10 µL of 1c in DMSO (12.5 mM) instead of 690 μl phosphate 
buffer (pH 7.0, 50 mM) and 10 µL of 1c in DMSO (12.5 mM); d)determined via CO-difference 
spectroscopy.  
 
8.2.4.3.2 Enzyme activity towards cyclodecane (1b) 
 
The measurements are performed as described above (SOP 4) to determine the 
enzyme activity of different cytochrome P450 monooxygenases from Bacillus 
megaterium (CYP BM-3) (solution of the lyophilisate: 10 mg/mL, NAD(P)H-
dependent, phosphate buffer: pH 7.0, 50 mM) for cyclodecane (1b). A solution of 
1b (25 mM: entry 1-4, 6-13; 12 mM: entry 5, assuming that 1b will dissolve 
completely) is prepared in DMSO. For this purpose 8.4 mg resp. 17.5 mg 
(0.06 mmol resp. 0.12 mmol) are weigh in a 5 mL volumetric flask which is filled 
up with DMSO. A 0.8 mM (entry 1-4) resp. 0.6 mM (entry 5-13) solution of 
NAD(P)H was used for the measurements. For all preparative experiments 0.762 U 
relative to 1b are used (Table 38). 
112 | EXPERIMENTAL SECTION 
 
Table 38. Results of the enzyme activity test with cyclodecane (1b) as substrate 
 
 
Entry CYP BM-3a) 
Specific 
activity 
[U/mg] 
0.762 U 
Content of CYPc) 
[nmol/g 
lyophilisate] 
TOF 
[min-1] 
1 F87V 0.006 127.0 mg 525 11 
2 19A12 (0) 0.039 19.6 mg 123 317 
3 WT 0.008 95.3 mg 1260 6 
4 
Empty vector 
E.coli BL21 
0.001 762.0 mg -- -- 
5 19A12 (2) 0.051 14.9 mg 120 425 
6 19A12 (1) 0.051 14.9 mg 60 850 
7 19A12 (2) 0.052 14.7 mg 120 433 
8 19A12 (3) 0.056 13.6 mg 115 487 
9 F87P (1) 0.076 10.0 mg 235 323 
10 F87V 0.005 152.4 mg 525 10 
11 
F87A A328V 
(1) 
0.020 38.1 mg 480 42 
12 WT 0.004 190.5 mg 1260 3 
13 
R255P-
P329Hb) 
0.014 54.4 mg 220 64 
Vt = 1 mL, f = 1, ɸ = 6.3 mL*μmol-1*cm-1, Vs = 0.1 mL, d = 1 cm; a)In parentheses the different enzyme 
formulations are given; b)NADH-dependent; c)determined via CO-difference spectroscopy.  
 
8.2.4.3.3 Enzyme activity towards cyclohexane (1a) 
 
The measurements are performed as described above (SOP 4) to determine the 
enzyme activity of different cytochrome P450 monooxygenase from Bacillus 
megaterium (CYP BM-3) (solution of the lyophilisate: 10 mg/mL, NAD(P)H-
dependent, phosphate buffer: pH 7.0, 50 mM) for cyclohexane (1a). A solution of 
1a (25 mM: entry 1-12; 12 mM: entry 13-14, assuming that 1a will dissolve 
completely) is prepared in DMSO. For this purpose 5.1 mg resp. 10.5 mg 
(0.06 mmol resp. 0.12 mmol) are weigh in a 5 mL volumetric flask which is filled 
up with DMSO. A 0.8 mM (entry 1-4) resp. 0.6 mM (entry 5-14) solution of 
NAD(P)H was used for the measurements. For all preparative experiments 0.762 U 
relative to 1a are used (Table 39). 
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Table 39. Results of the enzyme activity test with cyclohexane (1a) as substrate 
 
 
Entry CYP BM-3a) 
Specific 
activity 
[U/mg] 
0.762 U 
Content of 
CYPc) [nmol/g 
lyophilisate] 
TOF [min-1] 
1 F87V 0.002 343.24 mg 525 4 
2 19A12 (0) 0.146 5.22 mg 123 1187 
3 WT 0.007 109.17 mg 1260 6 
4 
Empty vector 
E.coli BL21 
0.004 1.772 g -- -- 
5 19A12 (1) 0.131 5.8 mg 60 2183 
6 19A12 (2) 0.161 4.7 mg 120 1342 
7 19A12 (3) 0.134 5.7 mg 115 1165 
8 F87P (1) 0.025 30.5 mg 235 106 
9 F87V 0 -- 525 -- 
10 
F87A A328V 
(1) 
0.010 76.2 mg 480 21 
11 WT 0.001 762.0 mg 1260 1 
12 
R255P-
P329Hb) 
0.009 84.7 mg 220 41 
13 19A12 (2) 0.074 10.3 mg 120 617 
14 19A12 (2) 0.047 16.2 mg 120 392 
Vt = 1 mL, f = 1, ɸ = 6.3 mL*μmol-1*cm-1, Vs = 0.1 mL, d = 1 cm; a)In parentheses the different enzyme 
formulations are given; b)NADH-dependent; c)determined via CO-difference spectroscopy.  
 
8.2.5 Standard operation procedure 5 (SOP 5): Analysis of the kinetics 
according to MICHAELIS-MENTEN of the cyclododecanol (2b)-formation 
 
 
The concentration of the saturated solution (~16 mM) of 1c 
in DMSO is identified via 1H-NMR-spectroscopy with pivalic 
acid (52) as standard. 1H-NMR (1cͿ① ;ϱϬϬ① MHz,① DM“OͿ:① ɷ①
(ppm) = 1.30 (24H, s); 1H-NMR (52Ϳ① ;ϱϬϬ① MHz,① DM“OͿ:① ɷ①
(ppm) = 12.03 (1H, s, HO-C1), 1.11 (9H, s, H-C2) 
 
The measurements are performed as described above (SOP 4) to determine the 
enzyme activity of the cytochrome P450 monooxygenase mutant from Bacillus 
megaterium CYP BM-3 F87A A328V (1) (solution of the lyophilisate: 10 mg/mL, 
NADPH-dependent, phosphate buffer: pH 7.0, 50 mM) for cyclododecane (1c). 
Solutions of 1c (0.5-16 mM) are prepared in DMSO.  
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For this purpose a stock solution of the substrate cyclododecane (1c) is prepared 
in DMSO in a 25 mL volumetric flask at a concentration of 16 mM. A set of serial 
dilution (16 mM, 12 mM, 8 mM, 4 mM, 2 mM, 1 mM, 0.5 mM) is prepared to 
measure the following absolute concentrations in a photometric assay: 160 µM, 
120 µM, 80 µM, 40 µM, 20 µM, 10 µM and 5 µM. A 0.6 mM solution of NADPH 
was used for the measurements (Table 40). In this way the kinetics according to 
MICHAELIS-MENTEN of the cyclododecanol (2c)-formation can be determined via an 
enzyme activity test with the CYP BM-3 and cyclododecane (1c) as substrate. 
 
Table 40. Results of the enzyme activity test with cyclododecane (1c) as substrate 
 
 
Entry Substrate concentration [mM] Initial slope vo [1/min] 
1 0.16 0.133 
2 0.12 0.131 
3 0.08 0.127 
4 0.04 0.121 
5 0.02 0.105 
6 0.01 0.081 
7 0.005 0.057 
Vt = 1 mL, f = ϭ,①ɸ = 6.3 ŵL*μŵol-1*cm-1, Vs = 0.1 mL, d = 1 cm 
 
8.2.6 Standard operation procedure 6 (SOP 6): Analysis of the stability of 
CYP BM-3 F87A A328V 
 
The measurements are performed in the manner of SOP 4 to determine the 
enzyme activities of the cytochrome P450 monooxygenase mutant from Bacillus 
megaterium CYP BM-3 F87A A328V (1) (solution of the lyophilisate: 10 mg/mL, 
NADPH-dependent, phosphate buffer: pH 7.0, 50 mM) for cyclododecane (1c) as a 
function of time. In a 25 mL round bottom flask 50.8 mg CYP BM-3 F87A A328V 
(0.762 U) and D-glucose monohydrate (22) (3.96 mg, 0.02 mmol) are mixed with 
900 µL phosphate buffer (pH 7.0, 50 mM) and 100 µL DMSO (10% v/v). The 
mixture is stirred and samples are taken at (regular) intervals over a period of 28h.  
 
A cuvette (1 mL) is filled with 680 μl phosphate buffer (pH 7.0, 50 mM) and 100 µL 
of 1c in DMSO (1.2 mM) is added. Then 20 µL of the enzyme containing mixture 
(50 mg/mL) are pipetted in the cuvette and mixed by inversion.  
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After 5 min 200 μl of a buffered solution of the cofactor NADPH (NADPH: 0.6 mM; 
phosphate buffer: pH 7.0, 50 mM) are pipetted in the cuvette and mixed by 
inversion. Hereafter the measurement is started immediately. Before every 
sampling at a certain time (Table 41), at first a measurement of the blank value 
(DMSO without substrate) is taken according to SOP 4 (680 μl phosphate buffer 
(pH 7.0, 50 mM), 100 μl DMSO, 20 μl of the enzyme containing mixture 
(50 mg/mL), 200 μl of a buffered solution of the cofactor NADPH (NADPH: 
0.6 mM; phosphate buffer: pH 7.0, 50 mM)). 
 
Table 41. Enzyme activity of CYP BM-3 F87A A328V as a function of time 
 
 
Entry Time [h] Initial slope v0 [1/min] 
1 0.167 0.0725 
2 1 0.0741 
3 2 0.0874 
4 4 0.0689 
5 6 0.0904 
6 28 0.0585 
Vt = 1 mL, f = ϭ,①ɸ = 6.3 ŵL*μŵol-1*cm-1, Vs = 0.1 mL, d = 1 cm 
 
8.2.7 Standard operation procedure 7 (SOP 7): Biocatalyzed oxidation of 
cyclododecene (18) with different CYP BM-3 and glucose dehydro-
genase (GDH) 
 
In a 25 mL round bottom flask cyclododecene (18) (16.63 mg, 0.1 mmol) is mixed 
with 900 µL phosphate buffer (pH 7.0, 50 mM). Then a cytochrome P450 mono-
oxygenase from Bacillus megaterium (CYP BM-3 F87P resp. CYP BM-3 F87A 
A328V) (0.762 U, 19.05 mg) and 100 μl GDH (7 U) dissolved in phosphate buffer 
(pH 7.0, 50 mM) and glycerol (1:1) are added. Then D-glucose monohydrate (22) 
(39.6 mg, 0.2 mmol) is weigh in. To start the reaction cofactor NADPH (8.3 mg, 
10 mol%) is added. The reaction mixture is stirred for 24 h at room temperature 
covered with a plug and is worked up according to SOP B using deuterated 
dichloromethane. This solution is analyzed via 1H-NMR-spectroscopy and 
compared to the spectra of the substrate 18. The formation of an oxidation 
product was not detected, neither with CYP BM-3 F87P nor with CYP BM-3 F87A 
A328V.  
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8.2.8 Standard operation procedure (SOP 8): Biocatalyzed oxidation of 
pentanal (19) with different CYP BM-3 and glucose dehydrogenase 
(GDH) 
 
 
Scheme 59. Anticipated biocatalyzed oxidation of pentanal (19)  
In a 25 mL round bottom flask pentanal (19) (8.6 mg, 0.1 mmol) is mixed with 
900 µL phosphate buffer (pH 7.0, 50 mM). Then 0.762 U of a cytochrome P450 
monooxygenase from Bacillus megaterium (CYP BM-3 19A12 (26.3 mg) resp. 
CYP BM-3 F87P (36.3 mg)) and 100 μl GDH (7 U) dissolved in phosphate buffer 
(pH 7.0, 50 mM) and glycerol (1:1) are added. Then D-glucose monohydrate (22) 
(39.6 mg, 0.2 mmol) is weigh in. To start the reaction cofactor NADPH (8.3 mg, 
10 mol%) is added. The reaction mixture is stirred for 24 h at room temperature 
covered with a plug and is worked up according to SOP B using 0.5 mL deuterated 
dichloromethane. The combined organic phases are transferred completely into a 
NMR-tube. This solution is analyzed via 1H-NMR-spectroscopy and compared to 
the spectrum of the substrate 19. Instead of the desired oxidation of pentanal 
(19), its reduction yielding 1-pentanol (53) took place, clearly identified via 
1H-NMR-spectroscopy: 
 
Pentanal (19): 1H-NMR (500 MHz, CD2Cl2):  
ɷ① ;ppŵͿ①=①ϵ.ϳϯ① ;ϭH,① t,① J①=①ϭ.ϴ Hz, H-C1), 2.40 (2H, td, J = 
7.4, 1.8 Hz, H-C2), 1.55-1.62 (2H, m, H-C3), 1.31-1.38 (2H, 
m, H-C4), 0.92 (3H, t, J = 7.4 Hz, H-C5) 
 
 
1-Pentanol (53): 1H-NMR (500 MHz, CD2Cl2):  
ɷ①;ppŵͿ①=①ϯ.ϱϴ①;ϮH,①t,①J = 5.0 Hz, H-C1), 1.51-1.61 (2H, m, 
H-C2), 1.26-1.37 (4H, m, H-C3, 4), 0.89-0.93 (3H, m, H-C5). 
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8.2.9 Standard operation procedure (SOP 9): Biocatalyzed hydroxylation of 
the higher homologous cycloalkane 1c with different CYP BM-3 and 
glucose dehydrogenase (GDH) 
 
 
 
Scheme 60. Biocatalyzed hydroxylation of cyclododecane (1c) 
In a 25 mL round bottom flask cyclododecane (1c) (0.168 - 16.8 mg, 
0.001 - 0.1 mmol) is mixed with 800 - 900 µL phosphate buffer (pH 7.0, 50 mM) 
depending on the amount of DMSO. Then a cytochrome P450 monooxygenase 
from Bacillus megaterium (CYP BM-3) (0.15 - 1.52 U), 0 - 200 μl GDH (0 - 14 U) 
diluted in phosphate buffer (pH 7.0, 50 mM) and 0 - 100 µL DMSO (containing the 
0.0001 mmol 1c) are added. Then D-glucose monohydrate (22) (0 - 39.6 mg, 
0 - 0.2 mmol) is weigh in. To start the reaction cofactor NADPH (8.3 - 83.4 mg, 
0.01 - 0.1 mmol) resp. NADH (0.67 mg, 0.001 mmol) is added. The reaction 
mixture is stirred for 2-24 h at room temperature covered with a plug and is 
worked up according to SOP B.  
 
8.2.9.1 Hydroxylation of cyclododecane (1c) with spectrophotometrically 
inactive mutants of CYP BM-3 
 
According to SOP 9 cyclododecane (1c) (1.68 mg, 0.01 mmol) is mixed with 900 µL 
phosphate buffer (pH 7.0, 50 mM) in a 25 mL round bottom flask. Then a 
cytochrome P450 monooxygenase from Bacillus megaterium (CYP BM-3) (50 mg) 
and 100 μl GDH (7 U) diluted in phosphate buffer (pH 7.0, 50 mM) are added. 
Then D-glucose monohydrate (22) (3.96 mg, 0.02 mmol) is weigh in. To start the 
reaction cofactor NADPH (0.83 mg, 0.001 mmol) resp. NADH (0.67 mg, 
0.001 mmol) is added. The reaction mixture is stirred for 24 h at room 
temperature covered with a plug. After that time the mixture is worked up 
according to SOP 9 (Table 42).  
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Table 42. Results of the hydroxylation of cyclododecane (1c) with 
spectrophotometrically inactive mutants of CYP BM-3 
 
Entry CYP BM-3a) 
Cyclododecanol 2c 
[mg/L]c) 
Conversion [%] 
1 19A12 (1) ˂ϱ -- 
2 19A12 (2) ˂ϱ -- 
3 19A12 (3) ˂ϱ -- 
4 F87V ~3 0.75 
5 WT ˂ϱ -- 
6 R255P P329Hb) ˂ϱ -- 
a)In parentheses the different enzyme formulations are given; b)NADH-dependent; c)Analysis via gas 
chromatography (method B). 
              
8.2.9.2 Hydroxylation of cyclododecane (1c) with different CYP BM-3 
 
According to SOP 9 cyclododecane (1c) (1.68 - 16.8 mg, 0.01 - 0.1 mmol) is mixed 
with 800 - 900 µL phosphate buffer (pH 7.0, 50 mM) in a 25 mL round bottom 
flask, depending on the amount of DMSO. Then a cytochrome P450 
monooxygenase from Bacillus megaterium (CYP BM-3, 0.15 - 1.52 U), 
0 - 200 μl GDH (0 - 14 U) diluted in phosphate buffer (pH 7.0, 50 mM) and 
0 - 100 µL DMSO are added. Then D-glucose monohydrate (22) (0 - 39.6 mg, 
0 - 0.2 mmol) is weigh in. To start the reaction cofactor NADPH (0.83 - 83.4 mg, 
0.001 - 0.1 mmol) is added. The reaction mixture is stirred for 24 h at room 
temperature covered with a plug. After that time the mixture is worked up 
according to SOP 9 (Table 43).  
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Table 43. Results of the hydroxylation of cyclododecane (1c) with different CYP 
BM-3 according to Scheme 60 
Entrya,b) CYP BM-3 
Activity CYP 
BM-3 [U] 
GDH 
[U] 
Substrate        
[mM] 
Glucose  
[mmol] 
NADPH 
[mol%] 
DMSO       
[% (v/v)] 
1 F87P 0.762 7 100 0.2 10 0 
2 F87P 0.762 -- 100 -- 30 0 
3 F87P 1.524 7 100 0.2 10 0 
4 F87P 0.762 14 100 0.2 10 0 
5 F87P 0.762 7 100 0.2 10 2 
6 F87P 0.762 7 100 0.2 10 0 
7 F87P 0.762 7 100 0.2 10 5 
8 F87P 0.762 7 100 0.2 10 10 
9 F87P 0.762 7 10 0.2 100 10 
10 19A12 0.15  7 10 0.2 100 10 
a)Analysis via gas chromatography (method B); b)The combined organic phases are transferred com-
pletely into a 2 mL volumetric flask for GC-analysis.  
 
In all experiments shown in Table 43 the formation of cyclododecanol (2c) was 
below 5 mg/L and conversion could not be determined.  
 
8.2.9.3 Hydroxylation of cyclododecane (1c) with CYP BM-3 F87A A328V 
 
According to SOP 9 cyclododecane (1c) (0.168 - 16.8 mg, 0.001 - 0.1 mmol) is 
mixed with 800 - 900 µL phosphate buffer (pH 7.0, 50 mM) (depending on the 
amount of DMSO) in a 25 mL round bottom flask. Then a cytochrome P450 
monooxygenase from Bacillus megaterium (CYP BM-3 F87A A328V, 0.762U), 
0 - 100 μl GDH (0 - 7 U) diluted in phosphate buffer (pH 7.0, 50 mM) and 
0 - 100 µL DMSO are added. Then D-glucose monohydrate (22) (3.96 - 39.6 mg, 
0.02 - 0.2 mmol) is weigh in. To start the reaction cofactor NADPH (0.83 - 83.4 mg, 
0.001 - 0.1 mmol) is added. The reaction mixture is stirred for 2 - 24 h at room 
temperature covered with a plug. After that time the mixture is worked up 
according to SOP 9 (Table 44).  
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Table 44. Results of the oxidation of cyclododecane (1c) with CYP BM-3 F87A 
A328V 
 
 
Entry 
GDH 
[U] 
Substrate      
[mM] 
Glucose  
[mmol] 
NADPH 
[mol%] 
DMSO         
[% (v/v)] 
Time 
[h] 
2c 
[mg/L]
a)
 
Conversion 
[%] 
1 7 100 0.2 10 0 24 ˂ϱ -- 
2 -- 100 -- 30 0 24 ˂ϱ -- 
3 7 100 0.2 10 5 24 33 0.17 
4 7 100 0.2 10 10 24 40 0.19 
5 7 10 0.2 100 10 24 ˂ϱ -- 
6 7 100 0.2 10 10 24 35 0.17 
7 -- 100 -- 100 10 24 n.d. n.d. 
8 7 10 0.02 10 10 24 27 1.76 
9 -- 10 -- 100 10 24 n.d. n.d. 
10 7 10 0.02 10 10 24 24 1.87 
11 7 1 0.02 100 10 24 n.d. n.d. 
12 7 10 0.02 10 10 2 16 0.72 
13 7 1 0.02 100 10 2 30 44.6 
a)Analysis via gas chromatography (new calibration line); b)The combined organic phases are 
transferred completely into a 3 mL volumetric flask for GC-analysis.  
 
8.2.10 Standard operation procedure 10 (SOP 10): Biocatalyzed hydroxylation 
of the higher homologous cycloalkanes 1a and 1b with CYP BM-3 
19A12 and glucose dehydrogenase (GDH) 
 
In a 25 mL round bottom flask a cycloalkane 1 (8.4 - 14.0 mg, 0.1 mmol) is mixed 
with 900 µL phosphate buffer (pH 7.0, 50 mM). Then a cytochrome P450 
monooxygenase from Bacillus megaterium (CYP BM-3 19A12) (0.762 U, 
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10.3 - 14.9 mg) and 100 μl GDH (7 U) dissolved in phosphate buffer (pH 7.0, 
50 mM) and glycerol (1:1) are added. Then D-glucose monohydrate (22) (39.6 mg, 
0.2 mmol) is weigh in. To start the reaction cofactor NADPH (8.3 mg, 0.01 mmol, 
10 mol%) is added. The reaction mixture is stirred for 24 h at room temperature 
covered with a plug and worked up according to SOP B.  
 
8.2.10.1 Hydroxylation of cyclodecane (1b) with CYP BM-3 19A12 
 
According to SOP 10 cyclodecane (1b) (14.0 mg, 0.1 mmol) is mixed with 900 µL 
phosphate buffer (pH 7.0, 50 mM) in a 25 mL round bottom flask. Then a 
cytochrome P450 monooxygenase from Bacillus megaterium (CYP BM-3 19A12, 
0.762U, 14.9 mg, the content of CYP BM-3 19A12 (2) amounts to 0.120 μmol/g 
lyophilized crude extract) and 100 μl GDH (7U) dissolved in phosphate buffer 
(pH 7.0, 50 mM) and glycerol (1:1) are added. Then D-glucose monohydrate (22) 
(39.6 mg, 0.2 mmol) is weigh in. To start the reaction cofactor NADPH (8.3 mg, 
0.01 mmol, 10 mol%) is added. The reaction mixture is stirred for 24 h at room 
temperature covered with a plug. After that time the mixture is worked up 
according to SOP B (Table 45).  
 
Table 45. Results of the oxidation of cyclodecane (1b) with CYP BM-3 19A12 
 
Entry 
Activity 
19A12 
[U]/[mg] 
GDH 
[U] 
Substrate      
[mmol] 
Glucose  
[mmol] 
NADPH 
[mol%] 
Time 
[h] 
Product 
formation 
 [g/L] 
1 0.762/14.9a) 7 0.1 0.2 10 24 0.15 
a)The content of CYP BM-3 19A12 (2) amounts to 0.120 μmol/g lyophilized crude extract. 
 
8.2.10.2 Hydroxylation of cyclohexane (1a) with CYP BM-3 19A12 
 
According to SOP 10 cyclohexane (1a) (8.4 mg, 0.1 mmol) is mixed with 900 µL 
phosphate buffer (pH 7.0, 50 mM) in a 25 mL round bottom flask.  
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Then a cytochrome P450 monooxygenase from Bacillus megaterium 
(CYP BM-3 19A12, 0.762U, 10.3 mg, the content of CYP BM-3 19A12 (2) amounts 
to 0.120 μmol/g lyophilized crude extract) and 100 μl GDH (7U) dissolved in 
phosphate buffer (pH 7.0, 50 mM) and glycerol (1:1) are added. Then D-glucose 
monohydrate (22) (39.6 mg, 0.2 mmol) is weigh in. To start the reaction cofactor 
NADPH (8.3 mg, 0.01 mmol, 10 mol%) is added. The reaction mixture is stirred for 
24 h at room temperature covered with a plug. After that time the mixture is 
worked up according to SOP B (Table 46).  
 
Table 46. Results of the oxidation of cyclohexane (1a) with CYP BM-3 19A12 
 
Entry 
activity 19A12 
[U]/[mg] 
GDH 
[U] 
substrate       
[mmol] 
glucose  
[mmol] 
NADPH 
[mol%] 
time 
[h] 
product 
formation 
 [g/L] 
1 0.762/10.3a) 7 0.1 0.2 10 24 1.33 
a)The content of CYP BM-3 19A12 (2) amounts to 0.120 μmol/g lyophilized crude extract. 
 
8.2.11 Standard operation procedure 11 (SOP 11): Photometric assay to 
determine the enzyme activity of the alcohol dehydrogenase from 
Lactobacillus kefir (LK-ADH) 
 
 
Scheme 61. General reaction equation of the photometric assay with LK-ADH 
The enzyme activities can be determined with an UV/VIS-spectrophotometer for 
NADP+ is used as cofactor. The formation of NADPH through reduction of NADP+ is 
measured spectrophotometrically at a wavelength of 340 nm in the presence of 
the LK-ADH and each one of the following compounds: 1-phenylethanol (71), 
cyclohexanol (2a) and cyclodecanol (2b).  
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A 10 mM solution of the reference compound 71 and the cycloalkanols 2a and 2b 
(10 mM, assuming that 71 and 2 will dissolve completely) is prepared in 
phosphate buffer (pH 7.0, 50 mM, 1 mM MgCl2). For this purpose 5.0 - 7.8 mg 
(mmol) of 2a, 2b and 71 are weigh in a 5 mL volumetric flask which is filled up 
with phosphate buffer (pH 7.0, 50 mM, 1 mM MgCl2). A cuvette (1 mL) is filled 
with each 960 μl of a buffered solution of 1-phenylethanol (71), cyclohexanol (2a) 
or cyclodecanol (2b) (71 and 2a - b, phosphate buffer: pH 7.0, 50 mM, 1 mM 
MgCl2). Then 20 μl of a buffered solution of the cofactor NADP+ (NADP+: 12.5 mM; 
phosphate buffer: pH 7.0, 50 mM, 1 mM MgCl2) are pipetted in the cuvette and 
mixed by inversion. After that 20 µL enzyme solution (diluted 1:160 resp. 1:300 
with phosphate buffer: pH 7.0, 50 mM, 1 mM MgCl2) are pipetted in the cuvette 
and mixed by inversion. Then the measurement is started immediately. At first a 
measurement of the blank value is taken in which 960 μl of the phosphate buffer 
(pH 7.0, 50 mM, 1 mM MgCl2), 20 μl buffered solution of the cofactor NADP+ 
(NADP+: 12.5 mM; phosphate buffer: pH 7.0, 50 mM, 1 mM MgCl2) and 20 µL 
enzyme solution (diluted 1:160 resp. 1:300 with phosphate buffer (pH 7.0, 50 mM, 
1 mM MgCl2)) are pipetted in the cuvette, mixed by inversion and measured 
immediately. This blank value is subtracted from the measured values resulting 
from the measurements including the substrate solutions of 71 and 2a-b. By 
means of the initial slope of the absorption curve and the following formula, the 
volumetric enzyme activity can be determined. 
 
 
 
With U/mL = volumetric enzyme activity; ΔE340nm/t = initial slope of the absorption curve, Vt = total 
volume [mL]; f = dilution factor; ɸ = molar extinction coefficient for NAD(P)H [6.3 mL*μmol-1*cm-1]; 
VS = sample volume [mL]; d = path length of the cuvette [cm] 
 
8.2.11.1 Photometric assay with cyclohexanol (2a) resp. cyclodecanol (2b) as 
substrate  
 
The measurements are taken as described above (SOP 11) to determine the 
enzyme activity of the LK-ADH (dilution of the crude extract: 1:160 or 1:300 with 
phosphate buffer: pH 7.0, 50 mM, 1 mM MgCl2, NADPH-dependent). For all 
preparative experiments 200 U/mmol relative to cyclohexanol (2a) resp. 
cyclodecanol (2b) are used (Table 47 - Table 50). 
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Table 47 - Table 50. Summarized results of all enzyme activity tests with LK-ADH 
and 2a - b as substrates 
 
 
 
Table 47. Results of the enzyme activity test with LK-ADH and 2a - b as substrates 
Entry Substrate 
Vol. activity 
[U/mL] 
200 U/mmol 
Relative activity 
[%] 
1 1-phenylethanol (71) 291.43 -- 100 
2 cyclohexanol (2a) 122.67 326 µLa) 42 
3 1-phenylethanol (71) 286.54 -- 100 
4 cyclodecanol (2b) 441.59 91 µLa) 154 
Vt = 1 mL, f = 160, ɸ = 6.3 mL*μmol-1*cm-1, Vs = 0.02 mL, d = 1 cm;  a)1:1-dilution in glycerol. 
 
Table 48. Results of the enzyme activity test with LK-ADH and 2a - b as substrates 
Entry Substrate 
Vol. activity 
[U/mL] 
200 U/mmol 
Relative activity 
[%] 
1 cyclohexanol (2a) 24.25 825 µLa) n.d.b) 
2 cyclodecanol (2b) 82.92 241 µLa) n.d.b) 
Vt = 1 mL, f = 160, ɸ = 6.3 mL*μmol-1*cm-1, Vs = 0.02 mL, d = 1 cm; a)1:1-dilution in glycerol b)not 
determined. 
 
Table 49. Results of the enzyme activity test with LK-ADH and 2a - b as substrates 
Entry Substrate 
Vol. activity  
[U/mL] 
200 U/mmol 
Relative activity 
[%] 
1 1-phenylethanol (71) 154.52 -- 100 
2 cyclohexanol (2a) 37.86 528 µLa) 25 
3 cyclodecanol (2b) 241.43 83 µLa) 156 
Vt = 1 mL, f = 300, ɸ = 6.3 mL*μmol-1*cm-1, Vs = 0.02 mL, d = 1 cm; a)crude extract without glycerol. 
 
Table 50. Results of the enzyme activity test with LK-ADH and 2a as substrate 
Entry Substrate 
Vol. activity  
[U/mL] 
200 U/mmol 
Relative 
activity [%] 
1 1-phenylethanol (71) 171.4 -- 100 
2 cyclohexanol (2a) 45.2 443 µLa) 26 
Vt = 1 mL, f = 300, ɸ = 6.3 mL*μmol-1*cm-1, Vs = 0.02 mL, d = 1 cm; a)crude extract without glycerol. 
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8.2.12 Standard operation procedure 12 (SOP 12): Biocatalyzed oxidation of 
cyclododecanol (2c) with different alcohol dehydrogenases 
 
 
Scheme 62. ADH-catalyzed oxidation of cyclododecanol (2c) 
In a 25 mL round bottom flask cyclododecanol (2c) (18.4 - 92.2 mg, 0.1 -0.5 mmol) 
is mixed with 2.5 mL acetone and 7.5 mL phosphate buffer (pH 7.0, 50 mM, 
1 mM MgCl2). Then 0.02 mmol cofactor NAD(P)
+ (13.3 - 15.8 mg) is added. To start 
the reaction an alcohol dehydrogenase (100 U/mmol - 1000 U/mmol, referred to 
the respective standard substrate (LK-ADH: acetophenone (72) (1544 U/mLa)); 
Rsp.-ADH: p-chloroacetophenone (73) (49 U/mLa)); ADH evo-1.1.200: ethyl aceto-
acetate (63) (4.5 U/mg) (a)diluted 1:1 in glycerol))) is added. The reaction mixture 
is stirred for 24 h at room temperature each time covered with a plug. Then the 
aqueous phase is extracted with dichloromethane (3 x 50 mL) very gently to get a 
well-defined phase boundary. The unified organic phase is dried over magnesium 
sulfate. After evaporation of the solvent the crude product is dissolved in 1.5 mL 
acetone again and the conversion is analyzed via gas chromatography. For this 
purpose the GC-areas of the substrate 2c and the product 3c are compared. In 
order to verify this method a mixture of each 0.25 mmol 2c and 3c is weigh in and 
measured, the resulting area-related conversion is compared to the expected 
weight-in conversion (Table 51). 
 
Table 51. Comparison of the weigh-in conversion to the area-related conversion 
2c 
0.25 mmol 
(46.08 mg) 
3c 
0.25 mmol  
(45.58 mg) 
Conversion [%] 
weigh in: 
46.15 mg 
weigh in: 
46.56 mg 
Weigh-in: 50.22% 
GC-Area-related: 49.99% 
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Table 52. Results of the ADH-catalyzed oxidation of cyclododecanol (2c) according 
to Scheme 62 
Entry ADH/µL a) 
Activityb) 
[U/mmol] 
Cofactor 
Substrate 
[mmol] 
Conversion 
[%] 
1 LK-ADH/32.4 µLa) 100 NADP+ 0.5 2 
2 Rsp.-ADH/2.5 mLa) 100 NAD+ 0.5 1 
3 
ADH evo-
1.1.200/11.1 mg 
100 NAD+ 0.5 2 
4 LK-ADH/64.8 µLa) 1000 NADP+ 0.1 10 
5 
ADH evo-
1.1.200/22.2 mg 
1000 NAD+ 0.1 5 
a)diluted 1:1 in glycerol; b)referred to the respective standard substrate (LK-ADH: acetophenone (72) 
(1544 U/mLa)); Rsp.-ADH: p-chloroacetophenone (73) (49 U/mLa)); ADH evo-1.1.200: ethyl 
acetoacetate (63) (4.5 U/mg)). 
 
8.2.13 Standard operation procedure 13 (SOP 13): Biocatalyzed double 
oxidation of cyclododecane (1c) with CYP BM-3 and LK-ADH 
 
 
Scheme 63. Double oxidation of cyclododecane (1c) 
In a 25 mL  round bottom flask cyclododecane (1c) (16.8 mg, 0.1 mmol) is mixed 
with 1 mL phosphate buffer (pH 7.0, 50 mM, 1 mM MgCl2) resp. 997.5 µL 
phosphate buffer (pH 7.0, 50 mM, 1 mM MgCl2) and 2.5 µL 2-propanol (2.5 ‰①
(v/v)). Then a cytochrome P450 monooxygenase from Bacillus megaterium 
(CYP BM-3) (lyophilisate, 0.762 U referred to cyclodecane (1b) (entry 1-2) and the 
alcohol dehydrogenase from Lactobacillus kefir (LK-ADH) (crude extract, 
200 U/mmol referred to cyclodecanol (2b), diluted 1:1 with glycerol, in total 
91 µL) are added. To start the reaction cofactor NADPH (8.3 mg, 0.01 mmol) resp. 
NADP+ (7.9 mg, 0.01 mmol) is added. The reaction mixture is stirred for 24 h at 
room temperature covered with a plug and worked up according to SOP A. The 
results are summarized in Table 53.  
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Table 53. Results of the double oxidation of cyclododecane (1c) according to 
Scheme 63 
Entry 
CYP BM-3 
(biomass) 
IPA Cofactor 
Cyclododecanone 
(3c) [g/l]] 
Recovery of 
substrate 1c [%] 
1 
19A12 
(19.6 mg)a) 
 NADP+ 0 92 
2 
F87V 
(127.0 mg)b) 
- NADPH 0 83 
a)The content of CYP BM-3 19A12 (0) amounts to 0.123 μmol/g lyophilized crude extract; b)The con-
tent of CYP BM-3 F87V amounts to 0.525 μmol/g lyophilized crude extract. 
 
8.2.14 Standard operation procedure 14 (SOP 14): Biocatalyzed double 
oxidation of cycloalkanes 1 with different CYP BM-3 and LK-ADH 
 
 
Scheme 64. Double oxidation of cycloalkanes 1 
In a 25 mL round bottom flask a cycloalkane 1 (8.4 - 14.0 mg, 0.1 mmol) is mixed 
with 1 mL phosphate buffer (pH 7.0, 50 mM, 1 mM MgCl2). Then a cytochrome 
P450 monooxygenase from Bacillus megaterium (CYP BM-3) (lyophilisate, 0.762 U 
referred to the corresponding cycloalkane 1) and the alcohol dehydrogenase from 
Lactobacillus kefir (LK-ADH) (crude extract, 200 U/mmol referred to the 
corresponding cycloalkanol 2, diluted 1:1 with glycerol) are added. To start the 
reaction cofactor NADPH (8.3 mg, 0.01 mmol) is added. The reaction mixture is 
stirred for 24 h at room temperature and worked up according to SOP A resp. 
SOP B. 
 
8.2.14.1 Double oxidation of cyclohexane (1a) 
 
According to SOP 14 cyclohexane (1a) (8.4 mg, 0.1 mmol) is mixed with 1 mL 
phosphate buffer (pH 7.0, 50 mM, 1 mM MgCl2) in a 25 mL round bottom flask. 
Then a cytochrome P450 monooxygenase from Bacillus megaterium 
(5.2 - 10.3 mg CYP BM-3 19A12, lyophilisate, 0.762 U referred to cyclohexane (1a)) 
and the alcohol dehydrogenase from Lactobacillus kefir (LK-ADH) (crude extract, 
200 U/mmol referred to cyclohexanol (2a), diluted 1:1 with glycerol) are added. 
To start the reaction cofactor NADPH (8.3 mg, 0.01 mmol) is added. The reaction 
mixture is stirred for 24 h at room temperature covered with a plug.  
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After that time the mixture is worked up according to SOP 14 (SOP A: entry 1-2; 
SOP B: entry 3-4) (Table 54).  
 
Table 54. Results of the double oxidation of cyclohexane (1a) with 
CYP BM-3 19A12 
 
 
Entry 
Activity 
19A12 
[U]/[mg] 
LK-ADH 
[U/mmol]/[µL] 
NADPH 
[mol%] 
Recovery/formationd) [g/L] 
of 
…1a …2a …3a 
1 0.762/5.2a) 200/326 10 1.01 0.43 0.41 
2 0.762/5.2a) 200/326 10 1.05 n.d.e) 0.40 
3 0.762/10.3b) 200/1057 10 0.61 0.53 0.96 
4 0.762/10.3b) 200/528c) 10 1.61 0.16 0.99 
a)The content of CYP BM-3 19A12 (0) amounts to 0.123 μmol/g lyophilized crude extract; b)The 
content of CYP BM-3 19A12 (2) amounts to 0.120 μmol/g lyophilized crude extract; c)Addition of LK-
ADH without dilution in glycerol; d)The①teƌŵ①͞ƌeĐoǀeƌǇ͞①desĐƌiďes①the①ŵass①ĐoŶĐeŶtƌatioŶ①iŶ①g/L①of①a①
compound initially added to the reaction, that is recovered after workup, here cycloalkane 1. The 
teƌŵ①͞foƌŵatioŶ͞①desĐƌiďes① the①ŵass①ĐoŶĐeŶtƌatioŶ① iŶ① g/L①of①a①ĐoŵpouŶd①ǁhiĐh① is formed during 
the reaction and isolated while workup (product formation of cycloalkanol 2 and cycloalkanone 3). 
All mass concentrations in g/L were determined via gas chromatography; e)n.d.: not determined, no 
clear assignment possible. 
 
8.2.14.2 Double oxidation of cyclodecane (1b) 
 
According to SOP 14 cyclodecane (1b) (14.0 mg, 0.1 mmol) is mixed with 1 mL 
phosphate buffer (pH 7.0, 50 mM, 1 mM MgCl2). Then a cytochrome P450 
monooxygenase from Bacillus megaterium (CYP BM-3) (lyophilisate, 0.762 U 
referred to cyclodecane (1b)) and the alcohol dehydrogenase from Lactobacillus 
kefir (LK-ADH) (crude extract, 200 U/mmol referred to cyclodecanol (2b), diluted 
1:1 with glycerol) are added. To start the reaction cofactor NADPH (8.3 mg, 
0.01 mmol) is added. The reaction mixture is stirred for 24 h at room temperature 
covered with a plug. After that time the mixture is worked up according to SOP 14 
(Table 55). 
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Table 55. Results of the double oxidation of cyclodecane (1b) 
 
Entry 
Activity 
F87V 
[U]/[mg] 
LK-ADH 
[U/mmol]/[µL] 
NADPH 
[mol%] 
Recovery/formationb) [g/L] 
of 
…1b …2b …3b 
1 0.762/127a) 200/91 10 3.21 n.d. 0.20 
a)The content of CYP BM-3 F87V amounts to 0.525 μmol/g lyophilized crude extract; b)The term 
͞ƌeĐoǀeƌǇ͞①desĐƌiďes①the①ŵass①ĐoŶĐeŶtƌatioŶ① iŶ①g/L①of①a①ĐoŵpouŶd① iŶitiallǇ①added①to①the① ƌeaĐtioŶ,①
that is recovered after workup, here cycloalkane 1.① The① teƌŵ① ͞foƌŵatioŶ͞① desĐƌiďes① the① ŵass①
concentration in g/L of a compound which is formed during the reaction and isolated while workup 
(product formation of cycloalkanol 2 and cycloalkanone 3). All mass concentrations in g/L were 
determined via gas chromatography. 
 
8.2.15 Standard operation procedure 15 (SOP 15): Biocatalyzed double 
oxidation of cycloalkanes 1 with different CYP BM-3 and LK-ADH and 
addition of 2-propanol 
 
 
Scheme 65. Double oxidation of cycloalkanes 1 with addition of 2-propanol 
In a 25 mL round bottom flask a cycloalkane 1 (8.4 - 14.0 mg, 0.1 mmol) is mixed 
with 997.5 µL phosphate buffer (pH 7.0, 50 mM, 1 mM MgCl2) and 2.5 µL 
2-propanol (2.5 ‰①;ǀ/ǀͿͿ. Then a cytochrome P450 monooxygenase from Bacillus 
megaterium (CYP BM-3) (lyophilisate, 0.762 U referred to the corresponding 
cycloalkane 1) and the alcohol dehydrogenase from Lactobacillus kefir (LK-ADH) 
(crude extract, 200 U/mmol referred to the corresponding cycloalkanol 2, diluted 
1:1 with glycerol) are added. To start the reaction cofactor NADP+ (7.9 mg, 
0.01 mmol) is added. The reaction mixture is stirred for 24 h at room temperature 
covered with a plug and worked up according to SOP A resp. SOP B. 
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8.2.15.1 Double oxidation of cyclohexane (1a) with addition of 2-propanol 
 
According to SOP 15 cyclohexane (1a) (8.4 mg, 0.1 mmol) is mixed with 997.5 µL 
phosphate buffer (pH 7.0, 50 mM, 1 mM MgCl2) and 2.5 µL 2-propanol (2.5 ‰①
(v/v)). Then a cytochrome P450 monooxygenase from Bacillus megaterium 
(CYP BM-3) (lyophilisate, 0.762 U referred to cyclohexane (1a)) and the alcohol 
dehydrogenase from Lactobacillus kefir (LK-ADH) (crude extract, 200 U/mmol 
referred to cyclohexanol (2a), diluted 1:1 with glycerol) are added. To start the 
reaction cofactor NADP+ (7.9 mg, 0.01 mmol) is added. The reaction mixture is 
stirred for 24 h at room temperature covered with a plug. After that time the 
mixture is worked up according to SOP A.  
 
Table 56. Results of the double oxidation of 1a with addition of 2-propanol 
 
 
Entry 
Activity CYP 
BM-3 
[U]/[mg] 
LK-ADH 
[U/mmol]/[µL] 
NADP+ 
[mol%] 
Recovery/formationc) [g/L] 
of 
…1a …2a …3a 
1 
WT 
0.762/109.2a) 
200/326 10 0.75 0.25 0.35 
2 
19A12 
0.762/5.2b) 
200/326 10 1.39 0.68 0.19 
3 
19A12 
0.762/5.2b) 
200/326 10 0.91 0.40 0.18 
a)The content of CYP BM-3 WT amounts to 1.260 μmol/g lyophilized crude extract; b)The content of 
CYP BM-3 19A12 (0) amounts to 0.123 μmol/g lyophilized crude extract; c)The① teƌŵ① ͞ƌeĐoǀeƌǇ͞①
describes the mass concentration in g/L of a compound initially added to the reaction, that is 
recovered after workup, here cycloalkane 1.①The①teƌŵ①͞foƌŵatioŶ͞①desĐƌiďes①the①ŵass①ĐoŶĐeŶtƌatioŶ①
in g/L of a compound which is formed during the reaction and isolated while workup (product 
formation of cycloalkanol 2 and cycloalkanone 3). All mass concentrations in g/L were determined 
via gas chromatography. 
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8.2.15.2 Double oxidation of cyclodecane (1b) with addition of 2-propanol 
 
According to SOP 15 cyclodecane (1b) (14.0 mg, 0.1 mmol) is mixed with 997.5 µL 
phosphate buffer (pH 7.0, 50 mM, 1 mM MgCl2) and 2.5 µL 2-propanol (2.5 ‰①
(v/v)) in a 25 mL round bottom flask. Then a cytochrome P450 monooxygenase 
from Bacillus megaterium (14.9 - 19.6 mg lyophilisate CYP BM-3 19A12, 0.762U 
referred to cyclodecane (1b)) and the alcohol dehydrogenase from Lactobacillus 
kefir (LK-ADH) (crude extract, 200 U/mmol referred to cyclodecanol (2b), diluted 
1:1 with glycerol) are added. To start the reaction cofactor NADP+ (7.9 mg, 
0.01 mmol) is added. The reaction mixture is stirred for 24 h at room temperature 
covered with a plug. After that time the mixture is worked up according to SOP 15 
(SOP A: entry 1; SOP B: entry 2-4) (Table 57).  
 
Table 57. Results of the double oxidation of cyclodecane (1b) with CYP 
BM-3 19A12 
 
 
Entry 
Activity 
19A12 
[U]/[mg] 
LK-ADH 
[U/mmol]/[µL] 
NADP+ 
[mol%] 
Recovery/formationc) [g/L] 
of 
…1b …2b …3b 
1 0.762/19.6a) 200/91 10 7.92 0.00 0.24 
2 0.762/14.9b) 200/166 10 9.66 0.00 0.27 
3 0.762/14.9b) 200/166 10 9.38 0.00 0.27 
4 0.762/14.9b) 200/166 10 10.28 0.00 0.25 
a)The content of CYP BM-3 19A12 (0) amounts to 0.123 μmol/g lyophilized crude extract; b)The 
content of CYP BM-3 19A12 (2) amounts to 0.120 μmol/g lyophilized crude extract; c)The term 
͞ƌeĐoǀeƌǇ͞①desĐƌiďes①the①ŵass①ĐoŶĐeŶtƌation in g/L of a compound initially added to the reaction, 
that is recovered after workup, here cycloalkane 1.① The① teƌŵ① ͞foƌŵatioŶ͞① desĐƌiďes① the① ŵass①
concentration in g/L of a compound which is formed during the reaction and isolated while workup 
(product formation of cycloalkanol 2 and cycloalkanone 3). All mass concentrations in g/L were 
determined via gas chromatography. 
 
 
 
 
132 | EXPERIMENTAL SECTION 
 
8.2.16 Standard operation procedure 16 (SOP 16): Biocatalyzed double 
oxidation of cycloalkanes 1 with different CYP BM-3 and LK-ADH with 
reduced amount of cofactor 
 
 
Scheme 66. Double oxidation of cycloalkanes 1 with reduced amount of cofactor 
In a 25 mL round bottom flask a cycloalkane 1 (8.4 - 14.0 mg, 0.1 mmol) is mixed 
with 1 mL phosphate buffer (pH 7.0, 50 mM, 1 mM MgCl2) resp. 997.5 µL 
phosphate buffer (pH 7.0, 50 mM, 1 mM MgCl2) and 2.5 µL 2-propanol (2.5 ‰①
(v/v)). Then a cytochrome P450 monooxygenase from Bacillus megaterium (CYP 
BM-3) (lyophilisate, 0.762 U referred to the corresponding cycloalkane 1) and the 
alcohol dehydrogenase from Lactobacillus kefir (LK-ADH) (crude extract, 
200 U/mmol referred to the corresponding cycloalkanol 2, diluted 1:1 with 
glycerol) are added. To start the reaction 1 resp. 2 mol% of cofactor (NADPH: 
0.83 - 1.67 mg, 0.001 - 0.002; NADP+: 0.79 mg - 1.57 mg, 0.001 - 0.002 mmol) resp. 
1 mol% NADPH (0.83 mg, 0.001 mmol) as well as 1 mol% NADP+ (0.79 mg, 
0.001 mmol) is added. The reaction mixture is stirred for 24 h at room 
temperature and worked up according to SOP A resp. SOP B. 
 
8.2.16.1 Double oxidation of cyclohexane (1a) with reduced amount of cofactor 
 
According to SOP 16 cyclohexane (1a) (8.4 mg, 0.1 mmol) is mixed with 1 mL 
phosphate buffer (pH 7.0, 50 mM, 1 mM MgCl2) in a 25 mL round bottom flask. 
Then a cytochrome P450 monooxygenase from Bacillus megaterium (CYP BM-3 
19A12) (lyophilisate, 0.762 U referred to cyclohexane (1a)) and the alcohol 
dehydrogenase from Lactobacillus kefir (LK-ADH) (crude extract, 200 U/mmol 
referred to cyclohexanol (2a), diluted 1:1 with glycerol) are added. To start the 
reaction 1 or 2 mol% of cofactor NADPH (0.83 - 1.67 mg, 0.001 - 0.002 mmol) 
resp. 1 mol% NADPH (0.83 mg, 0.001 mmol) as well as 1 mol% NADP+ (0.79 mg, 
0.001 mmol) is added. The reaction mixture is stirred for 24 h at room 
temperature covered with a plug. After that time the mixture is worked up 
according to SOP 16 (SOP A: entry 1-4; SOP B: entry 5) (Table 58). 
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Table 58. Results of the double oxidation of cyclohexane (1a) with different 
concentrations of cofactor NADPH 
 
En-
try 
Activity 
19A12 
[U]/[mg] 
LK-ADH 
[U/mmol]/[µL] 
Cofactor 
Recovery/formatione) [g/L] 
of 
…1a …2a …3a 
1 0.762/5.2a) 200/825 1 mol% 0.42 0.09 0.08 
2 0.762/5.2a) 200/825 1 mol% 1.04 0.09 0.10 
3 0.762/5.2a) 200/825 2 mol% 1.07 0.11 0.11 
4 0.762/5.2a) 200/825 2 mol%d) 0.98 0.09 0.10 
5 0.762/10.3b) 200/528c) 1 mol% 0.31 0.19 0.28 
a)The content of CYP BM-3 19A12 (0) amounts to 0.123 μmol/g lyophilized crude extract; b)The 
content of CYP BM-3 19A12 (2) amounts to 0.120 μmol/g lyophilized crude extract; c)Addition of LK-
ADH without dilution in glycerol; d)each 1 mol% cofactor in oxidized + reduced form; e)The term 
͞ƌeĐoǀeƌǇ͞①desĐƌiďes①the mass concentration in g/L of a compound initially added to the reaction, 
that is recovered after workup, here cycloalkane 1.① The① teƌŵ① ͞foƌŵatioŶ͞① desĐƌiďes① the① ŵass①
concentration in g/L of a compound which is formed during the reaction and isolated while workup 
(product formation of cycloalkanol 2 and cycloalkanone 3). All mass concentrations in g/L were 
determined via gas chromatography. 
 
8.2.16.2 Double oxidation of cyclodecane (1b) with reduced amount of cofactor 
 
According to SOP 16 cyclodecane (1b) (14.0 mg, 0.1 mmol) is mixed with 997.5 µL 
phosphate buffer (pH 7.0, 50 mM, 1 mM MgCl2) and 2.5 µL 2-propanol (2.5 ‰①
(v/v)) in a 25 mL round bottom flask. Then a cytochrome P450 monooxygenase 
from Bacillus megaterium (CYP BM-3 19A12) (lyophilisate, 0.762 U referred to 
cyclodecane (1b)) and the alcohol dehydrogenase from Lactobacillus kefir 
(LK-ADH) (crude extract, 200 U/mmol referred to cyclodecanol (2b), diluted 1:1 
with glycerol) are added. To start the reaction 1 resp. 2 mol% of cofactor NADP+ 
(0.79 - 1.57 mg, 0.001 - 0.002 mmol) resp. 1 mol% NADPH (0.83 mg, 0.001 mmol) 
as well as 1 mol% NADP+ (0.79 mg, 0.001 mmol) is added. The reaction mixture is 
stirred for 24 h at room temperature covered with a plug. After that time the 
mixture is worked up according to SOP 16 (SOP A: entry 1-4; SOP B: entry 5) (Table 
59).  
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Table 59. Results of the double oxidation of cyclodecane (1b) with different 
concentrations of cofactor NADP+ 
 
 
En 
try 
Activity 
19A12 
[U]/[mg] 
LK-ADH 
[U/mmol]/[µL] 
Cofactor 
Recovery/formatione) [g/L] 
of 
…1b …2b …3b 
1 0.762/19.aa) 200/241 1 mol% 7.34 n.d.f) 0.26 
2 0.762/19.6a) 200/241 1 mol% 3.25 n.d.f) 0.29 
3 0.762/19.6a) 200/241 2 mol% 7.08 n.d.f) 0.25 
4 0.762/19.6a) 200/241 2 mol%d) 4.23 n.d.f) 0.35 
5 0.762/14.9b) 200/83c) 1 mol% 7.88 n.d.f) 0.22 
a)The content of CYP BM-3 19A12 (0) amounts to 0.123 μmol/g lyophilized crude extract; b)The 
content of CYP BM-3 19A12 (2) amounts to 0.120 μmol/g lyophilized crude extract; c)Addition of LK-
ADH without dilution in glycerol; d)each 1 mol% cofactor in oxidized + reduced form; e)The term 
͞ƌeĐoǀeƌǇ͞①desĐƌiďes①the mass concentration in g/L of a compound initially added to the reaction, 
that is recovered after workup, here cycloalkane 1.① The① teƌŵ① ͞foƌŵatioŶ͞① desĐƌiďes① the① ŵass①
concentration in g/L of a compound which is formed during the reaction and isolated while workup 
(product formation of cycloalkanol 2 and cycloalkanone 3). All mass concentrations in g/L were 
determined via gas chromatography; f)not detected. 
 
8.2.17 Standard operation procedure 17 (SOP 17): Biocatalyzed double 
oxidation of cycloalkanes 1 with different CYP BM-3 and LK-ADH and 
reduction of the reaction time 
 
 
Scheme 67. Double oxidation of cycloalkanes 1 
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In a 25 mL round bottom flask a cycloalkane 1 (8.4 - 14.0 mg, 0.1 mmol) is mixed 
with 1 mL phosphate buffer (pH 7.0, 50 mM, 1 mM MgCl2) resp. 997.5 µL phos-
phate buffer (pH 7.0, 50 mM, 1 mM MgCl2) and 2.5 µL 2-propanol (2.5 ‰①;ǀ/ǀͿͿ. 
Then a cytochrome P450 monooxygenase from Bacillus megaterium (CYP BM-3) 
(lyophilisate, 0.762 U referred to the corresponding cycloalkane 1) and the alcohol 
dehydrogenase from Lactobacillus kefir (LK-ADH) (crude extract, 200 U/mmol 
referred to the corresponding cycloalkanol 2, diluted 1:1 with glycerol) are added. 
To start the reaction cofactor NADPH (8.3 mg, 0.01 mmol) resp. NADP+ (7.9 mg, 
0.01 mmol) is added. The reaction mixture is stirred for 2 - 4 h at room 
temperature covered with a plug and worked up according to SOP B. 
 
8.2.17.1 Double oxidation of cyclohexane (1a) with shortened reaction time 
 
According to SOP 17 cyclohexane (1a) (8.4 mg, 0.1 mmol) is mixed with 1 mL 
phosphate buffer (pH 7.0, 50 mM, 1 mM MgCl2) in a 25 mL round bottom flask. 
Then a cytochrome P450 monooxygenase from Bacillus megaterium 
(CYP BM-3 19A12, 0.762 U, 10.3 mg) and the alcohol dehydrogenase from 
Lactobacillus kefir (LK-ADH) (crude extract, 200 U/mmol referred to cyclohexanol 
(2a), diluted 1:1 with glycerol) are added. To start the reaction cofactor NADPH 
(8.3 mg, 0.01 mmol) is added. The reaction mixture is stirred for 2 - 4 h at room 
temperature covered with a plug. After that time the mixture is worked up 
according to SOP B (Table 60).  
 
Table 60. Results of the double oxidation of cyclohexane (1a) with shortened 
reaction time 
 
 
Entry 
Activity 
19A12 
[U]/[mg] 
LK-ADH 
[U/mmol]/[µL] 
Time 
[h] 
Recovery/formationc) [g/L] 
of 
…1a …2a …3a 
1 0.762/10.3a) 200/528b) 2 1.09 0.22 0.37 
2 0.762/10.3a) 200/528b) 4 0.66 0.23 0.51 
a)The content of CYP BM-3 19A12 (2) amounts to 0.120 μmol/g lyophilized crude extract; b)Addition 
of LK-ADH without dilution in glycerol; c)The①teƌŵ①͞ƌeĐoǀeƌǇ͞①desĐƌiďes①the①ŵass①ĐoŶĐeŶtƌatioŶ①iŶ①g/L①
of a compound initially added to the reaction, that is recovered after workup, here cycloalkane 1. 
The① teƌŵ① ͞foƌŵatioŶ͞① desĐƌiďes① the① ŵass① ĐoŶĐeŶtƌatioŶ① iŶ① g/L① of① a① ĐoŵpouŶd① ǁhiĐh① is① foƌŵed①
during the reaction and isolated while workup (product formation of cycloalkanol 2 and 
cycloalkanone 3). All mass concentrations in g/L were determined via gas chromatography. 
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8.2.17.2 Double oxidation of cyclodecane (1b) with shortened reaction time 
 
According to SOP 17 cyclodecane (1b) (14.0 mg, 0.1 mmol) is mixed with 997.5 µL 
phosphate buffer (pH 7.0, 50 mM, 1 mM MgCl2) and 2.5 µL 2-propanol (2.5 ‰①
(v/v)) in a 25 mL round bottom flask. Then a cytochrome P450 monooxygenase 
from Bacillus megaterium (CYP BM-3 19A12, 0.762 U, 14.9 mg) and the alcohol 
dehydrogenase from Lactobacillus kefir (LK-ADH) (crude extract, 200 U/mmol 
referred to cyclodecanol (2b), diluted 1:1 with glycerol) are added. To start the 
reaction cofactor NADP+ (7.9 mg, 0.01 mmol) is added. The reaction mixture is 
stirred for 2 - 4 h at room temperature covered with a plug. After that time the 
mixture is worked up according to SOP B (Table 61).  
 
Table 61. Results of the double oxidation of cyclodecane (1b) with shortened 
reaction time 
 
 
Entry 
Activity 
19A12 
[U]/[mg] 
LK-ADH 
[U/mmol]/[µL] 
Time 
[h] 
Recovery/formationb) [g/L] 
of 
…1a …2a …3a 
1 0.762/14.9a) 200/166 2 11.81 0.00 0.21 
2 0.762/14.9a) 200/166 4 10.98 0.00 0.23 
a)The content of CYP BM-3 19A12 (2) amounts to 0.120 μmol/g lyophilized crude extract; b)The term 
͞ƌeĐoǀeƌǇ͞①desĐƌiďes①the①ŵass①ĐoŶĐeŶtƌatioŶ① iŶ①g/L①of①a①ĐoŵpouŶd① iŶitiallǇ①added①to①the① ƌeaĐtioŶ,①
that is recovered after workup, here cycloalkane 1.① The① teƌŵ① ͞foƌŵatioŶ͞① desĐƌiďes① the① ŵass①
concentration in g/L of a compound which is formed during the reaction and isolated while workup 
(product formation of cycloalkanol 2 and cycloalkanone 3). All mass concentrations in g/L were 
determined via gas chromatography. 
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8.2.18 Standard operation procedure 18 (SOP 18): Biocatalyzed double 
oxidation of cyclodecane (1b) with increased initial substrate 
concentration 
 
 
Scheme 68. Double oxidation of cycloalkanes 1 with increased substrate 
concentration 
In a 25 mL round bottom flask cyclodecane (1b) (14.0 - 70.2 mg, 0.1 - 0.5 mmol) is 
mixed with 997.5 µL phosphate buffer (pH 7.0, 50 mM, 1 mM MgCl2) and 2.5 µL 
2-propanol (2.5 ‰① ;ǀ/ǀͿͿ. Then a cytochrome P450 monooxygenase from 
Bacillus megaterium (CYP BM-3 19A12, 0.762 U, 14.9 mg) and the alcohol 
dehydrogenase from Lactobacillus kefir (LK-ADH) (crude extract, 200 U/mmol 
referred to cyclodecanol (2b), diluted 1:1 with glycerol) are added. To start the 
reaction cofactor NADP+ (7.9 - 39.4 mg, 0.01 - 0.05 mmol, 10 mol%) is added. The 
reaction mixture is stirred for 24 h at room temperature covered with a plug and 
worked up according to SOP B. The results are summarized in Table 62. 
 
Table 62. Results of the double oxidation of cyclodecane (1b) with increased 
substrate concentration according to Scheme 68 
Entry 
Activity 
19A12 
[U]/[mg] 
LK-ADH 
[U/mmol]/[µL] 
1b 
[mmol] 
Recovery/formationb) [g/L] 
of 
…1a …2a …3a 
1 0.762/14.9a) 200/166 0.1 10.28 0.00 0.25 
2 0.762/14.9a) 200/166 0.5 64.32 0.00 0.82 
a)The content of CYP BM-3 19A12 (2) amounts to 0.120 μmol/g lyophilized crude extract; b)The term 
͞ƌeĐoǀeƌǇ͞①desĐƌiďes①the①ŵass①ĐoŶĐeŶtƌatioŶ① iŶ①g/L①of①a①ĐoŵpouŶd① iŶitiallǇ①added①to①the① ƌeaĐtion, 
that is recovered after workup, here cycloalkane 1.① The① teƌŵ① ͞foƌŵatioŶ͞① desĐƌiďes① the① ŵass①
concentration in g/L of a compound which is formed during the reaction and isolated while workup 
(product formation of cycloalkanol 2 and cycloalkanone 3). All mass concentrations in g/L were 
determined via gas chromatography. 
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8.2.19 Standard operation procedure 19 (SOP 19): Preparation of the 
superabsorbed enzyme tandem 
 
To① a① hoŵogeŶous① ŵiǆtuƌe① ĐoŶsistiŶg① of① ;②Ϳ ϴ.ϯϰ - ;BͿ ϭϲ.ϲϴ ŵg① N②DPH,①
;②Ϳ ϭ - ;BͿ Ϯ ŵL① phosphate① ďuffeƌ① ;pH ϳ,① ϱϬ ŵM,① ĐoŶtaiŶiŶg① ϭ ŵM MgClϮͿ,①
;②Ϳ ϭϲ.Ϯ - ;BͿ ϯϮ.ϰ ŵg①CYP①BM-ϯ①ϭϵ②ϭϮ①;Ϭ.ϳϲϮ U①ƌefeƌƌed①to①ĐǇĐloheǆaŶe①;ϭaͿͿ①aŶd①
;②Ϳ ϰϰϯ - ;BͿ ϴϴϲ µL①LK-②DH①;ϮϬϬ U/ŵŵol①ƌelatiǀe①to①the①oƌdiŶaƌilǇ①used①Ϭ.ϭ①ŵŵol①
suďstƌate① ϭaͿ① iŶ① a① ;②Ϳ ϭϬ - ;BͿ ϱϬ ŵL① ƌouŶd① ďottoŵ① oƌ① peaƌ① shaped① flask① ǁeƌe①
added① ;②Ϳ Ϯϰϴ - ;BͿ ϰϵϲ ŵg① of① the① supeƌaďsoƌďeŶt① polǇŵeƌ① Faǀoƌ① “XM① ϵϭϱϱ®①
;EǀoŶik①IŶdustƌies①②GͿ.①The①ŵiǆtuƌe①solidifies①ǁithiŶ①ϭ ŵiŶ①of①stiƌƌiŶg.① 
 
8.2.20 Standard operation procedure 20 (SOP 20): Double oxidation of 
cyclohexane (1a) using a superabsorbed enzyme tandem 
 
The① supeƌaďsoƌďed①eŶzǇŵe① taŶdeŵ① is①pƌepaƌed①aĐĐoƌdiŶg① to① “OP ϭϵ① iŶ① a①ϭϬ①ŵL①
ƌouŶd①ďottoŵ①oƌ①ϱϬ ŵL①peaƌ① shaped① flask.① The① iŵŵoďilizate① is① theŶ①ŵiǆed①ǁith①
ϱ ŵL①ĐǇĐloheǆaŶe①;ϭaͿ① ;satuƌated①ǁith①ǁateƌ①to①aǀoid①the①uŶǁaŶted①ƌeduĐtioŶ①of①
the①aƋueous①ƋuaŶtitǇͿ① aŶd① stiƌƌed①at①ϳϬ① ƌpŵ① foƌ①Ϯϰ h①at① ƌooŵ① teŵpeƌatuƌe.① The①
supeƌŶataŶt① oƌgaŶiĐ① phase① is① pipetted① iŶto① a① ϭϬ ŵL① ǀoluŵetƌiĐ① flask① ǁhile① the①
ƌeŵaiŶiŶg① hǇdƌogel① is① eǆtƌaĐted① tǁiĐe① ďǇ① addiŶg① eaĐh① Ϯ ŵL① diĐhloƌoŵethaŶe① oƌ①
ĐǇĐloheǆaŶe① ;ϭaͿ① ;satuƌated①ǁith①ǁateƌ① to① aǀoid① the① uŶǁaŶted① ƌeduĐtioŶ① of① the①
aƋueous①ƋuaŶtitǇͿ①aŶd①sǁiƌliŶg①the①suspeŶsioŶ.①The①ĐoŵďiŶed①oƌgaŶiĐ①phases①aƌe①
tƌaŶsfeƌƌed① ĐoŵpletelǇ① iŶto① the① ϭϬ ŵL① ǀoluŵetƌiĐ① flask① ǁhiĐh① is① filled① ǁith①
diĐhloƌoŵethaŶe①oƌ①ϭa.①BǇ①ŵeaŶs①of①a①stƌaight①ĐaliďƌatioŶ①liŶe①the①ĐoŶĐeŶtƌatioŶ①is①
aŶalǇzed① via① gas① ĐhƌoŵatogƌaphǇ.① TheŶ① ϱ ŵL① ĐǇĐloheǆaŶe① ;ϭaͿ① ;satuƌated① ǁith①
ǁateƌ①to①aǀoid①the①uŶǁaŶted①ƌeduĐtioŶ①of①the①aƋueous①ƋuaŶtitǇͿ①aƌe①added①to①the①
iŵŵoďilisate①aŶd①the①Ŷeǆt①ĐǇĐle① is①staƌted①ďǇ①stiƌƌiŶg①at①ϳϬ①ƌpŵ①foƌ①Ϯϰ h①at① ƌooŵ①
teŵpeƌatuƌe.① The① ƌesults① of① the① douďle① oǆidatioŶ① of① ĐǇĐloheǆaŶe① ;ϭaͿ① usiŶg① the①
supeƌaďsoƌďed①eŶzǇŵe①taŶdeŵ①aƌe①suŵŵaƌized① iŶ①Taďle①ϲϯ,①the①ƌeĐǇĐliŶg①of①the①
supeƌaďsoƌďed①eŶzǇŵe①taŶdeŵ①is①shoǁŶ①iŶ①Taďle①ϲϰ. 
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Table 63. Double oxidation of cyclohexane (1a) using the superabsorbed enzyme 
tandem 
 
 
Entrya) Method Flask 
Cyclohexane 
(1a) [g/L]  
Cyclohexanol 
(2a) [g/L] 
Cyclohexanone 
(3a) [g/L] 
1 A 
10 mL, 
round 
bottom  
-- d) 0.00 0.15 
2 B 
50 mLc) 
pear 
shaped 
-- d) 0.00 0.16 
3b) B 
50 mLc) 
pear 
shaped 
-- d) 0.00 0.18 
a)GC-measurements are conducted in a twofold determination; b)Extraction as described above, but 
instead of dichloromethane, cyclohexane (1a) (saturated with water to avoid the unwanted 
reduction of the aqueous quantity) was used; c)Enlargement of the air volume in the flask to rule out 
the deficiency of molecular oxygen; d)Concentration of 1a is over the detection limit of the straight 
calibration line.  
 
 
Table 64. Double oxidation of cyclohexane (1a) using the superabsorbed enzyme 
tandem for 1-3 cycles 
 
EŶtƌǇaͿ CǇĐle CǇĐloheǆaŶe ①;ϭaͿ①[g/L] 
CǇĐloheǆaŶol①
;ϮaͿ①[g/L] 
CǇĐloheǆaŶoŶe①;ϯaͿ① 
[g/L①iŵŵoďilized①
aƋueous①phase] 
ϭ ϭ --①ďͿ Ϭ.ϬϬ Ϭ.ϭϴ 
Ϯ Ϯ --①ďͿ Ϭ.ϬϬ Ϭ.Ϭϰ 
ϯ ϯ --①ďͿ Ϭ.ϬϬ <①Ϭ.Ϭϭ 
a)GC-measurements are conducted in a twofold determination; b)Concentration of 1a is over the 
detection limit of the straight calibration line.  
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8.2.21 Standard operation procedure 21 (SOP 21): Cultivation of recombinant 
cells for the biocatalyzed double oxidation of cycloalkanes 1
[31,32]
 
 
Overnight preculture: 
Under sterile conditions a preculture is prepared by inoculating 5 mL LB medium, 
5 µL kanamycin (50 g/l, sterile filtered) and 5 µL chloramphenicol (34 g/l, sterile 
filtered) with 5 µL of the construct A (E. coli BL21 (DE3) Gold LacIQ1 pALXtreme-1a 
P450 BM-3 19A12NADPH(KanR) + pKA1 LB-ADH (CmR)) or construct B (E. coli BL21 
(DE3) Gold LacIQ1 pALXtreme-1a P450 BM-3 19A12NADH::RE-ADH (KanR) + pKA1 LB-
ADH (CmR) (1 µL/mL)). The cultures are grown overnight (14 h) by shaking at 37°C.  
 
Expression culture:  
Under sterile conditions an expression culture is prepared. In a 2 L shaking flask 
400 mL TB medium is supplemented with 400 µL trace elements (3.40 mM CaCl2, 
0.63 mM ZnSO4, 0.59 mM MnSO4, 59.82 mM Na2-EDTA, 61.79 mM FeCl3, 0.64 mM 
CuSO4, 0.76 mM CoCl2, autoclaved and sterile filtered) and each 400 µL of the 
antibiotics kanamycin (50 g/l, sterile filtered) and chloramphenicol (34 g/l, sterile 
filtered). Then 4 mL of the preculture are added. The cultures are grown by 
shaking at 37°C. To monitor the bacterial growth, the optical density at 600 nm 
(OD600) of the bacterial culture is measured spectrophotometrically with an 
UV/VIS-spectrophotometer (BioPhotometer plus, Eppendorf). The spectrophoto-
meter is blanked by measuring the media without the preculture. After the initial 
cultivation (construct A: OD600 = 0.72 after 3h; construct B: OD600 = 0.80 after 4h) 
the culture is supplemented with each 400 µL aminolevulinic acid (ALA) (0.5 M, 
sterile filtered), ZnCl2 (1 M, sterile filtered) and thiamine (100 g/l). Then expression 
is induced by adding 400 µL isopropyl-β-D-thiogalactopyranoside (IPTG) (0.1 M, 
sterile filtered). Expression takes place while incubating the cultures at 25°C and 
250 rpm (construct A: 20 h; construct B: 19 h). The E. coli cells are transferred into 
tubes and harvested by centrifugation (10 min, 4000 rpm, 4 °C, Thermo 
“ĐieŶtifiĐ™①“oƌǀall™①‘C①ϲ①Plus①CeŶtƌifugeͿ.①The①supeƌŶataŶt①ŵedia①is①disĐaƌded①aŶd①
the cells are washed with 80 mL KPi-buffer (pH 8.0, 100 mM). After centrifugation 
the supernatant is discarded again and the cell pellets are stored at -20°C.  
 
8.2.22 Standard operation procedure (SOP 22): Oxidation of cyclohexane (1a) 
using whole cells 
 
The cell pellet is resuspended in KPi-buffer (pH 8.0, 100 mM) to an optical density 
of approximately 40 (construct A: OD600 = 40.2; construct B: OD600 = 39.0). 50 µL 
glucose solution (200 g/L, sterile filtered using 0.2 µm filters) are poured into a 
10 mL-glass vial with screw plug and 1 mL of the resuspended cells (OD600 = ca. 40) 
are added. This mixture is incubated for 5 min at room temperature before 20 µL 
of a 0.5 M stock solution of cyclohexane (1a) in ethanol are pipetted in the glass 
vial (10 mM). Then the vial is sealed and the reaction mixture is stirred at room 
temperature for 0.5 - 24 h.  
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After different time intervals the experiments are terminated by transferring the 
reaction mixture into an Eppendorf tube and admix with hydrochloric acid 
(100 µL, 37%) and MTBE (1 mL). The biphasic system is vortexed for 2 min and the 
phase separation is obtained by centrifugation at maximal speed for 2 min 
(Eppendorf centrifuge 5425). The organic phase is pipetted into another 
Eppendorf tube where it is vortexed and centrifuged as described above in the 
presence of magnesium sulphate. By means of a straight calibration line the 
concentration is analyzed via gas chromatography (Table 65 and Table 66).   
 
Table 65. Oxidation of cyclohexane (1a) using construct A, BL21 (DE3) Gold LacIQ1 
pALXtreme-1a P450 BM-3 19A12NADPH(KanR) + pKA1 LB-ADH (CmR) (SOP 22) 
OD600 = 40.2; CDW = 8.7 (cell dry weight; in gCDW L
-1) 
 
 
Entrya) 
Time 
[h] 
1a [g/L] 2a [g/L] 3a [g/L] 
Σ2a+3a 
[g/L] 
Product yield  on 
catalystb) 
[mgproduct/gCDW] 
1 0.5 0.06 0.10 0.02 0.12 14 
2 1 0.01 0.16 0.08 0.24 28 
3 2 0.02 0.21 0.14 0.35 40 
4 4 0.03 0.26 0.15 0.41 94 
5 18 0.02 0.36 0.04 0.40 47 
6 24 0.02 0.38 0.04 0.42 48 
a)Both, experiments and GC-measurements are conducted in a twofold determination with the 
result that for each reaction the average of a fourfold dataset is calculated; b)Product yield on 
catalyst describes the ratio between the sum of products mass concentrations (Σ2+3) in mg/L and 
the amount of catalyst as cell dry weight in gCDW L
-1. 
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Table 66. Oxidation of cyclohexane (1a) using construct B, BL21 (DE3) Gold LacIQ1 
pALXtreme-1a P450 BM-3 19A12NADH::RE-ADH (KanR) + pKA1 LB-ADH (CmR) 
(SOP 22) OD600 = 39.0; CDW = 5.0 (cell dry weight; in gCDW L
-1) 
 
 
Entrya) 
Time 
[h] 
1a [g/L] 2a [g/L] 3a [g/L] 
Σ2a+3a 
[g/L] 
Product yield  on 
catalystb) 
[mgproduct/gCDW] 
1 0.5 0.05 0.08 0.03 0.11 22 
2 1 0.03 0.14 0.09 0.23 46 
3 2 0.02 0.18 0.15 0.33 66 
4 4 0.01 0.25 0.21 0.46 92 
5 18 0.01 0.41 0.06 0.47 94 
6 24 0.01 0.43 0.08 0.51 102 
a)Both, experiments and GC-measurements are conducted in a twofold determination with the 
result that for each reaction the average of a fourfold dataset is calculated; b)Product yield on 
catalyst describes the ratio between the sum of products mass concentrations (Σ2+3) in mg/L and 
the amount of catalyst as cell dry weight in gCDW L
-1. 
 
8.2.23 Standard operation procedure (SOP 23): Oxidation of cyclodecane (1b) 
using whole cells 
 
The cell pellet is resuspended in KPi buffer (pH 8.0, 100 mM) to an optical density 
of approximately 40 (construct A: OD600 = 39.4; construct B: OD600 = 33.6). 50 µL 
glucose solution (200 g/L, sterile filtered using 0.2 µm filters) are poured into a 
glass vial and 1 mL of the resuspended cells (OD600 = ca. 40) are added. This 
mixture is incubated for 5 min at room temperature before 20 µL of a 5 M stock 
solution of cyclodecane (1b) in ethanol are pipetted in the glass vial (100 mM). 
Then the vial is sealed and the reaction mixture is stirred at room temperature for 
1 - 20 h. After different time intervals the experiments are terminated by 
transferring the reaction mixture into an Eppendorf tube and admix with 
hydrochloric acid (100 µL, 37%) and MTBE (1 mL). The biphasic system is vortexed 
for 2 min and the phase separation is obtained by centrifugation at maximal 
speed for 2 min (Eppendorf centrifuge 5425). The organic phase is pipetted into 
another Eppendorf tube where it is vortexed and centrifuged as described above 
in the presence of magnesium sulphate. By means of a straight calibration line the 
concentration is analyzed via gas chromatography (Table 67 and Table 68).   
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Table 67. Oxidation of cyclodecane (1b) using construct A, BL21 (DE3) Gold LacIQ1 
pALXtreme-1a P450 BM-3 19A12NADPH(KanR) + pKA1 LB-ADH (CmR) (SOP 23) 
OD600 = 39.4; CDW = 14.9 (cell dry weight; in gCDW L
-1) 
 
 
Entrya) 
Time 
[h] 
1b [g/L] 2b [g/L] 3b [g/L] 
Σ2b+3b 
[g/L] 
Product yield  on 
catalystb) 
 [mgproduct/gCDW] 
1 1 8.00 -- 0.06 0.06 4 
2 4.5 6.42 -- 0.10 0.10 7 
3 20 1.99 -- 0.06 0.06 4 
a)Both, experiments and GC-measurements are conducted in a twofold determination with the 
result that for each reaction the average of a fourfold dataset is calculated; b)Product yield on 
catalyst describes the ratio between the sum of products mass concentrations (Σ2+3) in mg/L and 
the amount of catalyst as cell dry weight in gCDW L
-1. 
 
Table 68. Oxidation of cyclodecane (1b) using construct B, BL21 (DE3) Gold LacIQ1 
pALXtreme-1a P450 BM-3 19A12NADH::RE-ADH (KanR) + pKA1 LB-ADH (CmR) 
(SOP 23) OD600 = 33.6; CDW = 10.4 (cell dry weight; in gCDW L
-1) 
 
 
Entrya) Time [h] 
1b 
[g/L] 
2b 
[g/L] 
3b 
[g/L] 
Σ2b+3b 
[g/L] 
Product yield  
on catalystb) 
[mgproduct/gCDW] 
1 1 7.97 -- 0.12 0.12 12 
2 4.5 7.17 -- 0.12 0.12 12 
3 20 4.95 -- 0.12 0.12 12 
a)Both, experiments and GC-measurements are conducted in a twofold determination with the 
result that for each reaction the average of a fourfold dataset is calculated; b)Product yield on 
catalyst describes the ratio between the sum of products mass concentrations (Σ2+3) in mg/L and 
the amount of catalyst as cell dry weight in gCDW L
-1. 
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10 List of Abbreviations 
 
%  percent 
(v/v)  volume/volume 
[S]  substrate concentration 
°C  degree Celsius 
µL  mikroliter 
µm  micromole 
‰  per mille 
1H-NMR-
spectroscopy 
 Nuclear Magnetic Resonance spectroscopy; studied 
nucleus: 1H 
1O2  singlet oxygen 
2p  2p atomic orbital 
2s  2s atomic orbital 
3O2  triplet oxygen 
A  absorption 
Å  Ångström (equals 0.1 nm) 
AaeUPO  Agrocybe aegerita  
ADH  alcohol dehydrogenase 
ADH evo-1.1.200   alcohol dehydrogenase available from evocatal GmbH 
ADH-A  alcohol dehydrogenase from Rhodococcus ruber DSM 
44541 
ALA  aminolevulinic acid 
API  active pharmaceutical ingredient 
Arg47  arginine residue at position 47 
AS  auxiliary substrate 
BC  before christ 
BSA  bovine serum albumin 
c  concentration 
CD2Cl2  deutero dichloromethane; dichloromethane-d2 
CDCl3  deutero chloroform 
CDW   cell dry weight (in gCDW L
-1) 
CmR  chloramphenicol resistance 
Construct A   BL21 (DE3) Gold LacIQ1 pALXtreme-1a P450 BM-3 
19A12NADPH(KanR) + pKA1 LB-ADH (CmR)  
Construct B  BL21 (DE3) Gold LacI
Q1 pALXtreme-1a P450 BM-3 
19A12NADH::RE-ADH (KanR) + pKA1 LB-ADH (CmR) 
content of CYP 
[µmol/g or 
nmol/g] 
 content of the cytochrome P450 monooxygenase from 
Bacillus megaterium in the lyophilized crude extract (in 
micromole per gram or nanomole per gram) 
CPR  NADPH-cytochrome P450 reductase 
CYPs  cytochrome P450 monooxygenases 
CYP BM-3 
 
 cytochrome P450 monooxygenase from Bacillus 
megaterium 
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CYP BM-3 WT 
 
wild type (WT) enzyme and genetically engineered 
mutants of the cytochrome P450 monooxygenase from 
Bacillus megaterium, mutated at the specified positions 
of the amino acid sequence 
CYP BM-3 19A12 
CYP BM-3 F87P 
CYP BM-3 F87V 
CYP BM-3 F87A 
A328V 
CYP BM-3 R255P-
P329H 
CYP BM-3 139-3 
CYP BM-3 R47L 
Y51F 
CYP BM-3 A328V 
CYP106A2  cytochrome P450 monooxygenase from B. megaterium 
ATCC 13368 
CYP153A13a  cytochrome P450 monooxygenase from Alcanivorax 
borkumensis SK2  
CYP1A2  
 
human cytochrome P450 enzymes 
CYP2C9 
CYP2D6 
CYP2E1 
CYP3A4 
CYP CAM  camphor hydroxylase from Pseudomonas putida 
d   path length of the cuvette 
d  doublet 
D2O  deuteriumoxide 
d5  d5-configuration 
DCM  dichloromethane 
dd  doublet of doublet 
DMSO  dimethyl sulfoxide 
DMSO-d6  dimethylsulfoxide-d6 
dt  doublet of triplet 
E  energy 
E. coli  Escherichia coli 
E.coli BL21  E. coli cells containing an empty vector 
E. coli BL21 (DE3) 
Gold LacIQ1 
 chemically competent E. coli cells 
ee  enantiomeric excess 
eq.  equivalents 
f   dilution factor 
FAD  flavin adenine dinucleotide 
Favor SXM 9155®   superabsorbent polymer commercially available from 
Evonik Industries 
FDH  formate dehydrogenase  
FdR  ferredoxin reductase 
Fdx  ferredoxin   
FID  flame ionization detector 
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FMN  flavin mononucleotide 
GC  gas chromatography 
GDH  glucose dehydrogenase from Bacillus sp. 
Glu47  glutamic acid residue at position 47 
h  hour 
H  hydrogen 
HLADH  alcohol dehydrogenase from horse liver 
hPa  hectopascal 
HPLC   high performance liquid chromatography 
hs  high spin 
Hz  Hertz 
IPA  2-propanol 
IPTG  isopropyl-β-D-thiogalactopyranoside 
J  scalar coupling constant 
K   NERNST distribution coefficient 
KanR  kanamycin resistance 
kDa  kilo Dalton 
kJ mol-1  kilo Joule per mole 
KOtBu  potassium t-butoxide 
KPi-buffer  potassium phosphate buffer 
LB medium  lysogeny broth medium 
LB-ADH  alcohol dehydrogenase from Lactobacillus brevis 
LDA  lithium diisopropylamide 
LK-ADH  alcohol dehydrogenase from Lactobacillus kefir 
log P value  decadic logarithm of the partition-coefficient 
ls  low spin 
LY 300164  an orally administered benzodiazepine (Eli Lilly) 
m  multiplet 
M [g/mol]  molecular weight  
MDL  method detection limit 
mg  milligram 
mgP450/gCDW  expression level of the recombinant P450 
monooxygenase in the cells (generally determined via 
CO-difference spectroscopy) 
mgproduct/gCDW  product yield on catalyst 
MHz  megahertz 
min  minute 
mL  millilitre 
mM  millimolar 
mmol  millimol 
mol%  mole fraction multiplied by 100 
Mt/a  metric tons per year 
MTBE  methyl tert-butyl ether 
mV  milli Volt 
n  number of subunits 
n.d.  not determined 
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n.d.  not detected 
NADH, NAD+  nicotinamide-adenine-dinucleotide 
NADPH, NADP+  nicotinamide-adenine-dinucleotide-phosphate 
NAPQI  N-acetyl-p-benzoquinone imine  
nm  nanometre 
NMR  nuclear magnetic resonance 
OD600   optical densitiy, measured at a wavelength of 600 nm 
OTC drug  over-the-counter drug 
P450   ͞P͟①staŶds①foƌ①pigŵeŶt①aŶd①͞ϰϱϬ͟①is①deƌiǀed①fƌoŵ①the①
UV absorption peak of the carbon monoxide complex 
P450 or CYP BM-
3; CYP102A1; EC 
1.14.14.1 
 Analogue abbreviations for the cytochrome P450 
monooxygenase from the soil bacterium Bacillus 
megaterium 
P450balk  P450 monooxygenase from Alcanivorax borkumensis 
SK2  
P450RhF  self-sufficient P450 monooxygenase 
pAlXtreme-1a  plasmid with P450 BM-3 19A12NADPH(KanR) resp. P450 
BM-3 19A12NADH::RE-ADH (KanR); kanamycin-resistant 
Phe87  phenylalanine at position 87  
pKA1  plasmid with LB-ADH; chloramphenicol-resistant 
ppm  parts per million 
pRED  expression vector 
q  quartet 
r.t.  room temperature 
RE-ADH  alcohol dehydrogenase from Rhodococcus erythropolis 
resp.  respectively 
rpm  rounds per minute 
Rsp.-ADH  alcohol dehydrogenase from Rhodococcus species 
s  singlet 
S  bond order 
SOP  Standard Operation Procedure 
SPAAC  strain-promoted alkyne azide cycloaddition 
SPP  stoichiometric side product 
t  triplet 
t/a  tons per year 
TB medium  terrific broth medium 
td  triplet of doublet 
THF  tetrahydrofuran 
TOF  turn over frequency 
tR  retention time 
TTN  Total Turnover Number 
U  enzyme unit (the amount of enzyme that catalyzes the 
conversion of 1 micromole of substrate per minute) 
U/mg  specific enzyme activity; gravimetric enzyme activity 
U/mL 
[μŵol·ŵiŶ-1·mL-1] 
 volumetric enzyme activity  
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U/mmol  units per millimole substrate 
UV/VIS  ultraviolet/visible 
v.s.  vide supra 
v0  initial rate 
vmax  the maximum rate achieved by the (enzymatic) system 
at maximum saturating substrate concentrations 
vol.  volumetric 
VS  sample volume 
Vt   total volume 
ɷ  chemical shift  
ɷ①[ppŵ]  chemical shift in parts per million 
ΔE340nm/t  initial slope of the absorption curve 
ɸ①[6.3 mL·μŵol-1· 
cm-1] 
 molar extinction coefficient for NAD(P)H  
 
π  bonding pi-molecular orbital 
π*  anti-bonding pi-molecular orbital 
σP  bonding sigma(P)-molecular orbital 
σP*  anti-bonding sigma(P)-molecular orbital 
σS  bonding sigma(S)-molecular orbital 
σS*  anti-bonding sigma(S)-molecular orbital 
ω  ω-positions 
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